{
    "5+2d": {
        "brands": [
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "5+2d",
        "regimen_names": [
            "5 & 2d",
            "5 / 2d",
            "5 and 2d",
            "5&2d",
            "5+2d",
            "5/2d",
            "52d"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin": {
        "brands": [
            "5-FU",
            "Leucovorin"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid"
        ],
        "regimen": "5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin",
        "regimen_names": [
            "5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3d & GO": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Mylotarg"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Gemtuzumab ozogamicin"
        ],
        "regimen": "7+3d & GO",
        "regimen_names": [
            "7 & 3d & GO",
            "7 / 3d & GO",
            "7 and 3d & GO",
            "7&3d & GO",
            "7+3d  and  GO",
            "7+3d & GO",
            "7+3d + GO",
            "7+3d / GO",
            "7+3d and GO",
            "7+3d+GO",
            "7+3d/GO",
            "7/3d & GO",
            "73d & GO",
            "73dGO"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3d & Glasdegib": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Daurismo"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Glasdegib"
        ],
        "regimen": "7+3d & Glasdegib",
        "regimen_names": [
            "7+3d  and  Glasdegib",
            "7+3d & Glasdegib",
            "7+3d + Glasdegib",
            "7+3d / Glasdegib",
            "7+3d and Glasdegib",
            "7+3d+Glasdegib",
            "7+3d/Glasdegib"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3d & Sorafenib": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Nexavar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_FLT3-positive"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Sorafenib"
        ],
        "regimen": "7+3d & Sorafenib",
        "regimen_names": [
            "7+3d  and  Sorafenib",
            "7+3d & Sorafenib",
            "7+3d + Sorafenib",
            "7+3d / Sorafenib",
            "7+3d and Sorafenib",
            "7+3d+Sorafenib",
            "7+3d/Sorafenib"
        ],
        "regimen_type": "First-line induction therapy, older patients or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3d (high-dose)": {
        "brands": [
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "7+3d (high-dose)",
        "regimen_names": [
            "7 & 3d",
            "7 / 3d",
            "7 and 3d",
            "7&3d",
            "7+3d",
            "7+3d (high-dose)",
            "7/3d",
            "73d"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3d (intermediate-dose)": {
        "brands": [
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "7+3d (intermediate-dose)",
        "regimen_names": [
            "7 & 3d",
            "7 / 3d",
            "7 and 3d",
            "7&3d",
            "7+3d",
            "7+3d (intermediate-dose)",
            "7/3d",
            "73d"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3d (standard-dose)": {
        "brands": [
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "7+3d (standard-dose)",
        "regimen_names": [
            "7 & 3d",
            "7 / 3d",
            "7 and 3d",
            "7&3d",
            "7+3d",
            "7+3d (standard-dose)",
            "7/3d",
            "73d"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3i": {
        "brands": [
            "Cytosar",
            "Idamycin"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Idarubicin"
        ],
        "regimen": "7+3i",
        "regimen_names": [
            "7 & 3i",
            "7 / 3i",
            "7 and 3i",
            "7&3i",
            "7+3i",
            "7/3i",
            "73i"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3i & Sorafenib": {
        "brands": [
            "Cytosar",
            "Idamycin",
            "Nexavar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Idarubicin",
            "Sorafenib"
        ],
        "regimen": "7+3i & Sorafenib",
        "regimen_names": [
            "7+3i  and  Sorafenib",
            "7+3i & Sorafenib",
            "7+3i + Sorafenib",
            "7+3i / Sorafenib",
            "7+3i and Sorafenib",
            "7+3i+Sorafenib",
            "7+3i/Sorafenib"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "7+3m": {
        "brands": [
            "Cytosar",
            "Novantrone"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Mitoxantrone"
        ],
        "regimen": "7+3m",
        "regimen_names": [
            "7 & 3m",
            "7 / 3m",
            "7 and 3m",
            "7&3m",
            "7+3m",
            "7/3m",
            "73m",
            "MAC"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "A+AVD": {
        "brands": [
            "Adcetris",
            "Adriamycin",
            "Velban",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Brentuximab vedotin",
            "Doxorubicin",
            "Vinblastine",
            "Dacarbazine"
        ],
        "regimen": "A+AVD",
        "regimen_names": [
            "A & AVD",
            "A / AVD",
            "A and AVD",
            "A&AVD",
            "A+AVD",
            "A/AVD",
            "AAVD",
            "BV  &  AVD",
            "BV  /  AVD",
            "BV  AVD",
            "BV  and  AVD",
            "BV & AVD",
            "BV + AVD",
            "BV / AVD",
            "BVAVD"
        ],
        "regimen_type": "Untreated, early-stage unfavorable (ESU)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABC": {
        "brands": [
            "Abraxane",
            "Avastin",
            "Paraplatin"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Paclitaxel, nanoparticle albumin-bound",
            "Bevacizumab",
            "Carboplatin"
        ],
        "regimen": "ABC",
        "regimen_names": [
            "ABC"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABCP": {
        "brands": [
            "Tecentriq",
            "Avastin",
            "Paraplatin",
            "Taxol"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Atezolizumab",
            "Bevacizumab",
            "Carboplatin",
            "Paclitaxel"
        ],
        "regimen": "ABCP",
        "regimen_names": [
            "ABCP"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, nonsquamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABV (Vinblastine)": {
        "brands": [
            "Adriamycin",
            "Blenoxane",
            "Velban"
        ],
        "cancers": [
            "Vascular_sarcoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Bleomycin",
            "Vinblastine"
        ],
        "regimen": "ABV (Vinblastine)",
        "regimen_names": [
            "ABV",
            "ABV (Vinblastine)"
        ],
        "regimen_type": "Kaposi sarcoma, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABV (Vincristine)": {
        "brands": [
            "Adriamycin",
            "Blenoxane",
            "Oncovin"
        ],
        "cancers": [
            "Vascular_sarcoma",
            "Vascular_sarcoma",
            "Vascular_sarcoma",
            "Vascular_sarcoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Bleomycin",
            "Vincristine"
        ],
        "regimen": "ABV (Vincristine)",
        "regimen_names": [
            "ABV",
            "ABV (Vincristine)"
        ],
        "regimen_type": "Kaposi sarcoma, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABVD": {
        "brands": [
            "Adriamycin",
            "Blenoxane",
            "Velban",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant"
        ],
        "drugs": [
            "Doxorubicin",
            "Bleomycin",
            "Vinblastine",
            "Dacarbazine"
        ],
        "regimen": "ABVD",
        "regimen_names": [
            "ABVD"
        ],
        "regimen_type": "Untreated, early-stage favorable (ESF)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABVD, DD-DI": {
        "brands": [
            "Adriamycin",
            "Blenoxane",
            "Velban",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Bleomycin",
            "Vinblastine",
            "Dacarbazine"
        ],
        "regimen": "ABVD, DD-DI",
        "regimen_names": [
            "ABVD, DD-DI"
        ],
        "regimen_type": "Untreated, advanced stage",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ABVE-PC": {
        "brands": [
            "Adriamycin",
            "Blenoxane",
            "Oncovin",
            "Vepesid",
            "Sterapred",
            "Cytoxan"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Bleomycin",
            "Vincristine",
            "Etoposide",
            "Prednisone",
            "Cyclophosphamide"
        ],
        "regimen": "ABVE-PC",
        "regimen_names": [
            "ABVE-PC",
            "ABVE/PC",
            "ABVEPC"
        ],
        "regimen_type": "Untreated, pediatric",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "AC": {
        "brands": [
            "Adriamycin",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer_triple_negative",
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Doxorubicin",
            "Cyclophosphamide"
        ],
        "regimen": "AC",
        "regimen_names": [
            "AC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "AC & Bevacizumab": {
        "brands": [
            "Adriamycin",
            "Cytoxan",
            "Avastin"
        ],
        "cancers": [
            "Breast_cancer"
        ],
        "drugs": [
            "Doxorubicin",
            "Cyclophosphamide",
            "Bevacizumab"
        ],
        "regimen": "AC & Bevacizumab",
        "regimen_names": [
            "AC  and  Bevacizumab",
            "AC & Bev",
            "AC & Bevacizumab",
            "AC + Bevacizumab",
            "AC / Bev",
            "AC / Bevacizumab",
            "AC and Bev",
            "AC and Bevacizumab",
            "AC&Bev",
            "AC+Bev",
            "AC+Bevacizumab",
            "AC/Bev",
            "AC/Bevacizumab",
            "ACBev"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ACVBP, dose-adjusted": {
        "brands": [
            "Adriamycin",
            "Cytoxan",
            "Eldisine",
            "Blenoxane",
            "Sterapred"
        ],
        "cancers": [
            "Post-transplant_lymphoproliferative_disorder"
        ],
        "drugs": [
            "Doxorubicin",
            "Cyclophosphamide",
            "Vindesine",
            "Bleomycin",
            "Prednisone"
        ],
        "regimen": "ACVBP, dose-adjusted",
        "regimen_names": [
            "ACVBP",
            "ACVBP, dose-adjusted"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ACVBP-R": {
        "brands": [
            "Adriamycin",
            "Cytoxan",
            "Eldisine",
            "Blenoxane",
            "Sterapred",
            "Rituxan"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Cyclophosphamide",
            "Vindesine",
            "Bleomycin",
            "Prednisone",
            "Rituximab"
        ],
        "regimen": "ACVBP-R",
        "regimen_names": [
            "ACVBP-R",
            "ACVBP/R",
            "ACVBPR",
            "R-ACVBP",
            "R/ACVBP",
            "RACVBP"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ADE & ATRA": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Vepesid",
            "ATRA"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Etoposide",
            "All-trans retinoic acid"
        ],
        "regimen": "ADE & ATRA",
        "regimen_names": [
            "ADE  and  ATRA",
            "ADE & ATRA",
            "ADE + ATRA",
            "ADE / ATRA",
            "ADE and ATRA",
            "ADE+ATRA",
            "ADE/ATRA"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ADE (high-dose Ara-C)": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Vepesid"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Etoposide"
        ],
        "regimen": "ADE (high-dose Ara-C)",
        "regimen_names": [
            "ADE",
            "ADE (high-dose Ara-C)",
            "HIDAC-3-5",
            "HIDAC-3-7",
            "HIDAC/3/5",
            "HIDAC/3/7",
            "HIDAC35",
            "HIDAC37"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ADE (standard-dose Ara-C)": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Vepesid"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Etoposide"
        ],
        "regimen": "ADE (standard-dose Ara-C)",
        "regimen_names": [
            "10-3-5",
            "10/3/5",
            "1035",
            "7-3-7",
            "7/3/7",
            "737",
            "8-3-5",
            "8/3/5",
            "835",
            "ADE",
            "ADE (standard-dose Ara-C)"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ADOC": {
        "brands": [
            "Adriamycin",
            "Platinol",
            "Oncovin",
            "Cytoxan"
        ],
        "cancers": [
            "Thymoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Cisplatin",
            "Vincristine",
            "Cyclophosphamide"
        ],
        "regimen": "ADOC",
        "regimen_names": [
            "ADOC"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "APO": {
        "brands": [
            "Adriamycin",
            "Sterapred",
            "Oncovin"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Prednisone",
            "Vincristine"
        ],
        "regimen": "APO",
        "regimen_names": [
            "APO"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "AT (Taxol)": {
        "brands": [
            "Adriamycin",
            "Taxol"
        ],
        "cancers": [
            "Breast_cancer"
        ],
        "drugs": [
            "Doxorubicin",
            "Paclitaxel"
        ],
        "regimen": "AT (Taxol)",
        "regimen_names": [
            "AT (Taxol)"
        ],
        "regimen_type": "Adjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Horse) & Cyclosporine": {
        "brands": [
            "Atgam",
            ":Category:Cyclosporines"
        ],
        "cancers": [
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Antithymocyte globulin, horse ATG",
            ":Category:Cyclosporines"
        ],
        "regimen": "ATG (Horse) & Cyclosporine",
        "regimen_names": [
            "ATG (Horse) & Cyclosporine"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Horse) monotherapy": {
        "brands": [
            "Atgam"
        ],
        "cancers": [
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Antithymocyte globulin, horse ATG"
        ],
        "regimen": "ATG (Horse) monotherapy",
        "regimen_names": [
            "ATG",
            "ATG (Horse) monotherapy"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Horse), Cyclosporine, Eltrombopag": {
        "brands": [
            "Atgam",
            ":Category:Cyclosporines"
        ],
        "cancers": [
            "Aplastic_anemia",
            "Aplastic_anemia"
        ],
        "drugs": [
            "Antithymocyte globulin, horse ATG",
            ":Category:Cyclosporines"
        ],
        "regimen": "ATG (Horse), Cyclosporine, Eltrombopag",
        "regimen_names": [
            "ATG (Horse), Cyclosporine, Eltrombopag"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Horse), Cyclosporine, G-CSF": {
        "brands": [
            "Atgam",
            ":Category:Cyclosporines"
        ],
        "cancers": [
            "Aplastic_anemia",
            "Aplastic_anemia"
        ],
        "drugs": [
            "Antithymocyte globulin, horse ATG",
            ":Category:Cyclosporines"
        ],
        "regimen": "ATG (Horse), Cyclosporine, G-CSF",
        "regimen_names": [
            "ATG (Horse), Cyclosporine, G-CSF"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Horse), Cyclosporine, Methylprednisolone": {
        "brands": [
            "Atgam",
            "Sandimmune",
            "Solumedrol"
        ],
        "cancers": [
            "Aplastic_anemia"
        ],
        "drugs": [
            "Antithymocyte globulin, horse ATG",
            "Cyclosporine non-modified",
            "Methylprednisolone"
        ],
        "regimen": "ATG (Horse), Cyclosporine, Methylprednisolone",
        "regimen_names": [
            "ATG (Horse), Cyclosporine, Methylprednisolone"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Horse), Cyclosporine, Sirolimus": {
        "brands": [
            "Atgam",
            ":Category:Cyclosporines",
            "Rapamune"
        ],
        "cancers": [
            "Aplastic_anemia",
            "Aplastic_anemia"
        ],
        "drugs": [
            "Antithymocyte globulin, horse ATG",
            ":Category:Cyclosporines",
            "Sirolimus"
        ],
        "regimen": "ATG (Horse), Cyclosporine, Sirolimus",
        "regimen_names": [
            "ATG (Horse), Cyclosporine, Sirolimus"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Rabbit) & Cyclosporine": {
        "brands": [
            "Thymoglobulin",
            ":Category:Cyclosporines"
        ],
        "cancers": [
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Aplastic_anemia"
        ],
        "drugs": [
            "Antithymocyte globulin, rabbit ATG",
            ":Category:Cyclosporines"
        ],
        "regimen": "ATG (Rabbit) & Cyclosporine",
        "regimen_names": [
            "ATG (Rabbit) & Cyclosporine"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATG (Rabbit) monotherapy": {
        "brands": [
            "Thymoglobulin"
        ],
        "cancers": [
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Antithymocyte globulin, rabbit ATG"
        ],
        "regimen": "ATG (Rabbit) monotherapy",
        "regimen_names": [
            "ATG",
            "ATG (Rabbit) monotherapy"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA & Danazol": {
        "brands": [
            "ATRA",
            "Danocrine"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Danazol"
        ],
        "regimen": "ATRA & Danazol",
        "regimen_names": [
            "ATRA  and  Danazol",
            "ATRA & Danazol",
            "ATRA + Danazol",
            "ATRA / Danazol",
            "ATRA and Danazol",
            "ATRA+Danazol",
            "ATRA/Danazol"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA & Daunorubicin": {
        "brands": [
            "ATRA",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Daunorubicin"
        ],
        "regimen": "ATRA & Daunorubicin",
        "regimen_names": [
            "ATRA  and  Daunorubicin",
            "ATRA & Daunorubicin",
            "ATRA + Daunorubicin",
            "ATRA / Daunorubicin",
            "ATRA and Daunorubicin",
            "ATRA+Daunorubicin",
            "ATRA/Daunorubicin"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA & Idarubicin": {
        "brands": [
            "ATRA",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Idarubicin"
        ],
        "regimen": "ATRA & Idarubicin",
        "regimen_names": [
            "AIDA",
            "ATRA  and  Idarubicin",
            "ATRA & Idarubicin",
            "ATRA + Idarubicin",
            "ATRA / Idarubicin",
            "ATRA and Idarubicin",
            "ATRA+Idarubicin",
            "ATRA/Idarubicin"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA monotherapy": {
        "brands": [
            "ATRA"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid"
        ],
        "regimen": "ATRA monotherapy",
        "regimen_names": [
            "ATRA monotherapy"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA, Cytarabine, Daunorubicin": {
        "brands": [
            "ATRA",
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "ATRA, Cytarabine, Daunorubicin",
        "regimen_names": [
            "ATRA, Cytarabine, Daunorubicin"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA, Cytarabine, Idarubicin": {
        "brands": [
            "ATRA",
            "Cytosar",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Cytarabine",
            "Idarubicin"
        ],
        "regimen": "ATRA, Cytarabine, Idarubicin",
        "regimen_names": [
            "ATRA, Cytarabine, Idarubicin"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ATRA, Mercaptopurine, Methotrexate": {
        "brands": [
            "ATRA",
            "Purinethol",
            "MTX",
            "MTX",
            "Purinethol",
            "MTX",
            "Purinethol"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Mercaptopurine",
            "Methotrexate",
            "Methotrexate",
            "Mercaptopurine",
            "Methotrexate",
            "Mercaptopurine"
        ],
        "regimen": "ATRA, Mercaptopurine, Methotrexate",
        "regimen_names": [
            "ATRA, Mercaptopurine, Methotrexate"
        ],
        "regimen_type": "Maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "AVD": {
        "brands": [
            "Adriamycin",
            "Velban",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Vinblastine",
            "Dacarbazine"
        ],
        "regimen": "AVD",
        "regimen_names": [
            "AVD"
        ],
        "regimen_type": "Untreated, early-stage favorable (ESF)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Acalabrutinib monotherapy": {
        "brands": [
            "Calquence"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Acalabrutinib"
        ],
        "regimen": "Acalabrutinib monotherapy",
        "regimen_names": [
            "Acalabrutinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Accelerated BEP": {
        "brands": [
            "Blenoxane",
            "Vepesid",
            "Platinol"
        ],
        "cancers": [
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Bleomycin",
            "Etoposide",
            "Cisplatin"
        ],
        "regimen": "Accelerated BEP",
        "regimen_names": [
            "Accelerated BEP"
        ],
        "regimen_type": "Upfront therapy for disseminated disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ado-trastuzumab emtansine monotherapy": {
        "brands": [
            "Kadcyla"
        ],
        "cancers": [
            "ERBB2_(HER2)"
        ],
        "drugs": [
            "Ado-trastuzumab emtansine"
        ],
        "regimen": "Ado-trastuzumab emtansine monotherapy",
        "regimen_names": [
            "Ado-trastuzumab emtansine monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Afatinib & Paclitaxel": {
        "brands": [
            "Gilotrif",
            "Taxol"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Afatinib",
            "Paclitaxel"
        ],
        "regimen": "Afatinib & Paclitaxel",
        "regimen_names": [
            "Afatinib & Paclitaxel"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Afatinib monotherapy": {
        "brands": [
            "Gilotrif"
        ],
        "cancers": [
            "CNS_carcinoma",
            "Head_and_neck_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Afatinib"
        ],
        "regimen": "Afatinib monotherapy",
        "regimen_names": [
            "Afatinib monotherapy"
        ],
        "regimen_type": "Non-small cell lung cancer, EGFR-mutated, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Alectinib monotherapy": {
        "brands": [
            "Alecensa"
        ],
        "cancers": [
            "CNS_carcinoma",
            "CNS_carcinoma",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive"
        ],
        "drugs": [
            "Alectinib"
        ],
        "regimen": "Alectinib monotherapy",
        "regimen_names": [
            "Alectinib monotherapy"
        ],
        "regimen_type": "Non-small cell lung cancer, ALK-mutated, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Alemtuzumab & Methylprednisolone": {
        "brands": [
            "Campath",
            "Solumedrol"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Alemtuzumab",
            "Methylprednisolone"
        ],
        "regimen": "Alemtuzumab & Methylprednisolone",
        "regimen_names": [
            "Alemtuzumab & Methylprednisolone"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Alemtuzumab & Rituximab": {
        "brands": [
            "Campath",
            "Rituxan",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Alemtuzumab",
            "Rituximab",
            "Rituximab"
        ],
        "regimen": "Alemtuzumab & Rituximab",
        "regimen_names": [
            "Alemtuzumab & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Alemtuzumab monotherapy": {
        "brands": [
            "Campath"
        ],
        "cancers": [
            "Adult_T-cell_leukemia-lymphoma",
            "Autoimmune_cytopenias",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Cutaneous_T-cell_lymphoma",
            "Hypereosinophilic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Alemtuzumab"
        ],
        "regimen": "Alemtuzumab monotherapy",
        "regimen_names": [
            "Alemtuzumab monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Altretamine monotherapy": {
        "brands": [
            "Hexalen"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Altretamine"
        ],
        "regimen": "Altretamine monotherapy",
        "regimen_names": [
            "Altretamine monotherapy"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Amrubicin monotherapy": {
        "brands": [
            "Calsed"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Amrubicin"
        ],
        "regimen": "Amrubicin monotherapy",
        "regimen_names": [
            "Amrubicin monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Anagrelide monotherapy": {
        "brands": [
            "Agrylin"
        ],
        "cancers": [
            "Polycythemia_vera"
        ],
        "drugs": [
            "Anagrelide"
        ],
        "regimen": "Anagrelide monotherapy",
        "regimen_names": [
            "Anagrelide monotherapy"
        ],
        "regimen_type": "Relapsed, refractory, or intolerant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Anakinra monotherapy": {
        "brands": [
            "Kineret"
        ],
        "cancers": [
            "Castleman_disease"
        ],
        "drugs": [
            "Anakinra"
        ],
        "regimen": "Anakinra monotherapy",
        "regimen_names": [
            "Anakinra monotherapy"
        ],
        "regimen_type": "HHV-8-negative/\"Idiopathic\" multicentric Castleman disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Apixaban monotherapy": {
        "brands": [
            "Eliquis"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Apixaban"
        ],
        "regimen": "Apixaban monotherapy",
        "regimen_names": [
            "Apixaban monotherapy"
        ],
        "regimen_type": "VTE primary prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Argatroban monotherapy": {
        "brands": [
            "Acova",
            "Acova",
            "Acova"
        ],
        "cancers": [
            "Heparin-induced_thrombocytopenia_(HIT)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Argatroban",
            "Argatroban",
            "Argatroban"
        ],
        "regimen": "Argatroban monotherapy",
        "regimen_names": [
            "Argatroban monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide & ATRA": {
        "brands": [
            "Trisenox",
            "ATRA"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Arsenic trioxide",
            "All-trans retinoic acid"
        ],
        "regimen": "Arsenic trioxide & ATRA",
        "regimen_names": [
            "Arsenic trioxide & ATRA"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide & Chlorambucil": {
        "brands": [
            "Trisenox",
            "Leukeran"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Arsenic trioxide",
            "Chlorambucil"
        ],
        "regimen": "Arsenic trioxide & Chlorambucil",
        "regimen_names": [
            "Arsenic trioxide & Chlorambucil"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide & Idarubicin": {
        "brands": [
            "Trisenox",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Arsenic trioxide",
            "Idarubicin"
        ],
        "regimen": "Arsenic trioxide & Idarubicin",
        "regimen_names": [
            "Arsenic trioxide & Idarubicin"
        ],
        "regimen_type": "Relapsed or refractory, salvage induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide monotherapy": {
        "brands": [
            "Trisenox"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Arsenic trioxide"
        ],
        "regimen": "Arsenic trioxide monotherapy",
        "regimen_names": [
            "Arsenic trioxide monotherapy"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide, ATRA, Gemtuzumab ozogamicin": {
        "brands": [
            "Trisenox",
            "ATRA",
            "Mylotarg"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Arsenic trioxide",
            "All-trans retinoic acid",
            "Gemtuzumab ozogamicin"
        ],
        "regimen": "Arsenic trioxide, ATRA, Gemtuzumab ozogamicin",
        "regimen_names": [
            "Arsenic trioxide, ATRA, Gemtuzumab ozogamicin"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide, ATRA, Idarubicin": {
        "brands": [
            "Trisenox",
            "ATRA",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Arsenic trioxide",
            "All-trans retinoic acid",
            "Idarubicin"
        ],
        "regimen": "Arsenic trioxide, ATRA, Idarubicin",
        "regimen_names": [
            "Arsenic trioxide, ATRA, Idarubicin"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Arsenic trioxide, then ATRA & Daunorubicin": {
        "brands": [
            "Trisenox"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Arsenic trioxide"
        ],
        "regimen": "Arsenic trioxide, then ATRA & Daunorubicin",
        "regimen_names": [
            "Arsenic trioxide, then ATRA & Daunorubicin"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "AspaMetDex": {
        "brands": [
            "Elspar",
            "Erwinaze",
            "MTX",
            "Decadron"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Asparaginase",
            "Asparaginase Erwinia chrysanthemi",
            "Methotrexate",
            "Dexamethasone"
        ],
        "regimen": "AspaMetDex",
        "regimen_names": [
            "AspaMetDex"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Aspirin & Anagrelide": {
        "brands": [
            "Aspirin",
            "Agrylin"
        ],
        "cancers": [
            "Essential_thrombocythemia",
            "Essential_thrombocythemia",
            "Essential_thrombocythemia"
        ],
        "drugs": [
            "Aspirin",
            "Anagrelide"
        ],
        "regimen": "Aspirin & Anagrelide",
        "regimen_names": [
            "Aspirin  and  Anagrelide",
            "Aspirin & Anagrelide",
            "Aspirin + Anagrelide",
            "Aspirin / Anagrelide",
            "Aspirin and Anagrelide",
            "Aspirin+Anagrelide",
            "Aspirin/Anagrelide"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Aspirin & Hydroxyurea": {
        "brands": [
            "Aspirin",
            "Hydrea"
        ],
        "cancers": [
            "Essential_thrombocythemia",
            "Essential_thrombocythemia",
            "Essential_thrombocythemia"
        ],
        "drugs": [
            "Aspirin",
            "Hydroxyurea"
        ],
        "regimen": "Aspirin & Hydroxyurea",
        "regimen_names": [
            "Aspirin & Hydroxyurea"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Aspirin monotherapy": {
        "brands": [
            "Aspirin"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Aspirin"
        ],
        "regimen": "Aspirin monotherapy",
        "regimen_names": [
            "Aspirin monotherapy"
        ],
        "regimen_type": "VTE primary prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Atezolizumab & Bevacizumab": {
        "brands": [
            "Tecentriq",
            "Avastin"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Atezolizumab",
            "Bevacizumab"
        ],
        "regimen": "Atezolizumab & Bevacizumab",
        "regimen_names": [
            "Atezolizumab & Bevacizumab"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Atezolizumab monotherapy": {
        "brands": [
            "Tecentriq"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Atezolizumab"
        ],
        "regimen": "Atezolizumab monotherapy",
        "regimen_names": [
            "Atezolizumab monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Axicabtagene ciloleucel monotherapy": {
        "brands": [
            "Yescarta"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Transformed_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Axicabtagene ciloleucel"
        ],
        "regimen": "Axicabtagene ciloleucel monotherapy",
        "regimen_names": [
            "Axicabtagene ciloleucel monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Axitinib & TACE": {
        "brands": [
            "Inlyta",
            "TACE"
        ],
        "cancers": [
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "Axitinib",
            "TACE"
        ],
        "regimen": "Axitinib & TACE",
        "regimen_names": [
            "Axitinib  and  TACE",
            "Axitinib & TACE",
            "Axitinib + TACE",
            "Axitinib / TACE",
            "Axitinib and TACE",
            "Axitinib+TACE",
            "Axitinib/TACE"
        ],
        "regimen_type": "Local therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Axitinib monotherapy": {
        "brands": [
            "Inlyta"
        ],
        "cancers": [
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Axitinib"
        ],
        "regimen": "Axitinib monotherapy",
        "regimen_names": [
            "Axitinib monotherapy"
        ],
        "regimen_type": "Metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Azacitidine & Gemtuzumab ozogamicin": {
        "brands": [
            "Vidaza",
            "Mylotarg"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Azacitidine",
            "Gemtuzumab ozogamicin"
        ],
        "regimen": "Azacitidine & Gemtuzumab ozogamicin",
        "regimen_names": [
            "Azacitidine & Gemtuzumab ozogamicin"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Azacitidine & Lenalidomide": {
        "brands": [
            "Vidaza",
            "Revlimid"
        ],
        "cancers": [
            "Chronic_myelomonocytic_leukemia",
            "Chronic_myelomonocytic_leukemia",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Azacitidine",
            "Lenalidomide"
        ],
        "regimen": "Azacitidine & Lenalidomide",
        "regimen_names": [
            "Azacitidine & Lenalidomide"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Azacitidine & Sorafenib": {
        "brands": [
            "Vidaza",
            "Nexavar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_FLT3-positive",
            "Acute_myeloid_leukemia_FLT3-positive"
        ],
        "drugs": [
            "Azacitidine",
            "Sorafenib"
        ],
        "regimen": "Azacitidine & Sorafenib",
        "regimen_names": [
            "Azacitidine & Sorafenib"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Azacitidine & Vorinostat": {
        "brands": [
            "Vidaza",
            "Zolinza"
        ],
        "cancers": [
            "Chronic_myelomonocytic_leukemia",
            "Chronic_myelomonocytic_leukemia",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Azacitidine",
            "Vorinostat"
        ],
        "regimen": "Azacitidine & Vorinostat",
        "regimen_names": [
            "Azacitidine & Vorinostat"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Azacitidine monotherapy": {
        "brands": [
            "Vidaza"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Chronic_myelomonocytic_leukemia",
            "Chronic_myelomonocytic_leukemia",
            "Chronic_myelomonocytic_leukemia",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Azacitidine"
        ],
        "regimen": "Azacitidine monotherapy",
        "regimen_names": [
            "Azacitidine monotherapy"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BBD": {
        "brands": [
            "Bendamustine",
            "Velcade",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bendamustine",
            "Bortezomib",
            "Dexamethasone"
        ],
        "regimen": "BBD",
        "regimen_names": [
            "BBD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BCHOP": {
        "brands": [
            "Velcade",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Millipred"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisolone"
        ],
        "regimen": "BCHOP",
        "regimen_names": [
            "BCHOP"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BCNU/TT": {
        "brands": [
            "BiCNU",
            "Thioplex"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Carmustine",
            "Thiotepa"
        ],
        "regimen": "BCNU/TT",
        "regimen_names": [
            "BCNU/TT",
            "BCNUTT"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BCNU/TT, then auto HSCT": {
        "brands": [
            "BiCNU",
            "Thioplex"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Carmustine",
            "Thiotepa"
        ],
        "regimen": "BCNU/TT, then auto HSCT",
        "regimen_names": [
            "BCNU/TT",
            "BCNU/TT, then auto HSCT",
            "BCNUTT"
        ],
        "regimen_type": "Consolidation and/or maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BDR": {
        "brands": [
            "Velcade",
            "Rituxan",
            "Decadron"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Bortezomib",
            "Rituximab",
            "Dexamethasone"
        ],
        "regimen": "BDR",
        "regimen_names": [
            "BDR",
            "BORID"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BEAC": {
        "brands": [
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Cytoxan"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Cyclophosphamide"
        ],
        "regimen": "BEAC",
        "regimen_names": [
            "BEAC"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BEACOPP": {
        "brands": [
            "Blenoxane",
            "Vepesid",
            "Adriamycin",
            "Cytoxan",
            "Oncovin",
            "Matulane",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Bleomycin",
            "Etoposide",
            "Doxorubicin",
            "Cyclophosphamide",
            "Vincristine",
            "Procarbazine",
            "Prednisone"
        ],
        "regimen": "BEACOPP",
        "regimen_names": [
            "BEACOPP"
        ],
        "regimen_type": "Untreated, early-stage unfavorable (ESU)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BEACOPP-14": {
        "brands": [
            "Blenoxane",
            "Vepesid",
            "Adriamycin",
            "Cytoxan",
            "Oncovin",
            "Matulane",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Bleomycin",
            "Etoposide",
            "Doxorubicin",
            "Cyclophosphamide",
            "Vincristine",
            "Procarbazine",
            "Prednisone"
        ],
        "regimen": "BEACOPP-14",
        "regimen_names": [
            "BEACOPP-14",
            "BEACOPP/14",
            "BEACOPP14"
        ],
        "regimen_type": "Untreated, advanced stage",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BEAM": {
        "brands": [
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "BEAM",
        "regimen_names": [
            "BEAM"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BEAM, then auto HSCT": {
        "brands": [
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "BEAM, then auto HSCT",
        "regimen_names": [
            "BEAM",
            "BEAM, then auto HSCT"
        ],
        "regimen_type": "Consolidation and/or maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BEP": {
        "brands": [
            "Blenoxane",
            "Vepesid",
            "Platinol"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Bleomycin",
            "Etoposide",
            "Cisplatin"
        ],
        "regimen": "BEP",
        "regimen_names": [
            "BEP",
            "PEB"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BFR": {
        "brands": [
            "Bendamustine",
            "Fludara",
            "Rituxan"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Bendamustine",
            "Fludarabine",
            "Rituximab"
        ],
        "regimen": "BFR",
        "regimen_names": [
            "BFR"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BLD": {
        "brands": [
            "Bendamustine",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bendamustine",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "BLD",
        "regimen_names": [
            "BLD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BMP": {
        "brands": [
            "Blenoxane",
            "MTX",
            "Platinol"
        ],
        "cancers": [
            "Penile_cancer",
            "Penile_cancer",
            "Penile_cancer",
            "Penile_cancer"
        ],
        "drugs": [
            "Bleomycin",
            "Methotrexate",
            "Cisplatin"
        ],
        "regimen": "BMP",
        "regimen_names": [
            "BMP",
            "MPB"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BO": {
        "brands": [
            "Blenoxane",
            "Oncovin"
        ],
        "cancers": [
            "Testicular_cancer"
        ],
        "drugs": [
            "Bleomycin",
            "Vincristine"
        ],
        "regimen": "BO",
        "regimen_names": [
            "BO"
        ],
        "regimen_type": "Upfront therapy for disseminated disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BR": {
        "brands": [
            "Bendamustine",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Cold_agglutinin_disease",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Hairy_cell_leukemia",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Bendamustine",
            "Rituximab"
        ],
        "regimen": "BR",
        "regimen_names": [
            "BR",
            "R-B",
            "R/B"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BR & Ibrutinib": {
        "brands": [
            "Bendamustine",
            "Rituxan",
            "Imbruvica"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Bendamustine",
            "Rituximab",
            "Ibrutinib"
        ],
        "regimen": "BR & Ibrutinib",
        "regimen_names": [
            "BR  and  Ibrutinib",
            "BR & Ibrutinib",
            "BR + Ibrutinib",
            "BR / Ibrutinib",
            "BR and Ibrutinib",
            "BR+Ibrutinib",
            "BR/Ibrutinib",
            "IBR"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BR & Idelalisib": {
        "brands": [
            "Bendamustine",
            "Rituxan",
            "Zydelig"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Bendamustine",
            "Rituximab",
            "Idelalisib"
        ],
        "regimen": "BR & Idelalisib",
        "regimen_names": [
            "BR  and  Idelalisib",
            "BR & Idelalisib",
            "BR + Idelalisib",
            "BR / Idelalisib",
            "BR and Idelalisib",
            "BR+Idelalisib",
            "BR/Idelalisib"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BTD": {
        "brands": [
            "Bendamustine",
            "Thalomid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bendamustine",
            "Thalidomide",
            "Dexamethasone"
        ],
        "regimen": "BTD",
        "regimen_names": [
            "BTD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BV-CHP": {
        "brands": [
            "Adcetris",
            "Cytoxan",
            "Adriamycin",
            "Sterapred"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Brentuximab vedotin",
            "Cyclophosphamide",
            "Doxorubicin",
            "Prednisone"
        ],
        "regimen": "BV-CHP",
        "regimen_names": [
            "BV-CHP",
            "BV/CHP",
            "BVCHP"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BVB": {
        "brands": [
            "Adcetris",
            "Bendamustine"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Brentuximab vedotin",
            "Bendamustine"
        ],
        "regimen": "BVB",
        "regimen_names": [
            "BVB"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BVR": {
        "brands": [
            "Velcade",
            "Bendamustine",
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Bendamustine",
            "Rituximab"
        ],
        "regimen": "BVR",
        "regimen_names": [
            "BVR",
            "VBR"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BeEAM": {
        "brands": [
            "Bendamustine",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Bendamustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "BeEAM",
        "regimen_names": [
            "BeEAM"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BeGEV": {
        "brands": [
            "Bendamustine",
            "Gemzar",
            "Navelbine",
            "Millipred"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Bendamustine",
            "Gemcitabine",
            "Vinorelbine",
            "Prednisolone"
        ],
        "regimen": "BeGEV",
        "regimen_names": [
            "BeGEV"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BeRT": {
        "brands": [
            "Bendamustine",
            "Rituxan",
            "Torisel"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Bendamustine",
            "Rituximab",
            "Temsirolimus"
        ],
        "regimen": "BeRT",
        "regimen_names": [
            "BeRT"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Belinostat monotherapy": {
        "brands": [
            "Beleodaq"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Belinostat"
        ],
        "regimen": "Belinostat monotherapy",
        "regimen_names": [
            "Belinostat monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Belotecan & Cisplatin": {
        "brands": [
            "Camptobell",
            "Platinol"
        ],
        "cancers": [
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Belotecan",
            "Cisplatin"
        ],
        "regimen": "Belotecan & Cisplatin",
        "regimen_names": [
            "Belotecan & Cisplatin"
        ],
        "regimen_type": "Extensive stage, induction",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bendamustine & Obinutuzumab": {
        "brands": [
            "Gazyva",
            "Bendamustine"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Obinutuzumab",
            "Bendamustine"
        ],
        "regimen": "Bendamustine & Obinutuzumab",
        "regimen_names": [
            "Bendamustine & Obinutuzumab",
            "G-B",
            "G/B"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bendamustine & Ofatumumab": {
        "brands": [
            "Bendamustine",
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Bendamustine",
            "Ofatumumab"
        ],
        "regimen": "Bendamustine & Ofatumumab",
        "regimen_names": [
            "BendOfa",
            "Bendamustine & Ofatumumab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bendamustine monotherapy": {
        "brands": [
            "Bendamustine"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Cutaneous_T-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Marginal_zone_lymphoma",
            "Peripheral_T-cell_lymphoma",
            "Small_cell_lung_cancer",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Bendamustine"
        ],
        "regimen": "Bendamustine monotherapy",
        "regimen_names": [
            "Bendamustine monotherapy"
        ],
        "regimen_type": "Low-dose conditioning regimens for cellular therapy, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Betrixaban monotherapy": {
        "brands": [
            "Bevyxxa"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Betrixaban"
        ],
        "regimen": "Betrixaban monotherapy",
        "regimen_names": [
            "Betrixaban monotherapy"
        ],
        "regimen_type": "VTE primary prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bevacizumab & RT": {
        "brands": [
            "Avastin",
            "External beam radiotherapy"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Bevacizumab",
            "External beam radiotherapy"
        ],
        "regimen": "Bevacizumab & RT",
        "regimen_names": [
            "Bevacizumab  and  RT",
            "Bevacizumab & RT",
            "Bevacizumab + RT",
            "Bevacizumab / RT",
            "Bevacizumab and RT",
            "Bevacizumab+RT",
            "Bevacizumab/RT"
        ],
        "regimen_type": "Adjuvant therapy, standard patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bevacizumab & Rituximab": {
        "brands": [
            "Avastin",
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Bevacizumab",
            "Rituximab"
        ],
        "regimen": "Bevacizumab & Rituximab",
        "regimen_names": [
            "Bevacizumab & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bevacizumab monotherapy": {
        "brands": [
            "Avastin"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Breast_cancer",
            "Cervical_cancer",
            "Colon_cancer",
            "Endometrial_cancer",
            "Glioblastoma",
            "Glioblastoma",
            "Hepatocellular_carcinoma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Small_cell_lung_cancer",
            "Vascular_sarcoma",
            "Vascular_sarcoma"
        ],
        "drugs": [
            "Bevacizumab"
        ],
        "regimen": "Bevacizumab monotherapy",
        "regimen_names": [
            "Bevacizumab monotherapy"
        ],
        "regimen_type": "Recurrent disease, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bexarotene & Pralatrexate": {
        "brands": [
            "Targretin",
            "Folotyn"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma"
        ],
        "drugs": [
            "Bexarotene",
            "Pralatrexate"
        ],
        "regimen": "Bexarotene & Pralatrexate",
        "regimen_names": [
            "Bexarotene & Pralatrexate"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bexarotene monotherapy": {
        "brands": [
            "Targretin"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma"
        ],
        "drugs": [
            "Bexarotene"
        ],
        "regimen": "Bexarotene monotherapy",
        "regimen_names": [
            "Bexarotene monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Binimetinib & Encorafenib": {
        "brands": [
            "Mektovi",
            "Braftovi"
        ],
        "cancers": [
            "Melanoma_BRAF-mutated"
        ],
        "drugs": [
            "Binimetinib",
            "Encorafenib"
        ],
        "regimen": "Binimetinib & Encorafenib",
        "regimen_names": [
            "Binimetinib & Encorafenib"
        ],
        "regimen_type": "Advanced or metastatic disease, BRAF inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Binimetinib monotherapy": {
        "brands": [
            "Mektovi"
        ],
        "cancers": [
            "Melanoma_NRAS-mutated"
        ],
        "drugs": [
            "Binimetinib"
        ],
        "regimen": "Binimetinib monotherapy",
        "regimen_names": [
            "Binimetinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, TKI-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bivalirudin monotherapy": {
        "brands": [
            "Angiomax"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Bivalirudin"
        ],
        "regimen": "Bivalirudin monotherapy",
        "regimen_names": [
            "Bivalirudin monotherapy"
        ],
        "regimen_type": "VTE treatment, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bleomycin & Cisplatin": {
        "brands": [
            "Platinol",
            "Blenoxane"
        ],
        "cancers": [
            "Cutaneous_basal_cell_carcinoma",
            "Cutaneous_squamous_cell_carcinoma"
        ],
        "drugs": [
            "Cisplatin",
            "Bleomycin"
        ],
        "regimen": "Bleomycin & Cisplatin",
        "regimen_names": [
            "Bleomycin & Cisplatin"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Blinatumomab monotherapy": {
        "brands": [
            "Blincyto"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Blinatumomab"
        ],
        "regimen": "Blinatumomab monotherapy",
        "regimen_names": [
            "Blinatumomab monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Cyclophosphamide": {
        "brands": [
            "Velcade",
            "Cytoxan"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Cyclophosphamide"
        ],
        "regimen": "Bortezomib & Cyclophosphamide",
        "regimen_names": [
            "Bortezomib & Cyclophosphamide"
        ],
        "regimen_type": "Maintenance after second-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Dexamethasone": {
        "brands": [
            "Velcade",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Dexamethasone"
        ],
        "regimen": "Bortezomib & Dexamethasone",
        "regimen_names": [
            "Bortezomib & Dexamethasone"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Doxorubicin liposomal": {
        "brands": [
            "Velcade",
            "Doxil"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Pegylated liposomal doxorubicin"
        ],
        "regimen": "Bortezomib & Doxorubicin liposomal",
        "regimen_names": [
            "Bortezomib & Doxorubicin liposomal"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Melphalan": {
        "brands": [
            "Velcade",
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Bortezomib",
            "Melphalan"
        ],
        "regimen": "Bortezomib & Melphalan",
        "regimen_names": [
            "Bor-HDM",
            "Bor/HDM",
            "BorHDM",
            "Bortezomib & Melphalan"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Melphalan, then auto HSCT": {
        "brands": [
            "Velcade",
            "Alkeran"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Bortezomib",
            "Melphalan"
        ],
        "regimen": "Bortezomib & Melphalan, then auto HSCT",
        "regimen_names": [
            "Bortezomib & Melphalan, then auto HSCT"
        ],
        "regimen_type": "Consolidation after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Panobinostat": {
        "brands": [
            "Velcade",
            "Farydak"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Panobinostat"
        ],
        "regimen": "Bortezomib & Panobinostat",
        "regimen_names": [
            "Bortezomib & Panobinostat"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib & Vorinostat": {
        "brands": [
            "Velcade",
            "Zolinza"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Vorinostat"
        ],
        "regimen": "Bortezomib & Vorinostat",
        "regimen_names": [
            "Bortezomib & Vorinostat"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib monotherapy": {
        "brands": [
            "Velcade"
        ],
        "cancers": [
            "Castleman_disease",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Multiple_myeloma_consolidation_and_maintenance",
            "Multiple_myeloma_consolidation_and_maintenance",
            "Multiple_myeloma_consolidation_and_maintenance",
            "Multiple_myeloma_consolidation_and_maintenance",
            "Multiple_myeloma_consolidation_and_maintenance",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Bortezomib"
        ],
        "regimen": "Bortezomib monotherapy",
        "regimen_names": [
            "Bortezomib monotherapy"
        ],
        "regimen_type": "HHV-8-negative/\"Idiopathic\" multicentric Castleman disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib, Thalidomide, Dexamethasone, Panobinostat": {
        "brands": [
            "Velcade",
            "Thalomid",
            "Decadron",
            "Farydak"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Thalidomide",
            "Dexamethasone",
            "Panobinostat"
        ],
        "regimen": "Bortezomib, Thalidomide, Dexamethasone, Panobinostat",
        "regimen_names": [
            "Bortezomib, Thalidomide, Dexamethasone, Panobinostat"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bortezomib-HyperCAD": {
        "brands": [
            "Velcade",
            "Cytoxan",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Cyclophosphamide",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "Bortezomib-HyperCAD",
        "regimen_names": [
            "Bortezomib-HyperCAD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bosutinib monotherapy": {
        "brands": [
            "Bosulif"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Bosutinib"
        ],
        "regimen": "Bosutinib monotherapy",
        "regimen_names": [
            "Bosutinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Brentuximab vedotin & Dacarbazine": {
        "brands": [
            "Adcetris",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Brentuximab vedotin",
            "Dacarbazine"
        ],
        "regimen": "Brentuximab vedotin & Dacarbazine",
        "regimen_names": [
            "Brentuximab vedotin & Dacarbazine"
        ],
        "regimen_type": "Untreated, elderly",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Brentuximab vedotin & Nivolumab": {
        "brands": [
            "Adcetris",
            "Opdivo"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Brentuximab vedotin",
            "Nivolumab"
        ],
        "regimen": "Brentuximab vedotin & Nivolumab",
        "regimen_names": [
            "Brentuximab vedotin & Nivolumab"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Brentuximab vedotin monotherapy": {
        "brands": [
            "Adcetris"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Cutaneous_T-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Mediastinal_gray-zone_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Brentuximab vedotin"
        ],
        "regimen": "Brentuximab vedotin monotherapy",
        "regimen_names": [
            "Brentuximab vedotin monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Brigatinib monotherapy": {
        "brands": [
            "Alunbrig"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_ALK-positive"
        ],
        "drugs": [
            "Brigatinib"
        ],
        "regimen": "Brigatinib monotherapy",
        "regimen_names": [
            "Brigatinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, ALK inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bu/TT": {
        "brands": [
            "Myleran",
            "Thioplex"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Busulfan",
            "Thiotepa"
        ],
        "regimen": "Bu/TT",
        "regimen_names": [
            "Bu/TT",
            "BuTT"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bu/TT, then auto HSCT": {
        "brands": [
            "Myleran",
            "Thioplex"
        ],
        "cancers": [
            "CNS_lymphoma"
        ],
        "drugs": [
            "Busulfan",
            "Thiotepa"
        ],
        "regimen": "Bu/TT, then auto HSCT",
        "regimen_names": [
            "Bu/TT",
            "Bu/TT, then auto HSCT",
            "BuTT"
        ],
        "regimen_type": "Consolidation and/or maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bu/TT/Cy": {
        "brands": [
            "Thioplex",
            "Myleran",
            "Cytoxan"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Thiotepa",
            "Busulfan",
            "Cyclophosphamide"
        ],
        "regimen": "Bu/TT/Cy",
        "regimen_names": [
            "Bu/TT/Cy",
            "BuTTCy",
            "TBC"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Bu/TT/Cy, then auto HSCT": {
        "brands": [
            "Myleran",
            "Thioplex",
            "Cytoxan"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Busulfan",
            "Thiotepa",
            "Cyclophosphamide"
        ],
        "regimen": "Bu/TT/Cy, then auto HSCT",
        "regimen_names": [
            "Bu/TT/Cy",
            "Bu/TT/Cy, then auto HSCT",
            "BuTTCy"
        ],
        "regimen_type": "Consolidation and/or maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "BuCyTBI": {
        "brands": [
            "Myleran",
            "Cytoxan",
            "External beam radiotherapy"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Busulfan",
            "Cyclophosphamide",
            "External beam radiotherapy"
        ],
        "regimen": "BuCyTBI",
        "regimen_names": [
            "BuCyTBI"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Busulfan & Cyclophosphamide": {
        "brands": [
            "Myleran",
            "Cytoxan"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Busulfan",
            "Cyclophosphamide"
        ],
        "regimen": "Busulfan & Cyclophosphamide",
        "regimen_names": [
            "BuCy",
            "Busulfan & Cyclophosphamide"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Busulfan & Fludarabine": {
        "brands": [
            "Myleran",
            "Fludara"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Busulfan",
            "Fludarabine"
        ],
        "regimen": "Busulfan & Fludarabine",
        "regimen_names": [
            "BuFlu",
            "Busulfan & Fludarabine",
            "Flu/Bu",
            "FluBu"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Busulfan & Melphalan": {
        "brands": [
            "Myleran",
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Busulfan",
            "Melphalan"
        ],
        "regimen": "Busulfan & Melphalan",
        "regimen_names": [
            "BuMel",
            "Busulfan  and  Melphalan",
            "Busulfan & Melphalan",
            "Busulfan + Melphalan",
            "Busulfan / Melphalan",
            "Busulfan and Melphalan",
            "Busulfan+Melphalan",
            "Busulfan/Melphalan"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Busulfan monotherapy": {
        "brands": [
            "Myleran"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Busulfan"
        ],
        "regimen": "Busulfan monotherapy",
        "regimen_names": [
            "Busulfan monotherapy"
        ],
        "regimen_type": "Chronic phase, relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "C-BOP": {
        "brands": [
            "Platinol",
            "Oncovin",
            "Blenoxane",
            "Paraplatin"
        ],
        "cancers": [
            "Testicular_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vincristine",
            "Bleomycin",
            "Carboplatin"
        ],
        "regimen": "C-BOP",
        "regimen_names": [
            "C-BOP",
            "C/BOP",
            "CBOP"
        ],
        "regimen_type": "Upfront therapy for disseminated disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "C-MOPP": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Sterapred",
            "Matulane"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Prednisone",
            "Procarbazine"
        ],
        "regimen": "C-MOPP",
        "regimen_names": [
            "C-MOPP",
            "C/MOPP",
            "CMOPP",
            "COPP"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "C-MOPP/ABV": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Matulane",
            "Sterapred",
            "Adriamycin",
            "Blenoxane",
            "Velban"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Procarbazine",
            "Prednisone",
            "Doxorubicin",
            "Bleomycin",
            "Vinblastine"
        ],
        "regimen": "C-MOPP/ABV",
        "regimen_names": [
            "C-MOPP/ABV",
            "C/MOPP/ABV",
            "CMOPP/ABV"
        ],
        "regimen_type": "Untreated, advanced stage",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CAD & G-CSF": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "CAD & G-CSF",
        "regimen_names": [
            "CAD",
            "CAD  and  G-CSF",
            "CAD & G-CSF",
            "CAD + G-CSF",
            "CAD / G-CSF",
            "CAD and G-CSF",
            "CAD+G-CSF",
            "CAD/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CAPIRI": {
        "brands": [
            "Xeloda",
            "Camptosar"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Irinotecan"
        ],
        "regimen": "CAPIRI",
        "regimen_names": [
            "CAPIRI",
            "CapeIRI",
            "XELIRI"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CAPIRI-Bev": {
        "brands": [
            "Xeloda",
            "Camptosar",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Irinotecan",
            "Bevacizumab"
        ],
        "regimen": "CAPIRI-Bev",
        "regimen_names": [
            "CAPIRI-Bev",
            "CAPIRI/Bev",
            "CAPIRIBev",
            "XELIRI-Bev",
            "XELIRI/Bev",
            "XELIRIBev"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CBV": {
        "brands": [
            "Cytoxan",
            "BiCNU",
            "Vepesid"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Carmustine",
            "Etoposide"
        ],
        "regimen": "CBV",
        "regimen_names": [
            "CBV"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CBV-Mx": {
        "brands": [
            "Cytoxan",
            "BiCNU",
            "Vepesid",
            "Novantrone"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Carmustine",
            "Etoposide",
            "Mitoxantrone"
        ],
        "regimen": "CBV-Mx",
        "regimen_names": [
            "CBV-Mx",
            "CBV/Mx",
            "CBVMx"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CC": {
        "brands": [
            "Leustatin",
            "Cytoxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Cladribine",
            "Cyclophosphamide"
        ],
        "regimen": "CC",
        "regimen_names": [
            "CC"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CF & Trastuzumab": {
        "brands": [
            "Platinol",
            "5-FU",
            "Herceptin"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil",
            "Trastuzumab"
        ],
        "regimen": "CF & Trastuzumab",
        "regimen_names": [
            "CF  and  Trastuzumab",
            "CF & Trastuzumab",
            "CF + Trastuzumab",
            "CF / Trastuzumab",
            "CF and Trastuzumab",
            "CF+Trastuzumab",
            "CF/Trastuzumab"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CFAR": {
        "brands": [
            "Cytoxan",
            "Fludara",
            "Campath",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Fludarabine",
            "Alemtuzumab",
            "Rituximab"
        ],
        "regimen": "CFAR",
        "regimen_names": [
            "CFAR"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHOEP": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Vepesid",
            "Sterapred"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Anaplastic_large_cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Etoposide",
            "Prednisone"
        ],
        "regimen": "CHOEP",
        "regimen_names": [
            "CHOEP"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHOEP-14": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Vepesid",
            "Sterapred"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Etoposide",
            "Prednisone"
        ],
        "regimen": "CHOEP-14",
        "regimen_names": [
            "CHOEP-14",
            "CHOEP/14",
            "CHOEP14"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHOP": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Anaplastic_large_cell_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "CHOP",
        "regimen_names": [
            "CHOP"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHOP & Everolimus": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred",
            "Afinitor"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone",
            "Everolimus"
        ],
        "regimen": "CHOP & Everolimus",
        "regimen_names": [
            "CHOP  and  Everolimus",
            "CHOP & Everolimus",
            "CHOP + Everolimus",
            "CHOP / Everolimus",
            "CHOP and Everolimus",
            "CHOP+Everolimus",
            "CHOP/Everolimus"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHOP-14": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Adult_T-cell_leukemia-lymphoma",
            "Adult_T-cell_leukemia-lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "CHOP-14",
        "regimen_names": [
            "CHOP-14",
            "CHOP-DI",
            "CHOP/14",
            "CHOP/DI",
            "CHOP14",
            "CHOPDI",
            "I-CHOP",
            "I/CHOP",
            "ICHOP"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHOP-AL": {
        "brands": [
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred",
            "Campath"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone",
            "Alemtuzumab"
        ],
        "regimen": "CHOP-AL",
        "regimen_names": [
            "CHOP-AL",
            "CHOP-C",
            "CHOP/AL",
            "CHOP/C",
            "CHOPAL",
            "CHOPC"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CHUT": {
        "brands": [
            "Cytoxan",
            "Thioplex"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Thiotepa"
        ],
        "regimen": "CHUT",
        "regimen_names": [
            "CHUT"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CIA": {
        "brands": [
            "Clolar",
            "Idamycin",
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Clofarabine",
            "Idarubicin",
            "Cytarabine"
        ],
        "regimen": "CIA",
        "regimen_names": [
            "CIA"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CIM": {
        "brands": [
            "Platinol",
            "Ifex"
        ],
        "cancers": [
            "Endometrial_cancer",
            "Endometrial_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Ifosfamide"
        ],
        "regimen": "CIM",
        "regimen_names": [
            "CIM"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CISCA": {
        "brands": [
            "Cytoxan",
            "Platinol",
            "Adriamycin"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Cisplatin",
            "Doxorubicin"
        ],
        "regimen": "CISCA",
        "regimen_names": [
            "CISCA"
        ],
        "regimen_type": "Locally advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CLAG": {
        "brands": [
            "Leustatin",
            "Cytosar",
            "Neupogen"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cladribine",
            "Cytarabine",
            "Filgrastim"
        ],
        "regimen": "CLAG",
        "regimen_names": [
            "CLAG"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CLAG-M": {
        "brands": [
            "Leustatin",
            "Cytosar",
            "Neupogen",
            "Novantrone"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cladribine",
            "Cytarabine",
            "Filgrastim",
            "Mitoxantrone"
        ],
        "regimen": "CLAG-M",
        "regimen_names": [
            "CLAG-M",
            "CLAG/M",
            "CLAGM"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CLARA": {
        "brands": [
            "Clolar",
            "Cytosar",
            "Neupogen"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Clofarabine",
            "Cytarabine",
            "Filgrastim"
        ],
        "regimen": "CLARA",
        "regimen_names": [
            "CLARA"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CLF": {
        "brands": [
            "Platinol",
            "Leucovorin",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Folinic acid",
            "Fluorouracil"
        ],
        "regimen": "CLF",
        "regimen_names": [
            "CLF",
            "PLF"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CMC": {
        "brands": [
            "Leustatin",
            "Novantrone",
            "Cytoxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Cladribine",
            "Mitoxantrone",
            "Cyclophosphamide"
        ],
        "regimen": "CMC",
        "regimen_names": [
            "CMC"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CMED": {
        "brands": [
            "Cytoxan",
            "MTX",
            "Vepesid",
            "Decadron"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Methotrexate",
            "Etoposide",
            "Dexamethasone"
        ],
        "regimen": "CMED",
        "regimen_names": [
            "CMED"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CMF": {
        "brands": [
            "Cytoxan",
            "MTX",
            "5-FU"
        ],
        "cancers": [
            "Breast_cancer_triple_negative",
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Methotrexate",
            "Fluorouracil"
        ],
        "regimen": "CMF",
        "regimen_names": [
            "CMF"
        ],
        "regimen_type": "Adjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CODOX-M": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Adriamycin",
            "MTX"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Doxorubicin",
            "Methotrexate"
        ],
        "regimen": "CODOX-M",
        "regimen_names": [
            "CODOX-M",
            "CODOX/M",
            "CODOXM"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CODOX-M/IVAC": {
        "brands": [
            "Cytosar",
            "MTX",
            "Cytosar",
            "MTX"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Cytarabine",
            "Methotrexate",
            "Cytarabine",
            "Methotrexate"
        ],
        "regimen": "CODOX-M/IVAC",
        "regimen_names": [
            "CODOX-M/IVAC"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "COPDAC": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Sterapred",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Prednisone",
            "Dacarbazine"
        ],
        "regimen": "COPDAC",
        "regimen_names": [
            "COPDAC"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CPD": {
        "brands": [
            "Kyprolis",
            "Pomalyst",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Carfilzomib",
            "Pomalidomide",
            "Dexamethasone"
        ],
        "regimen": "CPD",
        "regimen_names": [
            "CPD",
            "KPD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CPR": {
        "brands": [
            "Cytoxan",
            "Sterapred",
            "Revlimid"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Prednisone",
            "Lenalidomide"
        ],
        "regimen": "CPR",
        "regimen_names": [
            "CPR"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CPX-351 monotherapy": {
        "brands": [
            "Vyxeos"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine and daunorubicin liposomal"
        ],
        "regimen": "CPX-351 monotherapy",
        "regimen_names": [
            "CPX-351",
            "CPX-351 monotherapy",
            "CPX/351",
            "CPX351"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CRD (Cyclophosphamide)": {
        "brands": [
            "Cytoxan",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "CRD (Cyclophosphamide)",
        "regimen_names": [
            "CRD",
            "CRD (Cyclophosphamide)"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CRd (Carfilzomib)": {
        "brands": [
            "Kyprolis",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Carfilzomib",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "CRd (Carfilzomib)",
        "regimen_names": [
            "CRd",
            "CRd (Carfilzomib)",
            "KRd"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CRd (Cyclophosphamide)": {
        "brands": [
            "Cytoxan",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "CRd (Cyclophosphamide)",
        "regimen_names": [
            "CRd",
            "CRd (Cyclophosphamide)",
            "LDC",
            "RdC"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CTCb": {
        "brands": [
            "Cytoxan",
            "Thioplex",
            "Paraplatin"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Thiotepa",
            "Carboplatin"
        ],
        "regimen": "CTCb",
        "regimen_names": [
            "CTCb"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CTD": {
        "brands": [
            "Cytoxan",
            "Thalomid",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Thalidomide",
            "Dexamethasone"
        ],
        "regimen": "CTD",
        "regimen_names": [
            "CTD"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CVAD": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "CVAD",
        "regimen_names": [
            "CVAD"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CVD (Vinblastine)": {
        "brands": [
            "Platinol",
            "Velban",
            "DTIC"
        ],
        "cancers": [
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma"
        ],
        "drugs": [
            "Cisplatin",
            "Vinblastine",
            "Dacarbazine"
        ],
        "regimen": "CVD (Vinblastine)",
        "regimen_names": [
            "CVD",
            "CVD (Vinblastine)"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CVD (Vindesine)": {
        "brands": [
            "Platinol",
            "Eldisine",
            "DTIC"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Cisplatin",
            "Vindesine",
            "Dacarbazine"
        ],
        "regimen": "CVD (Vindesine)",
        "regimen_names": [
            "CVD",
            "CVD (Vindesine)"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CVP": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Millipred"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Prednisolone"
        ],
        "regimen": "CVP",
        "regimen_names": [
            "CVP"
        ],
        "regimen_type": "First-line therapy, pre-phase",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CX": {
        "brands": [
            "Xeloda",
            "Platinol"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Cisplatin"
        ],
        "regimen": "CX",
        "regimen_names": [
            "CX"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CX & Trastuzumab": {
        "brands": [
            "Platinol",
            "Xeloda",
            "Herceptin"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Capecitabine",
            "Trastuzumab"
        ],
        "regimen": "CX & Trastuzumab",
        "regimen_names": [
            "CX  and  Trastuzumab",
            "CX & Trastuzumab",
            "CX + Trastuzumab",
            "CX / Trastuzumab",
            "CX and Trastuzumab",
            "CX+Trastuzumab",
            "CX/Trastuzumab"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CX-C": {
        "brands": [
            "Platinol",
            "Xeloda",
            "Erbitux"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Capecitabine",
            "Cetuximab"
        ],
        "regimen": "CX-C",
        "regimen_names": [
            "CX-C",
            "CX/C",
            "CXC"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CYM": {
        "brands": [
            "Cytosar",
            "MTX"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Cytarabine",
            "Methotrexate"
        ],
        "regimen": "CYM",
        "regimen_names": [
            "CYM"
        ],
        "regimen_type": "Upfront therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CYVE": {
        "brands": [
            "Cytosar",
            "Vepesid"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Autologous_HSCT",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Cytarabine",
            "Etoposide"
        ],
        "regimen": "CYVE",
        "regimen_names": [
            "CYVE"
        ],
        "regimen_type": "Consolidation after salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CYVE & G-CSF": {
        "brands": [
            "Cytosar",
            "Vepesid"
        ],
        "cancers": [
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Cytarabine",
            "Etoposide"
        ],
        "regimen": "CYVE & G-CSF",
        "regimen_names": [
            "CYVE  and  G-CSF",
            "CYVE & G-CSF",
            "CYVE + G-CSF",
            "CYVE / G-CSF",
            "CYVE and G-CSF",
            "CYVE+G-CSF",
            "CYVE/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CaRD": {
        "brands": [
            "Kyprolis",
            "Rituxan",
            "Decadron"
        ],
        "cancers": [
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Carfilzomib",
            "Rituximab",
            "Dexamethasone"
        ],
        "regimen": "CaRD",
        "regimen_names": [
            "CaRD"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cabozantinib & Erlotinib": {
        "brands": [
            "Cometriq",
            "Tarceva"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cabozantinib",
            "Erlotinib"
        ],
        "regimen": "Cabozantinib & Erlotinib",
        "regimen_names": [
            "Cabozantinib & Erlotinib"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cabozantinib monotherapy": {
        "brands": [
            "Cometriq"
        ],
        "cancers": [
            "Hepatocellular_carcinoma",
            "Non-small_cell_lung_cancer",
            "Prostate_cancer",
            "Prostate_cancer",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Cabozantinib"
        ],
        "regimen": "Cabozantinib monotherapy",
        "regimen_names": [
            "Cabozantinib monotherapy"
        ],
        "regimen_type": "Subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CapeOx": {
        "brands": [
            "Xeloda",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Hepatocellular_carcinoma",
            "Pancreatic_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Oxaliplatin"
        ],
        "regimen": "CapeOx",
        "regimen_names": [
            "CAPOX",
            "CapeOX",
            "CapeOx",
            "XELOX"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CapeOx & Bevacizumab": {
        "brands": [
            "Xeloda",
            "Eloxatin",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "Capecitabine",
            "Oxaliplatin",
            "Bevacizumab"
        ],
        "regimen": "CapeOx & Bevacizumab",
        "regimen_names": [
            "CAPOX-B",
            "CAPOX/B",
            "CAPOXB",
            "CapeOX  and  Bevacizumab",
            "CapeOX & Bevacizumab",
            "CapeOX + Bevacizumab",
            "CapeOX / Bevacizumab",
            "CapeOX and Bevacizumab",
            "CapeOX+Bevacizumab",
            "CapeOX/Bevacizumab",
            "CapeOx  and  Bevacizumab",
            "CapeOx & Bevacizumab",
            "CapeOx + Bevacizumab",
            "CapeOx / Bevacizumab",
            "CapeOx and Bevacizumab",
            "CapeOx+Bevacizumab",
            "CapeOx/Bevacizumab",
            "XELOX  and  Bevacizumab",
            "XELOX & Bevacizumab",
            "XELOX + Bevacizumab",
            "XELOX / Bevacizumab",
            "XELOX and Bevacizumab",
            "XELOX+Bevacizumab",
            "XELOX/Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CapeOx & Panitumumab": {
        "brands": [
            "Xeloda",
            "Eloxatin",
            "Vectibix"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Capecitabine",
            "Oxaliplatin",
            "Panitumumab"
        ],
        "regimen": "CapeOx & Panitumumab",
        "regimen_names": [
            "CapeOx  and  Panitumumab",
            "CapeOx & Panitumumab",
            "CapeOx + Panitumumab",
            "CapeOx / Panitumumab",
            "CapeOx and Panitumumab",
            "CapeOx+Panitumumab",
            "CapeOx/Panitumumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "CapeOx, Cetuximab, RT": {
        "brands": [
            "Xeloda",
            "Eloxatin",
            "Erbitux",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Rectal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Oxaliplatin",
            "Cetuximab",
            "External_beam_radiotherapy"
        ],
        "regimen": "CapeOx, Cetuximab, RT",
        "regimen_names": [
            "CapeOX, Cetuximab, RT",
            "CapeOx, Cetuximab, RT"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Bevacizumab": {
        "brands": [
            "Xeloda",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "Capecitabine",
            "Bevacizumab"
        ],
        "regimen": "Capecitabine & Bevacizumab",
        "regimen_names": [
            "Capecitabine & Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Erlotinib": {
        "brands": [
            "Xeloda",
            "Tarceva"
        ],
        "cancers": [
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Erlotinib"
        ],
        "regimen": "Capecitabine & Erlotinib",
        "regimen_names": [
            "Capecitabine & Erlotinib"
        ],
        "regimen_type": "Metastatic disease, refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Gemcitabine": {
        "brands": [
            "Xeloda",
            "Gemzar"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Thymoma"
        ],
        "drugs": [
            "Capecitabine",
            "Gemcitabine"
        ],
        "regimen": "Capecitabine & Gemcitabine",
        "regimen_names": [
            "Capecitabine & Gemcitabine",
            "GemCap"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Ixabepilone": {
        "brands": [
            "Xeloda",
            "Ixempra"
        ],
        "cancers": [
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Capecitabine",
            "Ixabepilone"
        ],
        "regimen": "Capecitabine & Ixabepilone",
        "regimen_names": [
            "Capecitabine & Ixabepilone"
        ],
        "regimen_type": "Metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Lapatinib": {
        "brands": [
            "Xeloda",
            "Tykerb"
        ],
        "cancers": [
            "CNS_carcinoma"
        ],
        "drugs": [
            "Capecitabine",
            "Lapatinib"
        ],
        "regimen": "Capecitabine & Lapatinib",
        "regimen_names": [
            "Capecitabine & Lapatinib"
        ],
        "regimen_type": "Breast cancer, HER2-positive, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Mitomycin": {
        "brands": [
            "Xeloda",
            "Mutamycin"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Cholangiocarcinoma"
        ],
        "drugs": [
            "Capecitabine",
            "Mitomycin"
        ],
        "regimen": "Capecitabine & Mitomycin",
        "regimen_names": [
            "Capecitabine & Mitomycin"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & RT": {
        "brands": [
            "Xeloda",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine & RT",
        "regimen_names": [
            "Capecitabine  and  RT",
            "Capecitabine & RT",
            "Capecitabine + RT",
            "Capecitabine / RT",
            "Capecitabine and RT",
            "Capecitabine+RT",
            "Capecitabine/RT"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Temozolomide": {
        "brands": [
            "Xeloda",
            "Temodar"
        ],
        "cancers": [
            "Pancreatic_NET",
            "Pancreatic_NET"
        ],
        "drugs": [
            "Capecitabine",
            "Temozolomide"
        ],
        "regimen": "Capecitabine & Temozolomide",
        "regimen_names": [
            "Capecitabine & Temozolomide"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine & Trastuzumab": {
        "brands": [
            "Xeloda",
            "Herceptin"
        ],
        "cancers": [
            "CNS_carcinoma"
        ],
        "drugs": [
            "Capecitabine",
            "Trastuzumab"
        ],
        "regimen": "Capecitabine & Trastuzumab",
        "regimen_names": [
            "Capecitabine & Trastuzumab"
        ],
        "regimen_type": "Breast cancer, HER2-positive, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine monotherapy": {
        "brands": [
            "Xeloda"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer",
            "Cholangiocarcinoma",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Hepatocellular_carcinoma",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Capecitabine"
        ],
        "regimen": "Capecitabine monotherapy",
        "regimen_names": [
            "Capecitabine monotherapy"
        ],
        "regimen_type": "Adjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Carboplatin, Paclitaxel, RT": {
        "brands": [
            "Paraplatin",
            "Taxol",
            "Xeloda",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel",
            "Capecitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Carboplatin, Paclitaxel, RT",
        "regimen_names": [
            "Capecitabine, Carboplatin, Paclitaxel, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Cisplatin, RT": {
        "brands": [
            "Platinol",
            "Xeloda",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Capecitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Cisplatin, RT",
        "regimen_names": [
            "Capecitabine, Cisplatin, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Docetaxel, Oxaliplatin, RT": {
        "brands": [
            "Xeloda",
            "Taxotere",
            "Eloxatin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Docetaxel",
            "Oxaliplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Docetaxel, Oxaliplatin, RT",
        "regimen_names": [
            "Capecitabine, Docetaxel, Oxaliplatin, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Docetaxel, RT": {
        "brands": [
            "Taxotere",
            "Xeloda",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Capecitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Docetaxel, RT",
        "regimen_names": [
            "Capecitabine, Docetaxel, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Mitomycin, RT": {
        "brands": [
            "Xeloda",
            "Mutamycin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Anal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Mitomycin",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Mitomycin, RT",
        "regimen_names": [
            "Capecitabine, Mitomycin, RT"
        ],
        "regimen_type": "Definitive chemoradiotherapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Oxaliplatin, RT": {
        "brands": [
            "Xeloda",
            "Eloxatin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Oxaliplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Oxaliplatin, RT",
        "regimen_names": [
            "Capecitabine, Oxaliplatin, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Paclitaxel, RT": {
        "brands": [
            "Xeloda",
            "Taxol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Paclitaxel",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Paclitaxel, RT",
        "regimen_names": [
            "Capecitabine, Paclitaxel, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, Sorafenib, RT": {
        "brands": [
            "Xeloda",
            "Nexavar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Rectal_cancer"
        ],
        "drugs": [
            "Capecitabine",
            "Sorafenib",
            "External_beam_radiotherapy"
        ],
        "regimen": "Capecitabine, Sorafenib, RT",
        "regimen_names": [
            "Capecitabine, Sorafenib, RT"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Capecitabine, then Capecitabine & RT, then Capecitabine": {
        "brands": [
            "Xeloda"
        ],
        "cancers": [
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Capecitabine"
        ],
        "regimen": "Capecitabine, then Capecitabine & RT, then Capecitabine",
        "regimen_names": [
            "Capecitabine, then Capecitabine & RT, then Capecitabine"
        ],
        "regimen_type": "Adjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Bevacizumab": {
        "brands": [
            "Paraplatin",
            "Avastin"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Glioblastoma",
            "Glioblastoma"
        ],
        "drugs": [
            "Carboplatin",
            "Bevacizumab"
        ],
        "regimen": "Carboplatin & Bevacizumab",
        "regimen_names": [
            "Carboplatin & Bevacizumab"
        ],
        "regimen_type": "Recurrent disease, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Docetaxel": {
        "brands": [
            "Paraplatin",
            "Taxotere"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary",
            "Breast_cancer_triple_negative",
            "Cervical_cancer",
            "Cervical_cancer",
            "Head_and_neck_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Prostate_cancer",
            "Prostate_cancer",
            "Prostate_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Docetaxel"
        ],
        "regimen": "Carboplatin & Docetaxel",
        "regimen_names": [
            "Carboplatin & Docetaxel"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Doxorubicin liposomal": {
        "brands": [
            "Paraplatin",
            "Doxil"
        ],
        "cancers": [
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Pegylated liposomal doxorubicin"
        ],
        "regimen": "Carboplatin & Doxorubicin liposomal",
        "regimen_names": [
            "Carboplatin & Doxorubicin liposomal"
        ],
        "regimen_type": "Chemotherapy for advanced, recurrent, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Etoposide": {
        "brands": [
            "Paraplatin",
            "Vepesid"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Etoposide"
        ],
        "regimen": "Carboplatin & Etoposide",
        "regimen_names": [
            "Carboplatin & Etoposide"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Etoposide, then auto HSCT": {
        "brands": [
            "Paraplatin",
            "Vepesid"
        ],
        "cancers": [
            "Testicular_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Etoposide"
        ],
        "regimen": "Carboplatin & Etoposide, then auto HSCT",
        "regimen_names": [
            "Carboplatin & Etoposide, then auto HSCT",
            "TI-CE",
            "TI/CE",
            "TICE"
        ],
        "regimen_type": "Consolidation after salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Fluorouracil": {
        "brands": [
            "Paraplatin",
            "5-FU"
        ],
        "cancers": [
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Fluorouracil"
        ],
        "regimen": "Carboplatin & Fluorouracil",
        "regimen_names": [
            "Carboplatin & Fluorouracil"
        ],
        "regimen_type": "Recurrent or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Gemcitabine": {
        "brands": [
            "Paraplatin",
            "Gemzar"
        ],
        "cancers": [
            "Breast_cancer_triple_negative",
            "Breast_cancer_triple_negative",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Gemcitabine"
        ],
        "regimen": "Carboplatin & Gemcitabine",
        "regimen_names": [
            "Carboplatin & Gemcitabine"
        ],
        "regimen_type": "Metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Gemcitabine/Erlotinib": {
        "brands": [
            "Paraplatin",
            "Gemzar",
            "Tarceva"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Carboplatin",
            "Gemcitabine",
            "Erlotinib"
        ],
        "regimen": "Carboplatin & Gemcitabine/Erlotinib",
        "regimen_names": [
            "Carboplatin & Gemcitabine/Erlotinib"
        ],
        "regimen_type": "Advanced or metastatic disease, EGFR inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Ifosfamide": {
        "brands": [
            "Paraplatin",
            "Ifex"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Ifosfamide"
        ],
        "regimen": "Carboplatin & Ifosfamide",
        "regimen_names": [
            "Carboplatin & Ifosfamide"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Irinotecan": {
        "brands": [
            "Paraplatin",
            "Camptosar"
        ],
        "cancers": [
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Irinotecan"
        ],
        "regimen": "Carboplatin & Irinotecan",
        "regimen_names": [
            "Carboplatin & Irinotecan"
        ],
        "regimen_type": "Extensive stage, induction",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Paclitaxel": {
        "brands": [
            "Paraplatin",
            "Taxol"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary",
            "Bladder_cancer",
            "Breast_cancer_triple_negative",
            "Cervical_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Prostate_cancer",
            "Prostate_cancer",
            "Prostate_cancer",
            "Thymoma",
            "Thymoma"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel"
        ],
        "regimen": "Carboplatin & Paclitaxel",
        "regimen_names": [
            "Carboplatin & Paclitaxel"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Pemetrexed": {
        "brands": [
            "Paraplatin",
            "Alimta"
        ],
        "cancers": [
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Pemetrexed"
        ],
        "regimen": "Carboplatin & Pemetrexed",
        "regimen_names": [
            "Carboplatin & Pemetrexed"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & RT": {
        "brands": [
            "Paraplatin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Cervical_cancer",
            "Head_and_neck_cancer",
            "Nasopharyngeal_carcinoma",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "Carboplatin & RT",
        "regimen_names": [
            "Carboplatin  and  RT",
            "Carboplatin & RT",
            "Carboplatin + RT",
            "Carboplatin / RT",
            "Carboplatin and RT",
            "Carboplatin+RT",
            "Carboplatin/RT"
        ],
        "regimen_type": "Definitive chemoradiotherapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Teniposide": {
        "brands": [
            "Paraplatin",
            "Vumon"
        ],
        "cancers": [
            "Low-grade_glioma",
            "Low-grade_glioma"
        ],
        "drugs": [
            "Carboplatin",
            "Teniposide"
        ],
        "regimen": "Carboplatin & Teniposide",
        "regimen_names": [
            "Carboplatin & Teniposide"
        ],
        "regimen_type": "Recurrent or progressive, non-curative therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Vincristine": {
        "brands": [
            "Paraplatin",
            "Oncovin"
        ],
        "cancers": [
            "Low-grade_glioma",
            "Low-grade_glioma"
        ],
        "drugs": [
            "Carboplatin",
            "Vincristine"
        ],
        "regimen": "Carboplatin & Vincristine",
        "regimen_names": [
            "Carboplatin & Vincristine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & Vinorelbine": {
        "brands": [
            "Paraplatin",
            "Navelbine"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Vinorelbine"
        ],
        "regimen": "Carboplatin & Vinorelbine",
        "regimen_names": [
            "Carboplatin & Vinorelbine"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin & nab-Paclitaxel": {
        "brands": [
            "Paraplatin",
            "Abraxane"
        ],
        "cancers": [
            "Breast_cancer_triple_negative",
            "Melanoma",
            "Melanoma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel, nanoparticle albumin-bound"
        ],
        "regimen": "Carboplatin & nab-Paclitaxel",
        "regimen_names": [
            "Carboplatin & nab-Paclitaxel"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin monotherapy": {
        "brands": [
            "Paraplatin"
        ],
        "cancers": [
            "Cervical_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Carboplatin"
        ],
        "regimen": "Carboplatin monotherapy",
        "regimen_names": [
            "Carboplatin monotherapy"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine": {
        "brands": [
            "Paraplatin",
            "Cytoxan",
            "Vepesid",
            "MTX",
            "Oncovin"
        ],
        "cancers": [
            "Medulloblastoma"
        ],
        "drugs": [
            "Carboplatin",
            "Cyclophosphamide",
            "Etoposide",
            "Methotrexate",
            "Vincristine"
        ],
        "regimen": "Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine",
        "regimen_names": [
            "Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Docetaxel, Fluorouracil": {
        "brands": [
            "Paraplatin",
            "Taxotere",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Docetaxel",
            "Fluorouracil"
        ],
        "regimen": "Carboplatin, Docetaxel, Fluorouracil",
        "regimen_names": [
            "Carboplatin, Docetaxel, Fluorouracil"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Etoposide, Bevacizumab": {
        "brands": [
            "Paraplatin",
            "Vepesid",
            "Avastin"
        ],
        "cancers": [
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Etoposide",
            "Bevacizumab"
        ],
        "regimen": "Carboplatin, Etoposide, Bevacizumab",
        "regimen_names": [
            "Carboplatin, Etoposide, Bevacizumab"
        ],
        "regimen_type": "Extensive stage, induction",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Etoposide, RT": {
        "brands": [
            "Paraplatin",
            "Vepesid",
            "External beam radiotherapy"
        ],
        "cancers": [
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Etoposide",
            "External beam radiotherapy"
        ],
        "regimen": "Carboplatin, Etoposide, RT",
        "regimen_names": [
            "Carboplatin, Etoposide, RT",
            "EP  and  RT",
            "EP & RT",
            "EP + RT",
            "EP / RT",
            "EP and RT",
            "EP+RT",
            "EP/RT",
            "EPRT"
        ],
        "regimen_type": "Limited stage, definitive chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Fluorouracil, Cetuximab": {
        "brands": [
            "Paraplatin",
            "5-FU",
            "Erbitux"
        ],
        "cancers": [
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Fluorouracil",
            "Cetuximab"
        ],
        "regimen": "Carboplatin, Fluorouracil, Cetuximab",
        "regimen_names": [
            "Carboplatin, Fluorouracil, Cetuximab"
        ],
        "regimen_type": "Recurrent or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Fluorouracil, Cetuximab, RT": {
        "brands": [
            "Paraplatin",
            "5-FU",
            "Erbitux",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Fluorouracil",
            "Cetuximab",
            "External_beam_radiotherapy"
        ],
        "regimen": "Carboplatin, Fluorouracil, Cetuximab, RT",
        "regimen_names": [
            "Carboplatin, Fluorouracil, Cetuximab, RT"
        ],
        "regimen_type": "Locally advanced disease, definitive therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Fluorouracil, RT": {
        "brands": [
            "Paraplatin",
            "5-FU",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Fluorouracil",
            "External_beam_radiotherapy"
        ],
        "regimen": "Carboplatin, Fluorouracil, RT",
        "regimen_names": [
            "Carboplatin, Fluorouracil, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Gemcitabine, Bevacizumab": {
        "brands": [
            "Paraplatin",
            "Gemzar",
            "Avastin"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Gemcitabine",
            "Bevacizumab"
        ],
        "regimen": "Carboplatin, Gemcitabine, Bevacizumab",
        "regimen_names": [
            "Carboplatin, Gemcitabine, Bevacizumab"
        ],
        "regimen_type": "Second-line therapy for relapsed or recurrent disease, platinum-sensitive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Olaparib, Paclitaxel": {
        "brands": [
            "Paraplatin",
            "Lynparza",
            "Taxol"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Olaparib",
            "Paclitaxel"
        ],
        "regimen": "Carboplatin, Olaparib, Paclitaxel",
        "regimen_names": [
            "Carboplatin, Olaparib, Paclitaxel"
        ],
        "regimen_type": "Second-line therapy for relapsed or recurrent disease, platinum-sensitive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Paclitaxel, Bevacizumab": {
        "brands": [
            "Paraplatin",
            "Taxol",
            "Avastin"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel",
            "Bevacizumab"
        ],
        "regimen": "Carboplatin, Paclitaxel, Bevacizumab",
        "regimen_names": [
            "B & CP",
            "B / CP",
            "B and CP",
            "B&CP",
            "B+CP",
            "B/CP",
            "BCP",
            "Carboplatin, Paclitaxel, Bevacizumab",
            "PacCBev"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Paclitaxel, Pembrolizumab": {
        "brands": [
            "Paraplatin",
            "Taxol",
            "Keytruda"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel",
            "Pembrolizumab"
        ],
        "regimen": "Carboplatin, Paclitaxel, Pembrolizumab",
        "regimen_names": [
            "Carboplatin, Paclitaxel, Pembrolizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, squamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Paclitaxel, RT": {
        "brands": [
            "Paraplatin",
            "Taxol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel",
            "External_beam_radiotherapy"
        ],
        "regimen": "Carboplatin, Paclitaxel, RT",
        "regimen_names": [
            "Carboplatin, Paclitaxel, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Pemetrexed, Bevacizumab": {
        "brands": [
            "Paraplatin",
            "Alimta",
            "Avastin"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Pemetrexed",
            "Bevacizumab"
        ],
        "regimen": "Carboplatin, Pemetrexed, Bevacizumab",
        "regimen_names": [
            "Carboplatin, Pemetrexed, Bevacizumab",
            "PemCBev"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, nonsquamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, Vinorelbine, RT": {
        "brands": [
            "Paraplatin",
            "Navelbine",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Vinorelbine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Carboplatin, Vinorelbine, RT",
        "regimen_names": [
            "Carboplatin, Vinorelbine, RT"
        ],
        "regimen_type": "Definitive therapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carboplatin, nab-Paclitaxel, Pembrolizumab": {
        "brands": [
            "Paraplatin",
            "Abraxane",
            "Keytruda"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Carboplatin",
            "Paclitaxel, nanoparticle albumin-bound",
            "Pembrolizumab"
        ],
        "regimen": "Carboplatin, nab-Paclitaxel, Pembrolizumab",
        "regimen_names": [
            "Carboplatin, nab-Paclitaxel, Pembrolizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, squamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carfilzomib & Dexamethasone": {
        "brands": [
            "Kyprolis",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Carfilzomib",
            "Dexamethasone"
        ],
        "regimen": "Carfilzomib & Dexamethasone",
        "regimen_names": [
            "Carfilzomib & Dexamethasone"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carfilzomib & Panobinostat": {
        "brands": [
            "Kyprolis",
            "Farydak"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Carfilzomib",
            "Panobinostat"
        ],
        "regimen": "Carfilzomib & Panobinostat",
        "regimen_names": [
            "Carfilzomib & Panobinostat"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carfilzomib monotherapy": {
        "brands": [
            "Kyprolis"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Carfilzomib"
        ],
        "regimen": "Carfilzomib monotherapy",
        "regimen_names": [
            "Carfilzomib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carmustine & RT": {
        "brands": [
            "BiCNU"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Carmustine"
        ],
        "regimen": "Carmustine & RT",
        "regimen_names": [
            "BCNU  and  RT",
            "BCNU & RT",
            "BCNU + RT",
            "BCNU / RT",
            "BCNU and RT",
            "BCNU+RT",
            "BCNU/RT",
            "BCNURT",
            "Carmustine  and  RT",
            "Carmustine & RT",
            "Carmustine + RT",
            "Carmustine / RT",
            "Carmustine and RT",
            "Carmustine+RT",
            "Carmustine/RT"
        ],
        "regimen_type": "Adjuvant therapy, standard patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Carmustine monotherapy": {
        "brands": [
            "BiCNU"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Glioblastoma",
            "Glioblastoma"
        ],
        "drugs": [
            "Carmustine"
        ],
        "regimen": "Carmustine monotherapy",
        "regimen_names": [
            "Carmustine monotherapy"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cemiplimab monotherapy": {
        "brands": [
            "Libtayo"
        ],
        "cancers": [
            "Cutaneous_squamous_cell_carcinoma",
            "Cutaneous_squamous_cell_carcinoma"
        ],
        "drugs": [
            "Cemiplimab"
        ],
        "regimen": "Cemiplimab monotherapy",
        "regimen_names": [
            "Cemiplimab monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ceritinib monotherapy": {
        "brands": [
            "Zykadia"
        ],
        "cancers": [
            "CNS_carcinoma",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ROS1-positive"
        ],
        "drugs": [
            "Ceritinib"
        ],
        "regimen": "Ceritinib monotherapy",
        "regimen_names": [
            "Ceritinib monotherapy"
        ],
        "regimen_type": "Non-small cell lung cancer, ALK-mutated, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cetuximab & RT": {
        "brands": [
            "Erbitux",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cetuximab",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cetuximab & RT",
        "regimen_names": [
            "Cetuximab  and  RT",
            "Cetuximab & RT",
            "Cetuximab + RT",
            "Cetuximab / RT",
            "Cetuximab and RT",
            "Cetuximab+RT",
            "Cetuximab/RT"
        ],
        "regimen_type": "Locally advanced disease, definitive therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cetuximab monotherapy": {
        "brands": [
            "Erbitux"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Cutaneous_squamous_cell_carcinoma",
            "Cutaneous_squamous_cell_carcinoma",
            "Cutaneous_squamous_cell_carcinoma",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cetuximab"
        ],
        "regimen": "Cetuximab monotherapy",
        "regimen_names": [
            "Cetuximab monotherapy"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Chidamide monotherapy": {
        "brands": [
            "Epidaza"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Chidamide"
        ],
        "regimen": "Chidamide monotherapy",
        "regimen_names": [
            "Chidamide monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ChlVPP": {
        "brands": [
            "Leukeran",
            "Velban",
            "Matulane",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Chlorambucil",
            "Vinblastine",
            "Procarbazine",
            "Prednisone"
        ],
        "regimen": "ChlVPP",
        "regimen_names": [
            "ChlVPP"
        ],
        "regimen_type": "Untreated, elderly",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ChlVPP/EVA": {
        "brands": [
            "Leukeran",
            "Velban",
            "Matulane",
            "Millipred",
            "Vepesid",
            "Oncovin",
            "Adriamycin"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Chlorambucil",
            "Vinblastine",
            "Procarbazine",
            "Prednisolone",
            "Etoposide",
            "Vincristine",
            "Doxorubicin"
        ],
        "regimen": "ChlVPP/EVA",
        "regimen_names": [
            "ChlVPP/EVA"
        ],
        "regimen_type": "Untreated, elderly",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Chlorambucil & Obinutuzumab": {
        "brands": [
            "Gazyva",
            "Leukeran"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Obinutuzumab",
            "Chlorambucil"
        ],
        "regimen": "Chlorambucil & Obinutuzumab",
        "regimen_names": [
            "Chlorambucil & Obinutuzumab",
            "GClb"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Chlorambucil & Ofatumumab": {
        "brands": [
            "Leukeran",
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Chlorambucil",
            "Ofatumumab"
        ],
        "regimen": "Chlorambucil & Ofatumumab",
        "regimen_names": [
            "Chlorambucil & Ofatumumab"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Chlorambucil & Rituximab": {
        "brands": [
            "Leukeran",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma"
        ],
        "drugs": [
            "Chlorambucil",
            "Rituximab"
        ],
        "regimen": "Chlorambucil & Rituximab",
        "regimen_names": [
            "CLB-R",
            "CLB/R",
            "CLBR",
            "Chlorambucil & Rituximab",
            "RClb"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Chlorambucil monotherapy": {
        "brands": [
            "Leukeran"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Chlorambucil"
        ],
        "regimen": "Chlorambucil monotherapy",
        "regimen_names": [
            "Chlorambucil monotherapy"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Cetuximab": {
        "brands": [
            "Platinol",
            "Erbitux"
        ],
        "cancers": [
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Cetuximab"
        ],
        "regimen": "Cisplatin & Cetuximab",
        "regimen_names": [
            "Cisplatin & Cetuximab"
        ],
        "regimen_type": "Recurrent or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Dacarbazine": {
        "brands": [
            "Platinol",
            "DTIC"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Cisplatin",
            "Dacarbazine"
        ],
        "regimen": "Cisplatin & Dacarbazine",
        "regimen_names": [
            "Cisplatin & Dacarbazine"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Docetaxel": {
        "brands": [
            "Platinol",
            "Taxotere"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary",
            "Breast_cancer_triple_negative",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Head_and_neck_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Docetaxel"
        ],
        "regimen": "Cisplatin & Docetaxel",
        "regimen_names": [
            "Cisplatin & Docetaxel"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Doxorubicin": {
        "brands": [
            "Platinol",
            "Adriamycin"
        ],
        "cancers": [
            "Cutaneous_basal_cell_carcinoma",
            "Cutaneous_squamous_cell_carcinoma",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Hepatoblastoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Cisplatin",
            "Doxorubicin"
        ],
        "regimen": "Cisplatin & Doxorubicin",
        "regimen_names": [
            "Cisplatin & Doxorubicin"
        ],
        "regimen_type": "Advanced or metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Epirubicin": {
        "brands": [
            "Platinol",
            "Ellence"
        ],
        "cancers": [
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Epirubicin"
        ],
        "regimen": "Cisplatin & Epirubicin",
        "regimen_names": [
            "CIS-EPI",
            "CIS/EPI",
            "CISEPI",
            "Cisplatin & Epirubicin"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Etoposide": {
        "brands": [
            "Platinol",
            "Vepesid"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Testicular_cancer",
            "Thymoma",
            "Thymoma"
        ],
        "drugs": [
            "Cisplatin",
            "Etoposide"
        ],
        "regimen": "Cisplatin & Etoposide",
        "regimen_names": [
            "Cisplatin & Etoposide"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Fluorouracil": {
        "brands": [
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Nasopharyngeal_carcinoma",
            "Penile_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "Cisplatin & Fluorouracil",
        "regimen_names": [
            "Cisplatin & Fluorouracil"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Gemcitabine": {
        "brands": [
            "Platinol",
            "Gemzar"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Breast_cancer_triple_negative",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cholangiocarcinoma",
            "Cholangiocarcinoma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Gemcitabine"
        ],
        "regimen": "Cisplatin & Gemcitabine",
        "regimen_names": [
            "Cisplatin & Gemcitabine"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Gemcitabine/Erlotinib": {
        "brands": [
            "Platinol",
            "Gemzar",
            "Tarceva"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Cisplatin",
            "Gemcitabine",
            "Erlotinib"
        ],
        "regimen": "Cisplatin & Gemcitabine/Erlotinib",
        "regimen_names": [
            "Cisplatin & Gemcitabine/Erlotinib"
        ],
        "regimen_type": "Advanced or metastatic disease, EGFR inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Ifosfamide": {
        "brands": [
            "Platinol",
            "Ifex"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Ifosfamide"
        ],
        "regimen": "Cisplatin & Ifosfamide",
        "regimen_names": [
            "Cisplatin & Ifosfamide"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Irinotecan": {
        "brands": [
            "Platinol",
            "Camptosar"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Non-small_cell_lung_cancer",
            "Penile_cancer",
            "Penile_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Irinotecan"
        ],
        "regimen": "Cisplatin & Irinotecan",
        "regimen_names": [
            "Cisplatin & Irinotecan"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Mitomycin": {
        "brands": [
            "Platinol",
            "Mutamycin"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Mitomycin"
        ],
        "regimen": "Cisplatin & Mitomycin",
        "regimen_names": [
            "Cisplatin & Mitomycin"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Paclitaxel": {
        "brands": [
            "Platinol",
            "Taxol"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cutaneous_basal_cell_carcinoma",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Paclitaxel"
        ],
        "regimen": "Cisplatin & Paclitaxel",
        "regimen_names": [
            "Cisplatin & Paclitaxel"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Pemetrexed": {
        "brands": [
            "Platinol",
            "Alimta"
        ],
        "cancers": [
            "Mesothelioma",
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Pemetrexed"
        ],
        "regimen": "Cisplatin & Pemetrexed",
        "regimen_names": [
            "Cisplatin & Pemetrexed"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & RT": {
        "brands": [
            "Platinol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Nasopharyngeal_carcinoma",
            "Nasopharyngeal_carcinoma",
            "Nasopharyngeal_carcinoma",
            "Nasopharyngeal_carcinoma",
            "Nasopharyngeal_carcinoma",
            "Non-small_cell_lung_cancer",
            "Vulvar_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin & RT",
        "regimen_names": [
            "Cisplatin  and  RT",
            "Cisplatin & RT",
            "Cisplatin + RT",
            "Cisplatin / RT",
            "Cisplatin and RT",
            "Cisplatin+RT",
            "Cisplatin/RT"
        ],
        "regimen_type": "Induction chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Raltitrexed": {
        "brands": [
            "Platinol",
            "Tomudex"
        ],
        "cancers": [
            "Mesothelioma"
        ],
        "drugs": [
            "Cisplatin",
            "Raltitrexed"
        ],
        "regimen": "Cisplatin & Raltitrexed",
        "regimen_names": [
            "Cisplatin & Raltitrexed"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & S-1": {
        "brands": [
            "Platinol",
            "S-1"
        ],
        "cancers": [
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Tegafur, gimeracil, oteracil"
        ],
        "regimen": "Cisplatin & S-1",
        "regimen_names": [
            "Cisplatin  and  S-1",
            "Cisplatin & S-1",
            "Cisplatin + S-1",
            "Cisplatin / S-1",
            "Cisplatin and S-1",
            "Cisplatin+S-1",
            "Cisplatin/S-1"
        ],
        "regimen_type": "Metastatic or locally advanced disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Topotecan": {
        "brands": [
            "Platinol",
            "Hycamtin"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Topotecan"
        ],
        "regimen": "Cisplatin & Topotecan",
        "regimen_names": [
            "Cisplatin & Topotecan"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Vinblastine": {
        "brands": [
            "Platinol",
            "Velban"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vinblastine"
        ],
        "regimen": "Cisplatin & Vinblastine",
        "regimen_names": [
            "Cisplatin & Vinblastine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Vindesine": {
        "brands": [
            "Platinol",
            "Eldisine"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vindesine"
        ],
        "regimen": "Cisplatin & Vindesine",
        "regimen_names": [
            "Cisplatin & Vindesine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin & Vinorelbine": {
        "brands": [
            "Platinol",
            "Navelbine"
        ],
        "cancers": [
            "Cervical_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vinorelbine"
        ],
        "regimen": "Cisplatin & Vinorelbine",
        "regimen_names": [
            "Cisplatin & Vinorelbine"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin monotherapy": {
        "brands": [
            "Platinol"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Bladder_cancer",
            "Breast_cancer_triple_negative",
            "Cervical_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Hepatoblastoma",
            "Mesothelioma",
            "Mesothelioma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Cisplatin"
        ],
        "regimen": "Cisplatin monotherapy",
        "regimen_names": [
            "Cisplatin monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Cetuximab, RT": {
        "brands": [
            "Platinol",
            "Erbitux",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Cetuximab",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Cetuximab, RT",
        "regimen_names": [
            "Cisplatin, Cetuximab, RT"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine": {
        "brands": [
            "Platinol",
            "DTIC",
            "BiCNU",
            "Proleukin",
            "Intron-A"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Cisplatin",
            "Dacarbazine",
            "Carmustine",
            "Aldesleukin",
            "Interferon alfa-2b"
        ],
        "regimen": "Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine",
        "regimen_names": [
            "Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Dacarbazine, Paclitaxel": {
        "brands": [
            "Platinol",
            "DTIC",
            "Taxol"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Cisplatin",
            "Dacarbazine",
            "Paclitaxel"
        ],
        "regimen": "Cisplatin, Dacarbazine, Paclitaxel",
        "regimen_names": [
            "Cisplatin, Dacarbazine, Paclitaxel"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Docetaxel, RT": {
        "brands": [
            "Platinol",
            "Taxotere",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Docetaxel",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Docetaxel, RT",
        "regimen_names": [
            "Cisplatin, Docetaxel, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Doxorubicin liposomal, Fluorouracil": {
        "brands": [
            "Platinol",
            "Doxil",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Pegylated liposomal doxorubicin",
            "Fluorouracil"
        ],
        "regimen": "Cisplatin, Doxorubicin liposomal, Fluorouracil",
        "regimen_names": [
            "Cisplatin, Doxorubicin liposomal, Fluorouracil"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Doxorubicin, Paclitaxel": {
        "brands": [
            "Platinol",
            "Adriamycin",
            "Taxol"
        ],
        "cancers": [
            "Endometrial_cancer",
            "Endometrial_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Doxorubicin",
            "Paclitaxel"
        ],
        "regimen": "Cisplatin, Doxorubicin, Paclitaxel",
        "regimen_names": [
            "Cisplatin, Doxorubicin, Paclitaxel",
            "TAP"
        ],
        "regimen_type": "Chemotherapy for advanced, recurrent, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Epirubicin, Ifosfamide": {
        "brands": [
            "Platinol",
            "Ellence",
            "Ifex"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Cisplatin",
            "Epirubicin",
            "Ifosfamide"
        ],
        "regimen": "Cisplatin, Epirubicin, Ifosfamide",
        "regimen_names": [
            "Cisplatin, Epirubicin, Ifosfamide"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Etoposide, Bevacizumab": {
        "brands": [
            "Platinol",
            "Vepesid",
            "Avastin"
        ],
        "cancers": [
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Etoposide",
            "Bevacizumab"
        ],
        "regimen": "Cisplatin, Etoposide, Bevacizumab",
        "regimen_names": [
            "Cisplatin, Etoposide, Bevacizumab"
        ],
        "regimen_type": "Extensive stage, induction",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Etoposide, Irinotecan": {
        "brands": [
            "Platinol",
            "Vepesid",
            "Camptosar"
        ],
        "cancers": [
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Etoposide",
            "Irinotecan"
        ],
        "regimen": "Cisplatin, Etoposide, Irinotecan",
        "regimen_names": [
            "Cisplatin, Etoposide, Irinotecan"
        ],
        "regimen_type": "Relapsed or refractory disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Etoposide, RT": {
        "brands": [
            "Platinol",
            "Vepesid",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Etoposide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Etoposide, RT",
        "regimen_names": [
            "Cisplatin, Etoposide, RT",
            "EP  and  RT",
            "EP & RT",
            "EP + RT",
            "EP / RT",
            "EP and RT",
            "EP+RT",
            "EP/RT",
            "EPRT"
        ],
        "regimen_type": "Definitive therapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Fluorouracil, Cetuximab": {
        "brands": [
            "Platinol",
            "5-FU",
            "Erbitux"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil",
            "Cetuximab"
        ],
        "regimen": "Cisplatin, Fluorouracil, Cetuximab",
        "regimen_names": [
            "CF-C",
            "CF/C",
            "CFC",
            "Cisplatin, Fluorouracil, Cetuximab"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Fluorouracil, Hydroxyurea, RT": {
        "brands": [
            "Platinol",
            "5-FU",
            "Hydrea",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil",
            "Hydroxyurea",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Fluorouracil, Hydroxyurea, RT",
        "regimen_names": [
            "Cisplatin, Fluorouracil, Hydroxyurea, RT"
        ],
        "regimen_type": "Definitive chemoradiotherapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Fluorouracil, Panitumumab": {
        "brands": [
            "Platinol",
            "5-FU",
            "Vectibix"
        ],
        "cancers": [
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil",
            "Panitumumab"
        ],
        "regimen": "Cisplatin, Fluorouracil, Panitumumab",
        "regimen_names": [
            "Cisplatin, Fluorouracil, Panitumumab"
        ],
        "regimen_type": "Recurrent or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Fluorouracil, RT": {
        "brands": [
            "Platinol",
            "5-FU",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Fluorouracil, RT",
        "regimen_names": [
            "Cisplatin, Fluorouracil, RT"
        ],
        "regimen_type": "Induction chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Gemcitabine, Bevacizumab": {
        "brands": [
            "Platinol",
            "Gemzar",
            "Avastin"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Gemcitabine",
            "Bevacizumab"
        ],
        "regimen": "Cisplatin, Gemcitabine, Bevacizumab",
        "regimen_names": [
            "Cisplatin, Gemcitabine, Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, nonsquamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Gemcitabine, Necitumumab": {
        "brands": [
            "Platinol",
            "Gemzar",
            "Portrazza"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Gemcitabine",
            "Necitumumab"
        ],
        "regimen": "Cisplatin, Gemcitabine, Necitumumab",
        "regimen_names": [
            "Cisplatin, Gemcitabine, Necitumumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, squamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Gemcitabine, RT": {
        "brands": [
            "Platinol",
            "Gemzar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Gemcitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Gemcitabine, RT",
        "regimen_names": [
            "Cisplatin, Gemcitabine, RT"
        ],
        "regimen_type": "Definitive chemoradiotherapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Irinotecan, RT": {
        "brands": [
            "Platinol",
            "Camptosar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Irinotecan",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Irinotecan, RT",
        "regimen_names": [
            "Cisplatin, Irinotecan, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Lomustine, Vincristine": {
        "brands": [
            "Platinol",
            "Ceenu",
            "Oncovin"
        ],
        "cancers": [
            "Medulloblastoma"
        ],
        "drugs": [
            "Cisplatin",
            "Lomustine",
            "Vincristine"
        ],
        "regimen": "Cisplatin, Lomustine, Vincristine",
        "regimen_names": [
            "Cisplatin, Lomustine, Vincristine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Paclitaxel, Bevacizumab": {
        "brands": [
            "Platinol",
            "Taxol",
            "Avastin"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Paclitaxel",
            "Bevacizumab"
        ],
        "regimen": "Cisplatin, Paclitaxel, Bevacizumab",
        "regimen_names": [
            "CP & Bev",
            "CP / Bev",
            "CP and Bev",
            "CP&Bev",
            "CP+Bev",
            "CP/Bev",
            "CPBev",
            "Cisplatin, Paclitaxel, Bevacizumab"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Paclitaxel, RT": {
        "brands": [
            "Platinol",
            "Taxol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Paclitaxel",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Paclitaxel, RT",
        "regimen_names": [
            "Cisplatin, Paclitaxel, RT"
        ],
        "regimen_type": "Induction chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Pemetrexed, Bevacizumab": {
        "brands": [
            "Platinol",
            "Alimta",
            "Avastin"
        ],
        "cancers": [
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Pemetrexed",
            "Bevacizumab"
        ],
        "regimen": "Cisplatin, Pemetrexed, Bevacizumab",
        "regimen_names": [
            "Cisplatin, Pemetrexed, Bevacizumab",
            "PCB"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Vinblastine, RT": {
        "brands": [
            "Platinol",
            "Velban",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vinblastine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Vinblastine, RT",
        "regimen_names": [
            "Cisplatin, Vinblastine, RT"
        ],
        "regimen_type": "Definitive therapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Vinorelbine, Cetuximab": {
        "brands": [
            "Platinol",
            "Navelbine",
            "Erbitux"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vinorelbine",
            "Cetuximab"
        ],
        "regimen": "Cisplatin, Vinorelbine, Cetuximab",
        "regimen_names": [
            "Cisplatin, Vinorelbine, Cetuximab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cisplatin, Vinorelbine, RT": {
        "brands": [
            "Platinol",
            "Navelbine",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vinorelbine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cisplatin, Vinorelbine, RT",
        "regimen_names": [
            "Cisplatin, Vinorelbine, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cladribine & Cytarabine": {
        "brands": [
            "Leustatin",
            "Cytosar"
        ],
        "cancers": [
            "Hypereosinophilic_syndrome",
            "Langerhans_cell_histiocytosis"
        ],
        "drugs": [
            "Cladribine",
            "Cytarabine"
        ],
        "regimen": "Cladribine & Cytarabine",
        "regimen_names": [
            "Cladribine & Cytarabine"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cladribine & Rituximab": {
        "brands": [
            "Leustatin"
        ],
        "cancers": [
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Cladribine"
        ],
        "regimen": "Cladribine & Rituximab",
        "regimen_names": [
            "Cladribine & Rituximab"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cladribine monotherapy": {
        "brands": [
            "Leustatin"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Langerhans_cell_histiocytosis",
            "Langerhans_cell_histiocytosis",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis"
        ],
        "drugs": [
            "Cladribine"
        ],
        "regimen": "Cladribine monotherapy",
        "regimen_names": [
            "Cladribine monotherapy"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Clofarabine & Cytarabine": {
        "brands": [
            "Clolar",
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Clofarabine",
            "Cytarabine"
        ],
        "regimen": "Clofarabine & Cytarabine",
        "regimen_names": [
            "Clofarabine & Cytarabine"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Clofarabine & LoDAC": {
        "brands": [
            "Clolar",
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Clofarabine",
            "Cytarabine"
        ],
        "regimen": "Clofarabine & LoDAC",
        "regimen_names": [
            "Clofarabine  and  LoDAC",
            "Clofarabine & LoDAC",
            "Clofarabine + LoDAC",
            "Clofarabine / LoDAC",
            "Clofarabine and LoDAC",
            "Clofarabine+LoDAC",
            "Clofarabine/LoDAC"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Clofarabine & Melphalan": {
        "brands": [
            "Clolar",
            "Alkeran"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Clofarabine",
            "Melphalan"
        ],
        "regimen": "Clofarabine & Melphalan",
        "regimen_names": [
            "Clofarabine & Melphalan"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Clofarabine monotherapy": {
        "brands": [
            "Clolar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Clofarabine"
        ],
        "regimen": "Clofarabine monotherapy",
        "regimen_names": [
            "Clofarabine monotherapy"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cobimetinib & Vemurafenib": {
        "brands": [
            "Cotellic",
            "Zelboraf"
        ],
        "cancers": [
            "Melanoma_BRAF-mutated"
        ],
        "drugs": [
            "Cobimetinib",
            "Vemurafenib"
        ],
        "regimen": "Cobimetinib & Vemurafenib",
        "regimen_names": [
            "Cobimetinib & Vemurafenib"
        ],
        "regimen_type": "Advanced or metastatic disease, BRAF inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Colchicine monotherapy": {
        "brands": [
            "Colcrys"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Colchicine"
        ],
        "regimen": "Colchicine monotherapy",
        "regimen_names": [
            "Colchicine monotherapy"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Copanlisib monotherapy": {
        "brands": [
            "Aliqopa"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Copanlisib"
        ],
        "regimen": "Copanlisib monotherapy",
        "regimen_names": [
            "Copanlisib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Crizotinib monotherapy": {
        "brands": [
            "Xalkori"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ROS1-positive",
            "Non-small_cell_lung_cancer_ROS1-positive",
            "Non-small_cell_lung_cancer_ROS1-positive"
        ],
        "drugs": [
            "Crizotinib"
        ],
        "regimen": "Crizotinib monotherapy",
        "regimen_names": [
            "Crizotinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, ALK inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Dexamethasone": {
        "brands": [
            "Cytoxan",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Dexamethasone"
        ],
        "regimen": "Cyclophosphamide & Dexamethasone",
        "regimen_names": [
            "Cyclophosphamide & Dexamethasone"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Etoposide": {
        "brands": [
            "Cytoxan",
            "Vepesid"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Etoposide"
        ],
        "regimen": "Cyclophosphamide & Etoposide",
        "regimen_names": [
            "Cyclophosphamide & Etoposide"
        ],
        "regimen_type": "Relapsed, refractory, or metastatic, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & G-CSF": {
        "brands": [
            "Cytoxan"
        ],
        "cancers": [
            "Stem_cell_mobilization",
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Cyclophosphamide"
        ],
        "regimen": "Cyclophosphamide & G-CSF",
        "regimen_names": [
            "Cyclophosphamide & G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Prednisolone": {
        "brands": [
            "Cytoxan",
            "Millipred"
        ],
        "cancers": [
            "Acquired_coagulopathy"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Prednisolone"
        ],
        "regimen": "Cyclophosphamide & Prednisolone",
        "regimen_names": [
            "Cyclophosphamide & Prednisolone"
        ],
        "regimen_type": "Acquired hemophilia A, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Prednisone": {
        "brands": [
            "Cytoxan",
            "Sterapred"
        ],
        "cancers": [
            "Acquired_coagulopathy",
            "Acquired_coagulopathy",
            "Acquired_coagulopathy",
            "Large_granular_lymphocytic_leukemia",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Prednisone"
        ],
        "regimen": "Cyclophosphamide & Prednisone",
        "regimen_names": [
            "Cyclophosphamide & Prednisone"
        ],
        "regimen_type": "Acquired hemophilia A, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & TBI": {
        "brands": [
            "Cytoxan",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cyclophosphamide & TBI",
        "regimen_names": [
            "Cy/TBI",
            "CyTBI",
            "Cyclophosphamide & TBI"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Topotecan": {
        "brands": [
            "Cytoxan",
            "Hycamtin"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Topotecan"
        ],
        "regimen": "Cyclophosphamide & Topotecan",
        "regimen_names": [
            "Cyclophosphamide & Topotecan"
        ],
        "regimen_type": "Relapsed or refractory or metastatic",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Vincristine": {
        "brands": [
            "Cytoxan",
            "Oncovin"
        ],
        "cancers": [
            "Neuroblastoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine"
        ],
        "regimen": "Cyclophosphamide & Vincristine",
        "regimen_names": [
            "Cyclophosphamide & Vincristine"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide & Vincristine/Cisplatin & Etoposide": {
        "brands": [
            "Cytoxan",
            "Oncovin"
        ],
        "cancers": [
            "Medulloblastoma",
            "Medulloblastoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine"
        ],
        "regimen": "Cyclophosphamide & Vincristine/Cisplatin & Etoposide",
        "regimen_names": [
            "Cyclophosphamide & Vincristine/Cisplatin & Etoposide"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide monotherapy": {
        "brands": [
            "Cytoxan"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Follicular_lymphoma",
            "Glioblastoma",
            "Glioblastoma",
            "Large_granular_lymphocytic_leukemia",
            "Neuroblastoma"
        ],
        "drugs": [
            "Cyclophosphamide"
        ],
        "regimen": "Cyclophosphamide monotherapy",
        "regimen_names": [
            "Cyclophosphamide monotherapy"
        ],
        "regimen_type": "Recurrent disease, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide, Dacarbazine, Vincristine": {
        "brands": [
            "Cytoxan",
            "DTIC",
            "Oncovin"
        ],
        "cancers": [
            "Pheochromocytoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Dacarbazine",
            "Vincristine"
        ],
        "regimen": "Cyclophosphamide, Dacarbazine, Vincristine",
        "regimen_names": [
            "CVD",
            "Cyclophosphamide, Dacarbazine, Vincristine"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide, Etoposide, TBI": {
        "brands": [
            "Cytoxan",
            "Vepesid",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Etoposide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Cyclophosphamide, Etoposide, TBI",
        "regimen_names": [
            "Cyclophosphamide, Etoposide, TBI"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclophosphamide, Fludarabine, Thiotepa": {
        "brands": [
            "Cytoxan",
            "Fludara",
            "Thioplex"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Fludarabine",
            "Thiotepa"
        ],
        "regimen": "Cyclophosphamide, Fludarabine, Thiotepa",
        "regimen_names": [
            "Cyclophosphamide, Fludarabine, Thiotepa"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclosporine & Prednisone": {
        "brands": [
            ":Category:Cyclosporines",
            "Sterapred"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            ":Category:Cyclosporines",
            "Prednisone"
        ],
        "regimen": "Cyclosporine & Prednisone",
        "regimen_names": [
            "Cyclosporine & Prednisone"
        ],
        "regimen_type": "Treatment, cGVHD, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclosporine monotherapy": {
        "brands": [
            ":Category:Cyclosporines"
        ],
        "cancers": [
            "Aplastic_anemia",
            "Aplastic_anemia",
            "Castleman_disease",
            "Immune_thrombocytopenia_(ITP)",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            ":Category:Cyclosporines"
        ],
        "regimen": "Cyclosporine monotherapy",
        "regimen_names": [
            "Cyclosporine monotherapy"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclosporine, Corticosteroids, Rituximab": {
        "brands": [
            ":Category:Cyclosporines",
            ":Category:Steroids",
            "Sterapred",
            "Rituxan"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            ":Category:Cyclosporines",
            ":Category:Steroids",
            "Prednisone",
            "Rituximab"
        ],
        "regimen": "Cyclosporine, Corticosteroids, Rituximab",
        "regimen_names": [
            "Cyclosporine, Corticosteroids, Rituximab"
        ],
        "regimen_type": "Treatment, cGVHD, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclosporine, Methotrexate, MP": {
        "brands": [
            "Neoral",
            "MTX",
            "Solumedrol"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            "Cyclosporine modified",
            "Methotrexate",
            "Methylprednisolone"
        ],
        "regimen": "Cyclosporine, Methotrexate, MP",
        "regimen_names": [
            "Cyclosporine, Methotrexate, MP"
        ],
        "regimen_type": "Prevention",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclosporine, Methotrexate, Prednisone": {
        "brands": [
            "Neoral",
            "MTX",
            "Sterapred"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            "Cyclosporine modified",
            "Methotrexate",
            "Prednisone"
        ],
        "regimen": "Cyclosporine, Methotrexate, Prednisone",
        "regimen_names": [
            "Cyclosporine, Methotrexate, Prednisone"
        ],
        "regimen_type": "Prevention",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cyclosporine, Sirolimus, Prednisone": {
        "brands": [
            ":Category:Cyclosporines",
            "Rapamune",
            "Sterapred"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            ":Category:Cyclosporines",
            "Sirolimus",
            "Prednisone"
        ],
        "regimen": "Cyclosporine, Sirolimus, Prednisone",
        "regimen_names": [
            "Cyclosporine, Sirolimus, Prednisone"
        ],
        "regimen_type": "Treatment, cGVHD, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & Daunorubicin": {
        "brands": [
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "Cytarabine & Daunorubicin",
        "regimen_names": [
            "Cytarabine & Daunorubicin"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & G-CSF": {
        "brands": [
            "Cytosar"
        ],
        "cancers": [
            "Stem_cell_mobilization",
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Cytarabine"
        ],
        "regimen": "Cytarabine & G-CSF",
        "regimen_names": [
            "Cytarabine  and  G-CSF",
            "Cytarabine & G-CSF",
            "Cytarabine + G-CSF",
            "Cytarabine / G-CSF",
            "Cytarabine and G-CSF",
            "Cytarabine+G-CSF",
            "Cytarabine/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & Idarubicin": {
        "brands": [
            "Cytosar",
            "Idamycin"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Idarubicin"
        ],
        "regimen": "Cytarabine & Idarubicin",
        "regimen_names": [
            "Cytarabine & Idarubicin"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine": {
        "brands": [
            "Cytosar",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Idarubicin"
        ],
        "regimen": "Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine",
        "regimen_names": [
            "Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA": {
        "brands": [
            "ATRA",
            "Cytosar",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Cytarabine",
            "Idarubicin"
        ],
        "regimen": "Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA",
        "regimen_names": [
            "Cytarabine & Idarubicin, then Etoposide & Mitoxantrone, then Cytarabine, Idarubicin, Thioguanine, with ATRA"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & Mitoxantrone": {
        "brands": [
            "Cytosar",
            "Novantrone"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Mitoxantrone"
        ],
        "regimen": "Cytarabine & Mitoxantrone",
        "regimen_names": [
            "Cytarabine & Mitoxantrone",
            "MIDAC"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine & Thioguanine": {
        "brands": [
            "Cytosar",
            "Tabloid"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Thioguanine"
        ],
        "regimen": "Cytarabine & Thioguanine",
        "regimen_names": [
            "Cytarabine & Thioguanine"
        ],
        "regimen_type": "Consolidation after salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine, Daunorubicin, Gemtuzumab ozogamicin": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Mylotarg"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Gemtuzumab ozogamicin"
        ],
        "regimen": "Cytarabine, Daunorubicin, Gemtuzumab ozogamicin",
        "regimen_names": [
            "Cytarabine, Daunorubicin, Gemtuzumab ozogamicin"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine, Idarubicin, Imatinib": {
        "brands": [
            "Cytosar",
            "Idamycin",
            "Gleevec"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Cytarabine",
            "Idarubicin",
            "Imatinib"
        ],
        "regimen": "Cytarabine, Idarubicin, Imatinib",
        "regimen_names": [
            "Cytarabine, Idarubicin, Imatinib"
        ],
        "regimen_type": "Late intensification",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine, Idarubicin, Sorafenib": {
        "brands": [
            "Cytosar",
            "Idamycin",
            "Nexavar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Idarubicin",
            "Sorafenib"
        ],
        "regimen": "Cytarabine, Idarubicin, Sorafenib",
        "regimen_names": [
            "Cytarabine, Idarubicin, Sorafenib"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine, Ifosfamide, G-CSF": {
        "brands": [
            "Cytosar",
            "Ifex"
        ],
        "cancers": [
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Cytarabine",
            "Ifosfamide"
        ],
        "regimen": "Cytarabine, Ifosfamide, G-CSF",
        "regimen_names": [
            "Cytarabine, Ifosfamide, G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Cytarabine, Methotrexate, Rituximab": {
        "brands": [
            "Cytosar",
            "MTX",
            "Rituxan"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Cytarabine",
            "Methotrexate",
            "Rituximab"
        ],
        "regimen": "Cytarabine, Methotrexate, Rituximab",
        "regimen_names": [
            "Cytarabine, Methotrexate, Rituximab"
        ],
        "regimen_type": "Upfront therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "D-VMP": {
        "brands": [
            "Darzalex",
            "Velcade",
            "Alkeran",
            "Sterapred"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Daratumumab",
            "Bortezomib",
            "Melphalan",
            "Prednisone"
        ],
        "regimen": "D-VMP",
        "regimen_names": [
            "D-VMP",
            "D/VMP",
            "DVMP"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DA 3 + 10": {
        "brands": [
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "DA 3 + 10",
        "regimen_names": [
            "DA 3  &  10",
            "DA 3  /  10",
            "DA 3  10",
            "DA 3  and  10",
            "DA 3 & 10",
            "DA 3 + 10",
            "DA 3 / 10",
            "DA310"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DA 3 + 10, GO": {
        "brands": [
            "Cytosar",
            "Cerubidine",
            "Mylotarg"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Daunorubicin",
            "Gemtuzumab ozogamicin"
        ],
        "regimen": "DA 3 + 10, GO",
        "regimen_names": [
            "DA 3 + 10, GO"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DA-EPOCH": {
        "brands": [
            "Vepesid",
            "Sterapred",
            "Oncovin",
            "Cytoxan",
            "Adriamycin"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Anaplastic_large_cell_lymphoma",
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Etoposide",
            "Prednisone",
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin"
        ],
        "regimen": "DA-EPOCH",
        "regimen_names": [
            "DA-EPOCH",
            "DA/EPOCH",
            "DAEPOCH"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DA-R-EPOCH": {
        "brands": [
            "Rituxan",
            "Vepesid",
            "Sterapred",
            "Oncovin",
            "Cytoxan",
            "Adriamycin"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Mediastinal_gray-zone_lymphoma",
            "Mediastinal_gray-zone_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Etoposide",
            "Prednisone",
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin"
        ],
        "regimen": "DA-R-EPOCH",
        "regimen_names": [
            "DA-R-EPOCH",
            "DA/R/EPOCH",
            "DAREPOCH"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DAC": {
        "brands": [
            "Cerubidine",
            "Cytosar",
            "Leustatin"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Daunorubicin",
            "Cytarabine",
            "Cladribine"
        ],
        "regimen": "DAC",
        "regimen_names": [
            "DAC"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DCEP": {
        "brands": [
            "Decadron",
            "Cytoxan",
            "Vepesid",
            "Platinol"
        ],
        "cancers": [
            "Multiple_myeloma_consolidation_and_maintenance",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Dexamethasone",
            "Cyclophosphamide",
            "Etoposide",
            "Cisplatin"
        ],
        "regimen": "DCEP",
        "regimen_names": [
            "DCEP"
        ],
        "regimen_type": "Consolidation after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DCEP & G-CSF": {
        "brands": [
            "Decadron",
            "Cytoxan",
            "Vepesid",
            "Platinol"
        ],
        "cancers": [
            "Stem_cell_mobilization",
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Dexamethasone",
            "Cyclophosphamide",
            "Etoposide",
            "Cisplatin"
        ],
        "regimen": "DCEP & G-CSF",
        "regimen_names": [
            "DCEP  and  G-CSF",
            "DCEP & G-CSF",
            "DCEP + G-CSF",
            "DCEP / G-CSF",
            "DCEP and G-CSF",
            "DCEP+G-CSF",
            "DCEP/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DCF": {
        "brands": [
            "Taxotere",
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Nasopharyngeal_carcinoma",
            "Nasopharyngeal_carcinoma",
            "Nasopharyngeal_carcinoma",
            "Penile_cancer",
            "SCC_of_unknown_primary",
            "SCC_of_unknown_primary"
        ],
        "drugs": [
            "Docetaxel",
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "DCF",
        "regimen_names": [
            "DCF",
            "TCF"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DD-CHOP": {
        "brands": [
            "Ontak",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Denileukin diftitox",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "DD-CHOP",
        "regimen_names": [
            "DD-CHOP",
            "DD/CHOP",
            "DDCHOP"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DDGP": {
        "brands": [
            "Decadron",
            "Platinol",
            "Gemzar",
            "Oncaspar"
        ],
        "cancers": [
            "NKT-cell_lymphoma"
        ],
        "drugs": [
            "Dexamethasone",
            "Cisplatin",
            "Gemcitabine",
            "Pegaspargase"
        ],
        "regimen": "DDGP",
        "regimen_names": [
            "DDGP"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DE": {
        "brands": [
            "Taxotere",
            "Ellence"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Epirubicin"
        ],
        "regimen": "DE",
        "regimen_names": [
            "DE"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DEB-TACE": {
        "brands": [
            "TACE",
            "Adriamycin"
        ],
        "cancers": [
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "TACE",
            "Doxorubicin"
        ],
        "regimen": "DEB-TACE",
        "regimen_names": [
            "DEB-TACE",
            "DEB/TACE",
            "DEBTACE"
        ],
        "regimen_type": "Local therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DEP & RT": {
        "brands": [
            "Decadron",
            "Vepesid",
            "Platinol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Dexamethasone",
            "Etoposide",
            "Cisplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "DEP & RT",
        "regimen_names": [
            "DEP  and  RT",
            "DEP & RT",
            "DEP + RT",
            "DEP / RT",
            "DEP and RT",
            "DEP+RT",
            "DEP/RT",
            "DEPRT"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DHAP": {
        "brands": [
            "Decadron",
            "Cytosar",
            "Platinol"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Dexamethasone",
            "Cytarabine",
            "Cisplatin"
        ],
        "regimen": "DHAP",
        "regimen_names": [
            "DHAP"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DHAP - time intensified": {
        "brands": [
            "Decadron",
            "Cytosar",
            "Platinol"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Dexamethasone",
            "Cytarabine",
            "Cisplatin"
        ],
        "regimen": "DHAP - time intensified",
        "regimen_names": [
            "DHAP - time intensified"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DI EC": {
        "brands": [
            "Ellence",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Cyclophosphamide"
        ],
        "regimen": "DI EC",
        "regimen_names": [
            "DI EC",
            "DIEC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DOF": {
        "brands": [
            "Taxotere",
            "Eloxatin",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Oxaliplatin",
            "Fluorouracil"
        ],
        "regimen": "DOF",
        "regimen_names": [
            "DOF"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DRC": {
        "brands": [
            "Decadron",
            "Rituxan",
            "Cytoxan"
        ],
        "cancers": [
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Dexamethasone",
            "Rituximab",
            "Cyclophosphamide"
        ],
        "regimen": "DRC",
        "regimen_names": [
            "DRC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DRd": {
        "brands": [
            "Darzalex",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Daratumumab",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "DRd",
        "regimen_names": [
            "DRd"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DTPACE": {
        "brands": [
            "Decadron",
            "Thalomid",
            "Platinol",
            "Adriamycin",
            "Cytoxan",
            "Vepesid"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Dexamethasone",
            "Thalidomide",
            "Cisplatin",
            "Doxorubicin",
            "Cyclophosphamide",
            "Etoposide"
        ],
        "regimen": "DTPACE",
        "regimen_names": [
            "DTPACE"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DVd": {
        "brands": [
            "Darzalex",
            "Velcade",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Daratumumab",
            "Bortezomib",
            "Dexamethasone"
        ],
        "regimen": "DVd",
        "regimen_names": [
            "DVd"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dabigatran monotherapy": {
        "brands": [
            "Pradaxa"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Dabigatran"
        ],
        "regimen": "Dabigatran monotherapy",
        "regimen_names": [
            "Dabigatran monotherapy"
        ],
        "regimen_type": "VTE treatment, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dabrafenib & Trametinib": {
        "brands": [
            "Tafinlar",
            "Mekinist"
        ],
        "cancers": [
            "BRAF",
            "CNS_melanoma",
            "Melanoma_BRAF-mutated",
            "Non-small_cell_lung_cancer_BRAF-mutated",
            "Non-small_cell_lung_cancer_BRAF-mutated",
            "Thyroid_cancer_BRAF-mutated"
        ],
        "drugs": [
            "Dabrafenib",
            "Trametinib"
        ],
        "regimen": "Dabrafenib & Trametinib",
        "regimen_names": [
            "Dabrafenib & Trametinib"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dabrafenib monotherapy": {
        "brands": [
            "Tafinlar"
        ],
        "cancers": [
            "CNS_melanoma",
            "Melanoma_BRAF-mutated"
        ],
        "drugs": [
            "Dabrafenib"
        ],
        "regimen": "Dabrafenib monotherapy",
        "regimen_names": [
            "Dabrafenib monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dacarbazine & Doxorubicin": {
        "brands": [
            "DTIC",
            "Adriamycin"
        ],
        "cancers": [
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Dacarbazine",
            "Doxorubicin"
        ],
        "regimen": "Dacarbazine & Doxorubicin",
        "regimen_names": [
            "Dacarbazine & Doxorubicin"
        ],
        "regimen_type": "Locally advanced or metastatic disease, combination regimens",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dacarbazine & Gemcitabine": {
        "brands": [
            "DTIC",
            "Gemzar"
        ],
        "cancers": [
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Dacarbazine",
            "Gemcitabine"
        ],
        "regimen": "Dacarbazine & Gemcitabine",
        "regimen_names": [
            "Dacarbazine & Gemcitabine"
        ],
        "regimen_type": "Leiomyosarcoma (LMS), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dacarbazine & Interferon alfa": {
        "brands": [
            "DTIC",
            ":Category:Interferons"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Dacarbazine",
            ":Category:Interferons"
        ],
        "regimen": "Dacarbazine & Interferon alfa",
        "regimen_names": [
            "Dacarbazine & Interferon alfa"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dacarbazine & Ipilimumab": {
        "brands": [
            "DTIC",
            "Yervoy"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Dacarbazine",
            "Ipilimumab"
        ],
        "regimen": "Dacarbazine & Ipilimumab",
        "regimen_names": [
            "Dacarbazine & Ipilimumab"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dacarbazine monotherapy": {
        "brands": [
            "DTIC"
        ],
        "cancers": [
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Dacarbazine"
        ],
        "regimen": "Dacarbazine monotherapy",
        "regimen_names": [
            "Dacarbazine monotherapy"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dacomitinib monotherapy": {
        "brands": [
            "Vizimpro"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Dacomitinib"
        ],
        "regimen": "Dacomitinib monotherapy",
        "regimen_names": [
            "Dacomitinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, EGFR inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dactinomycin & Vincristine": {
        "brands": [
            "Cosmegen",
            "Oncovin"
        ],
        "cancers": [
            "Wilms_tumor"
        ],
        "drugs": [
            "Dactinomycin",
            "Vincristine"
        ],
        "regimen": "Dactinomycin & Vincristine",
        "regimen_names": [
            "Dactinomycin & Vincristine"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dactinomycin monotherapy": {
        "brands": [
            "Cosmegen"
        ],
        "cancers": [
            "Endometrial_cancer",
            "Gestational_trophoblastic_neoplasia",
            "Wilms_tumor"
        ],
        "drugs": [
            "Dactinomycin"
        ],
        "regimen": "Dactinomycin monotherapy",
        "regimen_names": [
            "Dactinomycin monotherapy"
        ],
        "regimen_type": "Chemotherapy for advanced, recurrent, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dalteparin monotherapy": {
        "brands": [
            "Fragmin"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Dalteparin"
        ],
        "regimen": "Dalteparin monotherapy",
        "regimen_names": [
            "Dalteparin monotherapy"
        ],
        "regimen_type": "VTE secondary prevention",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Danaparoid monotherapy": {
        "brands": [
            "Orgaran"
        ],
        "cancers": [
            "Heparin-induced_thrombocytopenia_(HIT)"
        ],
        "drugs": [
            "Danaparoid"
        ],
        "regimen": "Danaparoid monotherapy",
        "regimen_names": [
            "Danaparoid monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Daratumumab monotherapy": {
        "brands": [
            "Darzalex"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Daratumumab"
        ],
        "regimen": "Daratumumab monotherapy",
        "regimen_names": [
            "Daratumumab monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dasatinib & Prednisone": {
        "brands": [
            "Sprycel",
            "Sterapred"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Dasatinib",
            "Prednisone"
        ],
        "regimen": "Dasatinib & Prednisone",
        "regimen_names": [
            "Dasatinib & Prednisone"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dasatinib monotherapy": {
        "brands": [
            "Sprycel"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis"
        ],
        "drugs": [
            "Dasatinib"
        ],
        "regimen": "Dasatinib monotherapy",
        "regimen_names": [
            "Dasatinib monotherapy"
        ],
        "regimen_type": "Maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dasatinib, Vincristine, Prednisone": {
        "brands": [
            "Sprycel",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Dasatinib",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "Dasatinib, Vincristine, Prednisone",
        "regimen_names": [
            "Dasatinib, Vincristine, Prednisone"
        ],
        "regimen_type": "Maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Daunorubicin liposomal monotherapy": {
        "brands": [
            "DaunoXome"
        ],
        "cancers": [
            "Vascular_sarcoma",
            "Vascular_sarcoma"
        ],
        "drugs": [
            "Daunorubicin liposomal"
        ],
        "regimen": "Daunorubicin liposomal monotherapy",
        "regimen_names": [
            "Daunorubicin liposomal monotherapy"
        ],
        "regimen_type": "Kaposi sarcoma, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Daunorubicin monotherapy": {
        "brands": [
            "Cerubidine"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Daunorubicin"
        ],
        "regimen": "Daunorubicin monotherapy",
        "regimen_names": [
            "Daunorubicin monotherapy"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Imatinib": {
        "brands": [
            "Cerubidine",
            "Elspar",
            "Oncovin",
            "Sterapred",
            "Gleevec"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Daunorubicin",
            "Asparaginase",
            "Vincristine",
            "Prednisone",
            "Imatinib"
        ],
        "regimen": "Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Imatinib",
        "regimen_names": [
            "Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Imatinib"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Daunorubicin, Vincristine, Prednisolone, Nilotinib": {
        "brands": [
            "Cerubidine",
            "Oncovin",
            "Millipred",
            "Tasigna"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Daunorubicin",
            "Vincristine",
            "Prednisolone",
            "Nilotinib"
        ],
        "regimen": "Daunorubicin, Vincristine, Prednisolone, Nilotinib",
        "regimen_names": [
            "Daunorubicin, Vincristine, Prednisolone, Nilotinib"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Decitabine monotherapy": {
        "brands": [
            "Dacogen"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Chronic_myelomonocytic_leukemia",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Decitabine"
        ],
        "regimen": "Decitabine monotherapy",
        "regimen_names": [
            "Decitabine monotherapy"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Denileukin diftitox monotherapy": {
        "brands": [
            "Ontak"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma",
            "Cutaneous_T-cell_lymphoma",
            "Cutaneous_T-cell_lymphoma"
        ],
        "drugs": [
            "Denileukin diftitox"
        ],
        "regimen": "Denileukin diftitox monotherapy",
        "regimen_names": [
            "Denileukin diftitox monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Denosumab monotherapy": {
        "brands": [
            "Xgeva"
        ],
        "cancers": [
            "Bone_sarcoma",
            "Bone_sarcoma"
        ],
        "drugs": [
            "Denosumab"
        ],
        "regimen": "Denosumab monotherapy",
        "regimen_names": [
            "Denosumab monotherapy"
        ],
        "regimen_type": "Giant-cell tumor of bone, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DexaBEAM": {
        "brands": [
            "Decadron",
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Dexamethasone",
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "DexaBEAM",
        "regimen_names": [
            "DexaBEAM"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "DexaBEAM & G-CSF": {
        "brands": [
            "Decadron",
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Dexamethasone",
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "DexaBEAM & G-CSF",
        "regimen_names": [
            "DexaBEAM  and  G-CSF",
            "DexaBEAM & G-CSF",
            "DexaBEAM + G-CSF",
            "DexaBEAM / G-CSF",
            "DexaBEAM and G-CSF",
            "DexaBEAM+G-CSF",
            "DexaBEAM/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dexamethasone & Eltrombopag": {
        "brands": [
            "Decadron",
            "Promacta"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Dexamethasone",
            "Eltrombopag"
        ],
        "regimen": "Dexamethasone & Eltrombopag",
        "regimen_names": [
            "Dexamethasone & Eltrombopag"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dexamethasone & Rituximab": {
        "brands": [
            "Decadron",
            "Rituxan"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Dexamethasone",
            "Rituximab"
        ],
        "regimen": "Dexamethasone & Rituximab",
        "regimen_names": [
            "Dexamethasone & Rituximab"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dexamethasone & WBRT": {
        "brands": [
            "Decadron",
            "External beam radiotherapy"
        ],
        "cancers": [
            "CNS_carcinoma"
        ],
        "drugs": [
            "Dexamethasone",
            "External beam radiotherapy"
        ],
        "regimen": "Dexamethasone & WBRT",
        "regimen_names": [
            "Dexamethasone  and  WBRT",
            "Dexamethasone & WBRT",
            "Dexamethasone + WBRT",
            "Dexamethasone / WBRT",
            "Dexamethasone and WBRT",
            "Dexamethasone+WBRT",
            "Dexamethasone/WBRT"
        ],
        "regimen_type": "Non-small cell lung cancer, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dexamethasone monotherapy": {
        "brands": [
            "Decadron"
        ],
        "cancers": [
            "CNS_carcinoma",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Dexamethasone"
        ],
        "regimen": "Dexamethasone monotherapy",
        "regimen_names": [
            "Dexamethasone monotherapy"
        ],
        "regimen_type": "Non-small cell lung cancer, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Dinutuximab, GM-CSF, IL-2, Isotretinoin": {
        "brands": [
            "Unituxin",
            "Leukine",
            "Proleukin",
            "Accutane"
        ],
        "cancers": [
            "Neuroblastoma"
        ],
        "drugs": [
            "Dinutuximab",
            "Sargramostim",
            "Aldesleukin",
            "Isotretinoin"
        ],
        "regimen": "Dinutuximab, GM-CSF, IL-2, Isotretinoin",
        "regimen_names": [
            "Dinutuximab, GM-CSF, IL-2, Isotretinoin"
        ],
        "regimen_type": "High-risk, consolidation",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel & Bevacizumab": {
        "brands": [
            "Taxotere",
            "Avastin"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Docetaxel",
            "Bevacizumab"
        ],
        "regimen": "Docetaxel & Bevacizumab",
        "regimen_names": [
            "Bev & D",
            "Bev / D",
            "Bev and D",
            "Bev&D",
            "Bev+D",
            "Bev/D",
            "BevD",
            "Docetaxel & Bevacizumab",
            "T & Bev",
            "T / Bev",
            "T and Bev",
            "T&Bev",
            "T+Bev",
            "T/Bev",
            "TBev"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel & Gemcitabine": {
        "brands": [
            "Taxotere",
            "Gemzar"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Docetaxel",
            "Gemcitabine"
        ],
        "regimen": "Docetaxel & Gemcitabine",
        "regimen_names": [
            "Docetaxel & Gemcitabine"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel & Irinotecan": {
        "brands": [
            "Taxotere",
            "Camptosar"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Irinotecan"
        ],
        "regimen": "Docetaxel & Irinotecan",
        "regimen_names": [
            "Docetaxel & Irinotecan"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel & Ramucirumab": {
        "brands": [
            "Taxotere",
            "Cyramza"
        ],
        "cancers": [
            "Bladder_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Ramucirumab"
        ],
        "regimen": "Docetaxel & Ramucirumab",
        "regimen_names": [
            "Docetaxel & Ramucirumab"
        ],
        "regimen_type": "Locally advanced or metastatic disease, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel & Vandetanib": {
        "brands": [
            "Taxotere",
            "Caprelsa"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Vandetanib"
        ],
        "regimen": "Docetaxel & Vandetanib",
        "regimen_names": [
            "Docetaxel & Vandetanib"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel monotherapy": {
        "brands": [
            "Taxotere"
        ],
        "cancers": [
            "Bladder_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Melanoma",
            "Melanoma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Docetaxel"
        ],
        "regimen": "Docetaxel monotherapy",
        "regimen_names": [
            "Docetaxel monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel, Cetuximab, RT": {
        "brands": [
            "Taxotere",
            "Erbitux",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Cetuximab",
            "External_beam_radiotherapy"
        ],
        "regimen": "Docetaxel, Cetuximab, RT",
        "regimen_names": [
            "Docetaxel, Cetuximab, RT"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel, Fluorouracil, Hydroxyurea, RT": {
        "brands": [
            "Taxotere",
            "5-FU",
            "Hydrea",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Fluorouracil",
            "Hydroxyurea",
            "External_beam_radiotherapy"
        ],
        "regimen": "Docetaxel, Fluorouracil, Hydroxyurea, RT",
        "regimen_names": [
            "Docetaxel, Fluorouracil, Hydroxyurea, RT"
        ],
        "regimen_type": "Locally advanced disease, definitive therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel, Fluorouracil, RT": {
        "brands": [
            "Taxotere",
            "5-FU",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Fluorouracil",
            "External_beam_radiotherapy"
        ],
        "regimen": "Docetaxel, Fluorouracil, RT",
        "regimen_names": [
            "Docetaxel, Fluorouracil, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Docetaxel, Gemcitabine, RT": {
        "brands": [
            "Taxotere",
            "Gemzar"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Gemcitabine"
        ],
        "regimen": "Docetaxel, Gemcitabine, RT",
        "regimen_names": [
            "Docetaxel, Gemcitabine, RT"
        ],
        "regimen_type": "Induction therapy for locally advanced disease, potentially resectable",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin & Gemcitabine": {
        "brands": [
            "Adriamycin",
            "Gemzar"
        ],
        "cancers": [
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Gemcitabine"
        ],
        "regimen": "Doxorubicin & Gemcitabine",
        "regimen_names": [
            "Doxorubicin & Gemcitabine"
        ],
        "regimen_type": "Metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin & Ifosfamide": {
        "brands": [
            "Adriamycin",
            "Ifex"
        ],
        "cancers": [
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Ifosfamide"
        ],
        "regimen": "Doxorubicin & Ifosfamide",
        "regimen_names": [
            "AIM",
            "Doxorubicin & Ifosfamide"
        ],
        "regimen_type": "Locally advanced or metastatic disease, combination regimens",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin & Olaratumab": {
        "brands": [
            "Adriamycin",
            "Lartruvo"
        ],
        "cancers": [
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Olaratumab"
        ],
        "regimen": "Doxorubicin & Olaratumab",
        "regimen_names": [
            "Doxorubicin & Olaratumab"
        ],
        "regimen_type": "Locally advanced or metastatic disease, combination regimens",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin & Streptozocin": {
        "brands": [
            "Adriamycin",
            "Zanosar"
        ],
        "cancers": [
            "Pancreatic_NET"
        ],
        "drugs": [
            "Doxorubicin",
            "Streptozocin"
        ],
        "regimen": "Doxorubicin & Streptozocin",
        "regimen_names": [
            "Doxorubicin & Streptozocin"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin monotherapy": {
        "brands": [
            "Adriamycin"
        ],
        "cancers": [
            "Endometrial_cancer",
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma",
            "Mesothelioma",
            "Mesothelioma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Doxorubicin"
        ],
        "regimen": "Doxorubicin monotherapy",
        "regimen_names": [
            "Doxorubicin monotherapy"
        ],
        "regimen_type": "Chemotherapy for advanced, recurrent, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin pegylated liposomal & Bevacizumab": {
        "brands": [
            "Doxil",
            "Avastin"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Pegylated liposomal doxorubicin",
            "Bevacizumab"
        ],
        "regimen": "Doxorubicin pegylated liposomal & Bevacizumab",
        "regimen_names": [
            "Doxorubicin pegylated liposomal & Bevacizumab"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin pegylated liposomal & Gemcitabine": {
        "brands": [
            "Doxil",
            "Gemzar"
        ],
        "cancers": [
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Pegylated liposomal doxorubicin",
            "Gemcitabine"
        ],
        "regimen": "Doxorubicin pegylated liposomal & Gemcitabine",
        "regimen_names": [
            "Doxorubicin pegylated liposomal & Gemcitabine"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin pegylated liposomal & Trabectedin": {
        "brands": [
            "Doxil",
            "Yondelis"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Pegylated liposomal doxorubicin",
            "Trabectedin"
        ],
        "regimen": "Doxorubicin pegylated liposomal & Trabectedin",
        "regimen_names": [
            "Doxorubicin pegylated liposomal & Trabectedin"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Doxorubicin pegylated liposomal monotherapy": {
        "brands": [
            "Doxil"
        ],
        "cancers": [
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Vascular_sarcoma",
            "Vascular_sarcoma"
        ],
        "drugs": [
            "Pegylated liposomal doxorubicin"
        ],
        "regimen": "Doxorubicin pegylated liposomal monotherapy",
        "regimen_names": [
            "Doxorubicin pegylated liposomal monotherapy"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Durvalumab monotherapy": {
        "brands": [
            "Imfinzi"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Durvalumab"
        ],
        "regimen": "Durvalumab monotherapy",
        "regimen_names": [
            "Durvalumab monotherapy"
        ],
        "regimen_type": "Consolidation or maintenance after definitive therapy for inoperable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Duvelisib monotherapy": {
        "brands": [
            "Copiktra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Duvelisib"
        ],
        "regimen": "Duvelisib monotherapy",
        "regimen_names": [
            "Duvelisib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EAR & G-CSF": {
        "brands": [
            "Vepesid",
            "Cytosar",
            "Rituxan"
        ],
        "cancers": [
            "Stem_cell_mobilization",
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Etoposide",
            "Cytarabine",
            "Rituximab"
        ],
        "regimen": "EAR & G-CSF",
        "regimen_names": [
            "EAR  and  G-CSF",
            "EAR & G-CSF",
            "EAR + G-CSF",
            "EAR / G-CSF",
            "EAR and G-CSF",
            "EAR+G-CSF",
            "EAR/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EBVP": {
        "brands": [
            "Ellence",
            "Blenoxane",
            "Velban",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Epirubicin",
            "Bleomycin",
            "Vinblastine",
            "Prednisone"
        ],
        "regimen": "EBVP",
        "regimen_names": [
            "EBVP"
        ],
        "regimen_type": "Untreated, early-stage unfavorable (ESU)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EBd": {
        "brands": [
            "Empliciti",
            "Velcade",
            "Decadron",
            "Empliciti",
            "Empliciti",
            "Empliciti"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Elotuzumab",
            "Bortezomib",
            "Dexamethasone",
            "Elotuzumab",
            "Elotuzumab",
            "Elotuzumab"
        ],
        "regimen": "EBd",
        "regimen_names": [
            "EBd"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EC": {
        "brands": [
            "Ellence",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Cyclophosphamide"
        ],
        "regimen": "EC",
        "regimen_names": [
            "EC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EC & Bevacizumab": {
        "brands": [
            "Ellence",
            "Cytoxan",
            "Avastin"
        ],
        "cancers": [
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Epirubicin",
            "Cyclophosphamide",
            "Bevacizumab"
        ],
        "regimen": "EC & Bevacizumab",
        "regimen_names": [
            "EC  and  Bevacizumab",
            "EC & Bevacizumab",
            "EC + Bevacizumab",
            "EC / Bevacizumab",
            "EC and Bevacizumab",
            "EC+Bevacizumab",
            "EC/Bevacizumab"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ECF": {
        "brands": [
            "Ellence",
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "ECF",
        "regimen_names": [
            "ECF"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ECF, then 5-FU & RT, then ECF": {
        "brands": [
            "Ellence",
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "ECF, then 5-FU & RT, then ECF",
        "regimen_names": [
            "ECF, then 5-FU & RT, then ECF"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ECH": {
        "brands": [
            "Ellence",
            "Cytoxan",
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Epirubicin",
            "Cyclophosphamide",
            "Trastuzumab"
        ],
        "regimen": "ECH",
        "regimen_names": [
            "ECH"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ECX": {
        "brands": [
            "Ellence",
            "Platinol",
            "Xeloda"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Cisplatin",
            "Capecitabine"
        ],
        "regimen": "ECX",
        "regimen_names": [
            "ECX"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EIA": {
        "brands": [
            "Vepesid",
            "Ifex",
            "Adriamycin"
        ],
        "cancers": [
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Etoposide",
            "Ifosfamide",
            "Doxorubicin"
        ],
        "regimen": "EIA",
        "regimen_names": [
            "EIA"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ELd": {
        "brands": [
            "Empliciti",
            "Revlimid",
            "Decadron",
            "Empliciti"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Elotuzumab",
            "Lenalidomide",
            "Dexamethasone",
            "Elotuzumab"
        ],
        "regimen": "ELd",
        "regimen_names": [
            "ELd",
            "ERd"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EOF": {
        "brands": [
            "Ellence",
            "Eloxatin",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Oxaliplatin",
            "Fluorouracil"
        ],
        "regimen": "EOF",
        "regimen_names": [
            "EOF"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EOX": {
        "brands": [
            "Ellence",
            "Eloxatin",
            "Xeloda"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Oxaliplatin",
            "Capecitabine"
        ],
        "regimen": "EOX",
        "regimen_names": [
            "EOC",
            "EOX"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EP": {
        "brands": [
            "Ellence",
            "Taxol"
        ],
        "cancers": [
            "Breast_cancer"
        ],
        "drugs": [
            "Epirubicin",
            "Paclitaxel"
        ],
        "regimen": "EP",
        "regimen_names": [
            "EP"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EPOCH, dose-escalated": {
        "brands": [
            "Vepesid",
            "Sterapred",
            "Oncovin",
            "Cytoxan",
            "Adriamycin"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Etoposide",
            "Prednisone",
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin"
        ],
        "regimen": "EPOCH, dose-escalated",
        "regimen_names": [
            "EPOCH",
            "EPOCH, dose-escalated"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ESHAP": {
        "brands": [
            "Vepesid",
            "Solumedrol",
            "Cytosar",
            "Platinol"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Etoposide",
            "Methylprednisolone",
            "Cytarabine",
            "Cisplatin"
        ],
        "regimen": "ESHAP",
        "regimen_names": [
            "ESHAP"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "EVAIA": {
        "brands": [
            "Vepesid",
            "Oncovin",
            "Adriamycin",
            "Ifex",
            "Cosmegen"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma"
        ],
        "drugs": [
            "Etoposide",
            "Vincristine",
            "Doxorubicin",
            "Ifosfamide",
            "Dactinomycin"
        ],
        "regimen": "EVAIA",
        "regimen_names": [
            "EVAIA"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Eculizumab monotherapy": {
        "brands": [
            "Soliris"
        ],
        "cancers": [
            "Atypical_hemolytic-uremic_syndrome_(aHUS)",
            "Atypical_hemolytic-uremic_syndrome_(aHUS)",
            "Cold_agglutinin_disease",
            "Cold_agglutinin_disease",
            "Paroxysmal_nocturnal_hemoglobinuria_(PNH)",
            "Paroxysmal_nocturnal_hemoglobinuria_(PNH)",
            "Paroxysmal_nocturnal_hemoglobinuria_(PNH)",
            "Paroxysmal_nocturnal_hemoglobinuria_(PNH)",
            "Paroxysmal_nocturnal_hemoglobinuria_(PNH)"
        ],
        "drugs": [
            "Eculizumab"
        ],
        "regimen": "Eculizumab monotherapy",
        "regimen_names": [
            "Eculizumab monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Edoxaban monotherapy": {
        "brands": [
            ":Category:Low molecular weight heparins",
            "Savaysa"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            ":Category:Low molecular weight heparins",
            "Edoxaban"
        ],
        "regimen": "Edoxaban monotherapy",
        "regimen_names": [
            "Edoxaban monotherapy"
        ],
        "regimen_type": "VTE treatment, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Elo-Pom-dex": {
        "brands": [
            "Empliciti",
            "Pomalyst",
            "Decadron",
            "Empliciti",
            "Empliciti"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Elotuzumab",
            "Pomalidomide",
            "Dexamethasone",
            "Elotuzumab",
            "Elotuzumab"
        ],
        "regimen": "Elo-Pom-dex",
        "regimen_names": [
            "Elo-Pom-dex"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Emicizumab monotherapy": {
        "brands": [
            "Hemlibra"
        ],
        "cancers": [
            "Inherited_coagulopathy",
            "Inherited_coagulopathy"
        ],
        "drugs": [
            "Emicizumab"
        ],
        "regimen": "Emicizumab monotherapy",
        "regimen_names": [
            "Emicizumab monotherapy"
        ],
        "regimen_type": "Factor VIII deficiency (Hemophilia A), without inhibitors, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Enasidenib monotherapy": {
        "brands": [
            "Idhifa"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_IDH-mutated"
        ],
        "drugs": [
            "Enasidenib"
        ],
        "regimen": "Enasidenib monotherapy",
        "regimen_names": [
            "Enasidenib monotherapy"
        ],
        "regimen_type": "IDH2 Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Enoxaparin monotherapy": {
        "brands": [
            "Lovenox"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Enoxaparin"
        ],
        "regimen": "Enoxaparin monotherapy",
        "regimen_names": [
            "Enoxaparin monotherapy"
        ],
        "regimen_type": "VTE primary prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Epirubicin & Ifosfamide": {
        "brands": [
            "Ellence",
            "Ifex"
        ],
        "cancers": [
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Epirubicin",
            "Ifosfamide"
        ],
        "regimen": "Epirubicin & Ifosfamide",
        "regimen_names": [
            "Epirubicin & Ifosfamide"
        ],
        "regimen_type": "Relapsed or refractory disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Epirubicin monotherapy": {
        "brands": [
            "Ellence"
        ],
        "cancers": [
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Epirubicin"
        ],
        "regimen": "Epirubicin monotherapy",
        "regimen_names": [
            "Epirubicin monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, single-agent regimens",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Epoetin & Lenalidomide": {
        "brands": [
            "Revlimid"
        ],
        "cancers": [
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Lenalidomide"
        ],
        "regimen": "Epoetin & Lenalidomide",
        "regimen_names": [
            "Epoetin & Lenalidomide"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Eribulin monotherapy": {
        "brands": [
            "Halaven"
        ],
        "cancers": [
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Eribulin"
        ],
        "regimen": "Eribulin monotherapy",
        "regimen_names": [
            "Eribulin monotherapy"
        ],
        "regimen_type": "Leiomyosarcoma (LMS), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Erlotinib & Bevacizumab": {
        "brands": [
            "Tarceva",
            "Avastin"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Cholangiocarcinoma",
            "Hepatocellular_carcinoma",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Erlotinib",
            "Bevacizumab"
        ],
        "regimen": "Erlotinib & Bevacizumab",
        "regimen_names": [
            "Erlotinib & Bevacizumab"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Erlotinib & Gemcitabine": {
        "brands": [
            "Tarceva",
            "Gemzar"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Erlotinib",
            "Gemcitabine"
        ],
        "regimen": "Erlotinib & Gemcitabine",
        "regimen_names": [
            "Erlotinib & Gemcitabine"
        ],
        "regimen_type": "Induction therapy for locally advanced disease, unresectable",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Erlotinib monotherapy": {
        "brands": [
            "Tarceva"
        ],
        "cancers": [
            "EGFR",
            "Esophageal_cancer",
            "Myelodysplastic_syndrome",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Erlotinib"
        ],
        "regimen": "Erlotinib monotherapy",
        "regimen_names": [
            "Erlotinib monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Etoposide & Mitoxantrone": {
        "brands": [
            "Vepesid",
            "Novantrone"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Etoposide",
            "Mitoxantrone"
        ],
        "regimen": "Etoposide & Mitoxantrone",
        "regimen_names": [
            "Etoposide & Mitoxantrone"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Etoposide & Prednisone": {
        "brands": [
            "Vepesid",
            "Sterapred"
        ],
        "cancers": [
            "Langerhans_cell_histiocytosis"
        ],
        "drugs": [
            "Etoposide",
            "Prednisone"
        ],
        "regimen": "Etoposide & Prednisone",
        "regimen_names": [
            "Etoposide & Prednisone"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Etoposide & TBI": {
        "brands": [
            "External_beam_radiotherapy",
            "Vepesid"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "External_beam_radiotherapy",
            "Etoposide"
        ],
        "regimen": "Etoposide & TBI",
        "regimen_names": [
            "Etoposide  and  TBI",
            "Etoposide & TBI",
            "Etoposide + TBI",
            "Etoposide / TBI",
            "Etoposide and TBI",
            "Etoposide+TBI",
            "Etoposide/TBI"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Etoposide monotherapy": {
        "brands": [
            "Vepesid"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Esophageal_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Vascular_sarcoma"
        ],
        "drugs": [
            "Etoposide"
        ],
        "regimen": "Etoposide monotherapy",
        "regimen_names": [
            "Etoposide monotherapy"
        ],
        "regimen_type": "Recurrent disease, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Everolimus & Lenvatinib": {
        "brands": [
            "Afinitor",
            "Lenvima"
        ],
        "cancers": [
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Everolimus",
            "Lenvatinib"
        ],
        "regimen": "Everolimus & Lenvatinib",
        "regimen_names": [
            "Everolimus & Lenvatinib"
        ],
        "regimen_type": "Metastatic disease, second-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Everolimus & Rituximab": {
        "brands": [
            "Afinitor",
            "Rituxan"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Everolimus",
            "Rituximab"
        ],
        "regimen": "Everolimus & Rituximab",
        "regimen_names": [
            "Everolimus & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Everolimus monotherapy": {
        "brands": [
            "Afinitor"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Mantle_cell_lymphoma",
            "Neuroendocrine_tumors",
            "Pancreatic_NET",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Thymoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Everolimus"
        ],
        "regimen": "Everolimus monotherapy",
        "regimen_names": [
            "Everolimus monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "F-SHAI": {
        "brands": [
            "Fludara",
            "Cytosar",
            "Idamycin"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Fludarabine",
            "Cytarabine",
            "Idarubicin"
        ],
        "regimen": "F-SHAI",
        "regimen_names": [
            "F-SHAI",
            "F/SHAI",
            "FSHAI"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FAC": {
        "brands": [
            "5-FU",
            "Adriamycin",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Fluorouracil",
            "Doxorubicin",
            "Cyclophosphamide"
        ],
        "regimen": "FAC",
        "regimen_names": [
            "FAC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FAS": {
        "brands": [
            "5-FU",
            "Adriamycin",
            "Zanosar"
        ],
        "cancers": [
            "Pancreatic_NET"
        ],
        "drugs": [
            "Fluorouracil",
            "Doxorubicin",
            "Streptozocin"
        ],
        "regimen": "FAS",
        "regimen_names": [
            "FAS"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FC": {
        "brands": [
            "Fludara",
            "Cytoxan"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Fludarabine",
            "Cyclophosphamide"
        ],
        "regimen": "FC",
        "regimen_names": [
            "FC"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FCA": {
        "brands": [
            "Fludara",
            "Cytoxan",
            "Campath"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Fludarabine",
            "Cyclophosphamide",
            "Alemtuzumab"
        ],
        "regimen": "FCA",
        "regimen_names": [
            "FCA",
            "FCCam"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FCM": {
        "brands": [
            "Fludara",
            "Cytoxan",
            "Novantrone"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Fludarabine",
            "Cyclophosphamide",
            "Mitoxantrone"
        ],
        "regimen": "FCM",
        "regimen_names": [
            "FCM"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FCR": {
        "brands": [
            "Fludara",
            "Cytoxan",
            "Rituxan"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Fludarabine",
            "Cyclophosphamide",
            "Rituximab"
        ],
        "regimen": "FCR",
        "regimen_names": [
            "FCR"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FEAM": {
        "brands": [
            "Muphoran",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Fotemustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "FEAM",
        "regimen_names": [
            "FEAM"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FEC": {
        "brands": [
            "5-FU",
            "Ellence",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Epirubicin",
            "Cyclophosphamide"
        ],
        "regimen": "FEC",
        "regimen_names": [
            "FEC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FEC & H": {
        "brands": [
            "5-FU",
            "Ellence",
            "Cytoxan",
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Fluorouracil",
            "Epirubicin",
            "Cyclophosphamide",
            "Trastuzumab"
        ],
        "regimen": "FEC & H",
        "regimen_names": [
            "FEC  and  H",
            "FEC & H",
            "FEC + H",
            "FEC / H",
            "FEC and H",
            "FEC+H",
            "FEC/H",
            "FECH"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FELV": {
        "brands": [
            "5-FU",
            "Vepesid",
            "Leucovorin"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Cholangiocarcinoma"
        ],
        "drugs": [
            "Fluorouracil",
            "Etoposide",
            "Folinic acid"
        ],
        "regimen": "FELV",
        "regimen_names": [
            "FELV"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FLAG": {
        "brands": [
            "Fludara",
            "Cytosar",
            "Neupogen",
            "Granocyte"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Fludarabine",
            "Cytarabine",
            "Filgrastim",
            "Lenograstim"
        ],
        "regimen": "FLAG",
        "regimen_names": [
            "FLAG"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FLAG-Ida": {
        "brands": [
            "Fludara",
            "Cytosar",
            "Granocyte",
            "Idamycin"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Fludarabine",
            "Cytarabine",
            "Lenograstim",
            "Idarubicin"
        ],
        "regimen": "FLAG-Ida",
        "regimen_names": [
            "FLAG-Ida",
            "FLAG/Ida",
            "FLAGIda"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FLEP": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Vepesid",
            "Platinol"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Etoposide",
            "Cisplatin"
        ],
        "regimen": "FLEP",
        "regimen_names": [
            "FLEP"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FLOT": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Taxotere"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Docetaxel"
        ],
        "regimen": "FLOT",
        "regimen_names": [
            "FLOT"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FLOX": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin"
        ],
        "regimen": "FLOX",
        "regimen_names": [
            "FLOX"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRI": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Camptosar"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Irinotecan"
        ],
        "regimen": "FOLFIRI",
        "regimen_names": [
            "FOLFIRI"
        ],
        "regimen_type": "Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRI & Bevacizumab": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Camptosar",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Irinotecan",
            "Bevacizumab"
        ],
        "regimen": "FOLFIRI & Bevacizumab",
        "regimen_names": [
            "FOLFIRI & Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRI & Cetuximab": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Camptosar",
            "Erbitux"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Irinotecan",
            "Cetuximab"
        ],
        "regimen": "FOLFIRI & Cetuximab",
        "regimen_names": [
            "FOLFIRI  and  Cetuximab",
            "FOLFIRI & Cetuximab",
            "FOLFIRI + Cetuximab",
            "FOLFIRI / Cetuximab",
            "FOLFIRI and Cetuximab",
            "FOLFIRI+Cetuximab",
            "FOLFIRI/Cetuximab"
        ],
        "regimen_type": "Perioperative therapy for oligometastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRI & Panitumumab": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Camptosar",
            "Vectibix"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Irinotecan",
            "Panitumumab"
        ],
        "regimen": "FOLFIRI & Panitumumab",
        "regimen_names": [
            "FOLFIRI & Panitumumab"
        ],
        "regimen_type": "Advanced or metastatic disease, second-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRI & Ramucirumab": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Camptosar",
            "Cyramza"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Irinotecan",
            "Ramucirumab"
        ],
        "regimen": "FOLFIRI & Ramucirumab",
        "regimen_names": [
            "FOLFIRI & Ramucirumab"
        ],
        "regimen_type": "Advanced or metastatic disease, second-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRI & Ziv-aflibercept": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Camptosar",
            "Zaltrap"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Irinotecan",
            "Ziv-aflibercept"
        ],
        "regimen": "FOLFIRI & Ziv-aflibercept",
        "regimen_names": [
            "FOLFIRI & Ziv-aflibercept"
        ],
        "regimen_type": "Advanced or metastatic disease, second-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRINOX": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Camptosar"
        ],
        "cancers": [
            "Colon_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Irinotecan"
        ],
        "regimen": "FOLFIRINOX",
        "regimen_names": [
            "FOLFIRINOX",
            "FOLFOXIRI"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFIRINOX & Bevacizumab": {
        "brands": [
            "5-FU",
            "Fusilev",
            "Eloxatin",
            "Camptosar",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Levoleucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Bevacizumab"
        ],
        "regimen": "FOLFIRINOX & Bevacizumab",
        "regimen_names": [
            "FOLFIRINOX & Bevacizumab",
            "FOLFOXIRI & Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Eloxatin"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Oxaliplatin"
        ],
        "regimen": "FOLFOX",
        "regimen_names": [
            "FOLFOX"
        ],
        "regimen_type": "Metastatic disease, refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX2": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Oxaliplatin"
        ],
        "regimen": "FOLFOX2",
        "regimen_names": [
            "FOLFOX2"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX4": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Esophageal_cancer",
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin"
        ],
        "regimen": "FOLFOX4",
        "regimen_names": [
            "FOLFOX4"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX4 & Bevacizumab": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Bevacizumab"
        ],
        "regimen": "FOLFOX4 & Bevacizumab",
        "regimen_names": [
            "FOLFOX-B",
            "FOLFOX/B",
            "FOLFOX4 & Bevacizumab",
            "FOLFOXB"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX4 & Cetuximab": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Erbitux"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Cetuximab"
        ],
        "regimen": "FOLFOX4 & Cetuximab",
        "regimen_names": [
            "FOLFOX4  and  Cetuximab",
            "FOLFOX4 & Cetuximab",
            "FOLFOX4 + Cetuximab",
            "FOLFOX4 / Cetuximab",
            "FOLFOX4 and Cetuximab",
            "FOLFOX4+Cetuximab",
            "FOLFOX4/Cetuximab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX4 & Panitumumab": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Vectibix"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Panitumumab"
        ],
        "regimen": "FOLFOX4 & Panitumumab",
        "regimen_names": [
            "FOLFOX4 & Panitumumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FOLFOX4 & RT": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "FOLFOX4 & RT",
        "regimen_names": [
            "FOLFOX4  and  RT",
            "FOLFOX4 & RT",
            "FOLFOX4 + RT",
            "FOLFOX4 / RT",
            "FOLFOX4 and RT",
            "FOLFOX4+RT",
            "FOLFOX4/RT"
        ],
        "regimen_type": "Definitive therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FP, then Capecitabine & RT, then FP": {
        "brands": [
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "FP, then Capecitabine & RT, then FP",
        "regimen_names": [
            "FP, then Capecitabine & RT, then FP"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FR": {
        "brands": [
            "Fludara",
            "Rituxan"
        ],
        "cancers": [
            "Cold_agglutinin_disease",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Fludarabine",
            "Rituximab"
        ],
        "regimen": "FR",
        "regimen_names": [
            "FR"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FRD": {
        "brands": [
            "Farydak",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Panobinostat",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "FRD",
        "regimen_names": [
            "FRD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "FluCam": {
        "brands": [
            "Fludara",
            "Campath"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Fludarabine",
            "Alemtuzumab"
        ],
        "regimen": "FluCam",
        "regimen_names": [
            "FluCam"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine & Alemtuzumab": {
        "brands": [
            "Fludara",
            "Campath"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Fludarabine",
            "Alemtuzumab"
        ],
        "regimen": "Fludarabine & Alemtuzumab",
        "regimen_names": [
            "Fludarabine & Alemtuzumab"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine & Melphalan": {
        "brands": [
            "Fludara",
            "Alkeran",
            ":Category:Antithymocyte globulin"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "Melphalan",
            ":Category:Antithymocyte globulin"
        ],
        "regimen": "Fludarabine & Melphalan",
        "regimen_names": [
            "Flu-Mel",
            "Flu/Mel",
            "FluMel",
            "Fludarabine & Melphalan"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine & Prednisone": {
        "brands": [
            "Fludara",
            "Sterapred"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Fludarabine",
            "Prednisone"
        ],
        "regimen": "Fludarabine & Prednisone",
        "regimen_names": [
            "Fludarabine & Prednisone"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine & TBI": {
        "brands": [
            "Fludara",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fludarabine & TBI",
        "regimen_names": [
            "Fludarabine  and  TBI",
            "Fludarabine & TBI",
            "Fludarabine + TBI",
            "Fludarabine / TBI",
            "Fludarabine and TBI",
            "Fludarabine+TBI",
            "Fludarabine/TBI"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine monotherapy": {
        "brands": [
            "Fludara"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Fludarabine"
        ],
        "regimen": "Fludarabine monotherapy",
        "regimen_names": [
            "Fludarabine monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine, Busulfan, ATG": {
        "brands": [
            "Fludara",
            "Myleran",
            "Thymoglobulin"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "Busulfan",
            "Antithymocyte globulin, rabbit ATG"
        ],
        "regimen": "Fludarabine, Busulfan, ATG",
        "regimen_names": [
            "Fludarabine, Busulfan, ATG"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine, Busulfan, Cyclophosphamide": {
        "brands": [
            "Fludara",
            "Myleran",
            "Cytoxan"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "Busulfan",
            "Cyclophosphamide"
        ],
        "regimen": "Fludarabine, Busulfan, Cyclophosphamide",
        "regimen_names": [
            "FluBuCy",
            "Fludarabine, Busulfan, Cyclophosphamide"
        ],
        "regimen_type": "Myeloablative regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine, Cyclophosphamide, ATG": {
        "brands": [
            "Fludara",
            "Cytoxan",
            "Grafalon"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "Cyclophosphamide",
            "Antithymocyte globulin, rabbit ATG"
        ],
        "regimen": "Fludarabine, Cyclophosphamide, ATG",
        "regimen_names": [
            "Fludarabine, Cyclophosphamide, ATG"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant": {
        "brands": [
            "Fludara",
            "Cytoxan",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT",
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "Cyclophosphamide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant",
        "regimen_names": [
            "Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant",
            "dUCB"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fludarabine, Melphalan, Alemtuzumab": {
        "brands": [
            "Fludara",
            "Alkeran",
            "Campath"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Fludarabine",
            "Melphalan",
            "Alemtuzumab"
        ],
        "regimen": "Fludarabine, Melphalan, Alemtuzumab",
        "regimen_names": [
            "Fludarabine, Melphalan, Alemtuzumab"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil & Folinic acid": {
        "brands": [
            "5-FU",
            "Leucovorin"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer",
            "Cholangiocarcinoma",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Esophageal_cancer",
            "Hepatocellular_carcinoma",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid"
        ],
        "regimen": "Fluorouracil & Folinic acid",
        "regimen_names": [
            "Fluorouracil & Folinic acid"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil & RT": {
        "brands": [
            "5-FU",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Cervical_cancer",
            "Head_and_neck_cancer",
            "Pancreatic_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fluorouracil & RT",
        "regimen_names": [
            "Fluorouracil  and  RT",
            "Fluorouracil & RT",
            "Fluorouracil + RT",
            "Fluorouracil / RT",
            "Fluorouracil and RT",
            "Fluorouracil+RT",
            "Fluorouracil/RT"
        ],
        "regimen_type": "Definitive chemoradiotherapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil & Streptozocin": {
        "brands": [
            "5-FU",
            "Zanosar"
        ],
        "cancers": [
            "Neuroendocrine_tumors",
            "Pancreatic_NET"
        ],
        "drugs": [
            "Fluorouracil",
            "Streptozocin"
        ],
        "regimen": "Fluorouracil & Streptozocin",
        "regimen_names": [
            "Fluorouracil & Streptozocin"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil monotherapy": {
        "brands": [
            "5-FU"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Head_and_neck_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil"
        ],
        "regimen": "Fluorouracil monotherapy",
        "regimen_names": [
            "Fluorouracil monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Folinic acid, Gemcitabine": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Gemzar"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Gemcitabine"
        ],
        "regimen": "Fluorouracil, Folinic acid, Gemcitabine",
        "regimen_names": [
            "Fluorouracil, Folinic acid, Gemcitabine"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Folinic acid, Mitomycin": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Mutamycin"
        ],
        "cancers": [
            "Gastric_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Mitomycin"
        ],
        "regimen": "Fluorouracil, Folinic acid, Mitomycin",
        "regimen_names": [
            "Fluorouracil, Folinic acid, Mitomycin"
        ],
        "regimen_type": "Metastatic or locally advanced disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Folinic acid, RT": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fluorouracil, Folinic acid, RT",
        "regimen_names": [
            "Fluorouracil, Folinic acid, RT"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Folinic acid, nanoliposomal Irinotecan": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Onivyde"
        ],
        "cancers": [
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Irinotecan liposome"
        ],
        "regimen": "Fluorouracil, Folinic acid, nanoliposomal Irinotecan",
        "regimen_names": [
            "Fluorouracil, Folinic acid, nanoliposomal Irinotecan"
        ],
        "regimen_type": "Metastatic disease, refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Hydroxyurea, RT": {
        "brands": [
            "5-FU",
            "Hydrea",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Hydroxyurea",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fluorouracil, Hydroxyurea, RT",
        "regimen_names": [
            "Fluorouracil, Hydroxyurea, RT"
        ],
        "regimen_type": "Locally advanced disease, definitive therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Mitomycin, RT": {
        "brands": [
            "5-FU",
            "Mutamycin",
            "External beam radiotherapy",
            "External_beam_radiotherapy",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Bladder_cancer",
            "Cervical_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Mitomycin",
            "External beam radiotherapy",
            "External_beam_radiotherapy",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fluorouracil, Mitomycin, RT",
        "regimen_names": [
            "Fluorouracil, Mitomycin, RT"
        ],
        "regimen_type": "Induction chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Oxaliplatin, RT": {
        "brands": [
            "5-FU",
            "Eloxatin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Oxaliplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fluorouracil, Oxaliplatin, RT",
        "regimen_names": [
            "Fluorouracil, Oxaliplatin, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, Paclitaxel, RT": {
        "brands": [
            "5-FU",
            "Taxol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Esophageal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Paclitaxel",
            "External_beam_radiotherapy"
        ],
        "regimen": "Fluorouracil, Paclitaxel, RT",
        "regimen_names": [
            "Fluorouracil, Paclitaxel, RT"
        ],
        "regimen_type": "Neoadjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil, then Fluorouracil & RT, then Fluorouracil": {
        "brands": [
            "5-FU"
        ],
        "cancers": [
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Fluorouracil"
        ],
        "regimen": "Fluorouracil, then Fluorouracil & RT, then Fluorouracil",
        "regimen_names": [
            "Fluorouracil, then Fluorouracil & RT, then Fluorouracil"
        ],
        "regimen_type": "Adjuvant chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fluorouracil/Fluorouracil & RT": {
        "brands": [
            "5-FU"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Fluorouracil"
        ],
        "regimen": "Fluorouracil/Fluorouracil & RT",
        "regimen_names": [
            "Fluorouracil/Fluorouracil & RT"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fondaparinux monotherapy": {
        "brands": [
            "Arixtra"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Fondaparinux"
        ],
        "regimen": "Fondaparinux monotherapy",
        "regimen_names": [
            "Fondaparinux monotherapy"
        ],
        "regimen_type": "VTE treatment, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fondaprinux monotherapy": {
        "brands": [
            "Arixtra"
        ],
        "cancers": [
            "Heparin-induced_thrombocytopenia_(HIT)"
        ],
        "drugs": [
            "Fondaparinux"
        ],
        "regimen": "Fondaprinux monotherapy",
        "regimen_names": [
            "Fondaprinux monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Forodesine monotherapy": {
        "brands": [
            "Fodosine"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Forodesine"
        ],
        "regimen": "Forodesine monotherapy",
        "regimen_names": [
            "Forodesine monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fostamatinib monotherapy": {
        "brands": [
            "Tavalisse"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Fostamatinib"
        ],
        "regimen": "Fostamatinib monotherapy",
        "regimen_names": [
            "Fostamatinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Fotemustine monotherapy": {
        "brands": [
            "Muphoran"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Fotemustine"
        ],
        "regimen": "Fotemustine monotherapy",
        "regimen_names": [
            "Fotemustine monotherapy"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "G-CHOP": {
        "brands": [
            "Gazyva",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Obinutuzumab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "G-CHOP",
        "regimen_names": [
            "G-CHOP",
            "G/CHOP",
            "GCHOP"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "G-CVP": {
        "brands": [
            "Gazyva",
            "Cytoxan",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Obinutuzumab",
            "Cyclophosphamide",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "G-CVP",
        "regimen_names": [
            "G-CVP",
            "G/CVP",
            "GCVP"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "G-FC": {
        "brands": [
            "Gazyva",
            "Fludara",
            "Cytoxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Obinutuzumab",
            "Fludarabine",
            "Cyclophosphamide"
        ],
        "regimen": "G-FC",
        "regimen_names": [
            "G-FC",
            "G/FC",
            "GFC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GCD": {
        "brands": [
            "Gemzar",
            "Paraplatin",
            "Decadron"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Carboplatin",
            "Dexamethasone"
        ],
        "regimen": "GCD",
        "regimen_names": [
            "GCD"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GCD-R": {
        "brands": [
            "Gemzar",
            "Paraplatin",
            "Decadron",
            "Rituxan"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Carboplatin",
            "Dexamethasone",
            "Rituximab"
        ],
        "regimen": "GCD-R",
        "regimen_names": [
            "GCD-R",
            "GCD/R",
            "GCDR"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GCP": {
        "brands": [
            "Gemzar",
            "Paraplatin",
            "Taxol"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary"
        ],
        "drugs": [
            "Gemcitabine",
            "Carboplatin",
            "Paclitaxel"
        ],
        "regimen": "GCP",
        "regimen_names": [
            "GCP"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GDP": {
        "brands": [
            "Gemzar",
            "Decadron",
            "Platinol"
        ],
        "cancers": [
            "Anaplastic_large_cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Dexamethasone",
            "Cisplatin"
        ],
        "regimen": "GDP",
        "regimen_names": [
            "GDP"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GDPT": {
        "brands": [
            "Gemzar",
            "Platinol",
            "Sterapred",
            "Thalomid"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Cisplatin",
            "Prednisone",
            "Thalidomide"
        ],
        "regimen": "GDPT",
        "regimen_names": [
            "GDPT"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GELOX, then RT": {
        "brands": [
            "Gemzar",
            "Elspar",
            "Eloxatin"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Gemcitabine",
            "Asparaginase",
            "Oxaliplatin"
        ],
        "regimen": "GELOX, then RT",
        "regimen_names": [
            "GELOX, then RT"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GEMOX-B": {
        "brands": [
            "Gemzar",
            "Eloxatin",
            "Avastin"
        ],
        "cancers": [
            "Cholangiocarcinoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Oxaliplatin",
            "Bevacizumab"
        ],
        "regimen": "GEMOX-B",
        "regimen_names": [
            "GEMOX-B",
            "GEMOX/B",
            "GEMOXB"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GIP": {
        "brands": [
            "Gemzar",
            "Ifex",
            "Platinol"
        ],
        "cancers": [
            "Testicular_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "Ifosfamide",
            "Cisplatin"
        ],
        "regimen": "GIP",
        "regimen_names": [
            "GIP"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GTX": {
        "brands": [
            "Gemzar",
            "Taxotere",
            "Xeloda"
        ],
        "cancers": [
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "Docetaxel",
            "Capecitabine"
        ],
        "regimen": "GTX",
        "regimen_names": [
            "GTX"
        ],
        "regimen_type": "Metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GVD": {
        "brands": [
            "Gemzar",
            "Navelbine",
            "Doxil"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Vinorelbine",
            "Pegylated liposomal doxorubicin"
        ],
        "regimen": "GVD",
        "regimen_names": [
            "GVD"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GVP": {
        "brands": [
            "Gemzar",
            "Navelbine",
            "Millipred"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Vinorelbine",
            "Prednisolone"
        ],
        "regimen": "GVP",
        "regimen_names": [
            "GVP"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gefitinib & Pemetrexed": {
        "brands": [
            "Iressa",
            "Alimta"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Gefitinib",
            "Pemetrexed"
        ],
        "regimen": "Gefitinib & Pemetrexed",
        "regimen_names": [
            "Gefitinib & Pemetrexed",
            "P & G",
            "P / G",
            "P and G",
            "P&G",
            "P+G",
            "P/G"
        ],
        "regimen_type": "Advanced or metastatic disease, EGFR inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gefitinib monotherapy": {
        "brands": [
            "Iressa"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Gefitinib"
        ],
        "regimen": "Gefitinib monotherapy",
        "regimen_names": [
            "Gefitinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, nonsquamous",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "GemOx": {
        "brands": [
            "Gemzar",
            "Eloxatin"
        ],
        "cancers": [
            "Hepatocellular_carcinoma",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "Oxaliplatin"
        ],
        "regimen": "GemOx",
        "regimen_names": [
            "GemOx"
        ],
        "regimen_type": "First-line therapy for advanced or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & Irinotecan": {
        "brands": [
            "Gemzar",
            "Camptosar"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary"
        ],
        "drugs": [
            "Gemcitabine",
            "Irinotecan"
        ],
        "regimen": "Gemcitabine & Irinotecan",
        "regimen_names": [
            "Gemcitabine & Irinotecan"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & Mitomycin": {
        "brands": [
            "Gemzar",
            "Mutamycin"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Cholangiocarcinoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Mitomycin"
        ],
        "regimen": "Gemcitabine & Mitomycin",
        "regimen_names": [
            "Gemcitabine & Mitomycin"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & Paclitaxel": {
        "brands": [
            "Gemzar",
            "Taxol"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "Paclitaxel"
        ],
        "regimen": "Gemcitabine & Paclitaxel",
        "regimen_names": [
            "Gemcitabine & Paclitaxel"
        ],
        "regimen_type": "Locally advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & RT": {
        "brands": [
            "Gemzar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Gemcitabine & RT",
        "regimen_names": [
            "Gemcitabine  and  RT",
            "Gemcitabine & RT",
            "Gemcitabine + RT",
            "Gemcitabine / RT",
            "Gemcitabine and RT",
            "Gemcitabine+RT",
            "Gemcitabine/RT"
        ],
        "regimen_type": "Induction therapy for locally advanced disease, potentially resectable",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & Rituximab": {
        "brands": [
            "Gemzar",
            "Rituxan"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Rituximab"
        ],
        "regimen": "Gemcitabine & Rituximab",
        "regimen_names": [
            "Gemcitabine & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & Sunitinib": {
        "brands": [
            "Gemzar",
            "Sutent"
        ],
        "cancers": [
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Sunitinib"
        ],
        "regimen": "Gemcitabine & Sunitinib",
        "regimen_names": [
            "Gemcitabine & Sunitinib"
        ],
        "regimen_type": "Metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & Vinorelbine": {
        "brands": [
            "Gemzar",
            "Navelbine"
        ],
        "cancers": [
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Gemcitabine",
            "Vinorelbine"
        ],
        "regimen": "Gemcitabine & Vinorelbine",
        "regimen_names": [
            "Gemcitabine & Vinorelbine"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine & nab-Paclitaxel": {
        "brands": [
            "Gemzar",
            "Abraxane"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "Paclitaxel, nanoparticle albumin-bound"
        ],
        "regimen": "Gemcitabine & nab-Paclitaxel",
        "regimen_names": [
            "Gemcitabine & nab-Paclitaxel"
        ],
        "regimen_type": "Metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine monotherapy": {
        "brands": [
            "Gemzar"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Cervical_cancer",
            "Cholangiocarcinoma",
            "Cholangiocarcinoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Hodgkin_lymphoma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Osteosarcoma",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Gemcitabine"
        ],
        "regimen": "Gemcitabine monotherapy",
        "regimen_names": [
            "Gemcitabine monotherapy"
        ],
        "regimen_type": "Intravesical chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine, Cetuximab, RT": {
        "brands": [
            "Erbitux",
            "Gemzar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Cetuximab",
            "Gemcitabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Gemcitabine, Cetuximab, RT",
        "regimen_names": [
            "Gemcitabine, Cetuximab, RT"
        ],
        "regimen_type": "Induction therapy for locally advanced disease, potentially resectable",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine, Oxaliplatin, Paclitaxel": {
        "brands": [
            "Gemzar",
            "Eloxatin",
            "Taxol"
        ],
        "cancers": [
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "Oxaliplatin",
            "Paclitaxel"
        ],
        "regimen": "Gemcitabine, Oxaliplatin, Paclitaxel",
        "regimen_names": [
            "GOP",
            "Gemcitabine, Oxaliplatin, Paclitaxel"
        ],
        "regimen_type": "Subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine, then Fluorouracil & RT, then Gemcitabine": {
        "brands": [
            "Gemzar"
        ],
        "cancers": [
            "Cholangiocarcinoma",
            "Cholangiocarcinoma",
            "Cholangiocarcinoma"
        ],
        "drugs": [
            "Gemcitabine"
        ],
        "regimen": "Gemcitabine, then Fluorouracil & RT, then Gemcitabine",
        "regimen_names": [
            "Gemcitabine, then Fluorouracil & RT, then Gemcitabine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemcitabine/Fluorouracil & RT": {
        "brands": [
            "Gemzar"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Gemcitabine"
        ],
        "regimen": "Gemcitabine/Fluorouracil & RT",
        "regimen_names": [
            "Gemcitabine/Fluorouracil & RT"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gemtuzumab ozogamicin monotherapy": {
        "brands": [
            "Mylotarg"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Gemtuzumab ozogamicin"
        ],
        "regimen": "Gemtuzumab ozogamicin monotherapy",
        "regimen_names": [
            "Gemtuzumab ozogamicin monotherapy"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gilteritinib monotherapy": {
        "brands": [
            "Xospata"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_FLT3-positive"
        ],
        "drugs": [
            "Gilteritinib"
        ],
        "regimen": "Gilteritinib monotherapy",
        "regimen_names": [
            "Gilteritinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Glasdegib & LoDAC": {
        "brands": [
            "Daurismo",
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Glasdegib",
            "Cytarabine"
        ],
        "regimen": "Glasdegib & LoDAC",
        "regimen_names": [
            "Glasdegib  and  LoDAC",
            "Glasdegib & LoDAC",
            "Glasdegib + LoDAC",
            "Glasdegib / LoDAC",
            "Glasdegib and LoDAC",
            "Glasdegib+LoDAC",
            "Glasdegib/LoDAC"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Gliadel wafer": {
        "brands": [
            "Gliadel"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Carmustine wafer, polifeprosan 20"
        ],
        "regimen": "Gliadel wafer",
        "regimen_names": [
            "Gliadel wafer"
        ],
        "regimen_type": "Recurrent disease, non-curative therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HAA": {
        "brands": [
            "Synribo",
            "Cytosar",
            "Aclacinon"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Omacetaxine",
            "Cytarabine",
            "Aclarubicin"
        ],
        "regimen": "HAA",
        "regimen_names": [
            "HAA"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HAD": {
        "brands": [
            "Synribo",
            "Cytosar",
            "Cerubidine"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Omacetaxine",
            "Cytarabine",
            "Daunorubicin"
        ],
        "regimen": "HAD",
        "regimen_names": [
            "HAD"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HAM": {
        "brands": [
            "Cytosar",
            "Novantrone"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Mitoxantrone"
        ],
        "regimen": "HAM",
        "regimen_names": [
            "HAM"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HAM & Imatinib": {
        "brands": [
            "Cytosar",
            "Novantrone",
            "Gleevec"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Cytarabine",
            "Mitoxantrone",
            "Imatinib"
        ],
        "regimen": "HAM & Imatinib",
        "regimen_names": [
            "HAM  and  Imatinib",
            "HAM & Imatinib",
            "HAM + Imatinib",
            "HAM / Imatinib",
            "HAM and Imatinib",
            "HAM+Imatinib",
            "HAM/Imatinib"
        ],
        "regimen_type": "Consolidation after upfront therapy (including post-remission therapy)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HDAC & G-CSF": {
        "brands": [
            "Cytosar",
            "Neupogen"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Filgrastim"
        ],
        "regimen": "HDAC & G-CSF",
        "regimen_names": [
            "HDAC  and  G-CSF",
            "HDAC & G-CSF",
            "HDAC + G-CSF",
            "HDAC / G-CSF",
            "HDAC and G-CSF",
            "HDAC+G-CSF",
            "HDAC/G-CSF"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HDMP-R": {
        "brands": [
            "Solumedrol",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Methylprednisolone",
            "Rituximab"
        ],
        "regimen": "HDMP-R",
        "regimen_names": [
            "HDMP-R",
            "HDMP/R",
            "HDMPR"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Heparin monotherapy": {
        "brands": [
            "Heparin"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Heparin"
        ],
        "regimen": "Heparin monotherapy",
        "regimen_names": [
            "Heparin monotherapy"
        ],
        "regimen_type": "VTE treatment, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hepatic arterial chemotherapy": {
        "brands": [
            "FUDR"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Floxuridine"
        ],
        "regimen": "Hepatic arterial chemotherapy",
        "regimen_names": [
            "Hepatic arterial chemotherapy"
        ],
        "regimen_type": "Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HiDAC": {
        "brands": [
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Cytarabine"
        ],
        "regimen": "HiDAC",
        "regimen_names": [
            "HDAC",
            "HDAraC",
            "HiDAC"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "High-dose Interleukin-2": {
        "brands": [
            "Proleukin"
        ],
        "cancers": [
            "Melanoma",
            "Melanoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Aldesleukin"
        ],
        "regimen": "High-dose Interleukin-2",
        "regimen_names": [
            "HD IL-2",
            "HD IL/2",
            "HD IL2",
            "HDIL2",
            "High-dose Interleukin-2"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hydroxyurea & Imatinib": {
        "brands": [
            "Hydrea",
            "Gleevec"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Hydroxyurea",
            "Imatinib"
        ],
        "regimen": "Hydroxyurea & Imatinib",
        "regimen_names": [
            "Hydroxyurea & Imatinib"
        ],
        "regimen_type": "Recurrent disease, non-curative therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hydroxyurea & RT": {
        "brands": [
            "Hydrea",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Hydroxyurea",
            "External_beam_radiotherapy"
        ],
        "regimen": "Hydroxyurea & RT",
        "regimen_names": [
            "Hydroxyurea  and  RT",
            "Hydroxyurea & RT",
            "Hydroxyurea + RT",
            "Hydroxyurea / RT",
            "Hydroxyurea and RT",
            "Hydroxyurea+RT",
            "Hydroxyurea/RT"
        ],
        "regimen_type": "Definitive chemoradiotherapy for locally advanced disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hydroxyurea monotherapy": {
        "brands": [
            "Hydrea"
        ],
        "cancers": [
            "Essential_thrombocythemia",
            "Glioblastoma",
            "Hypereosinophilic_syndrome",
            "Polycythemia_vera",
            "Polycythemia_vera",
            "Sickle_cell_anemia"
        ],
        "drugs": [
            "Hydroxyurea"
        ],
        "regimen": "Hydroxyurea monotherapy",
        "regimen_names": [
            "Hydroxyurea monotherapy"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hyper-CVAD": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "Hyper-CVAD",
        "regimen_names": [
            "Hyper-CVAD",
            "Hyper/CVAD",
            "HyperCVAD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hyper-CVAD & Dasatinib": {
        "brands": [
            "MTX",
            "Cytosar"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Methotrexate",
            "Cytarabine"
        ],
        "regimen": "Hyper-CVAD & Dasatinib",
        "regimen_names": [
            "Hyper-CVAD & Dasatinib"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Hyper-CVAD & Imatinib": {
        "brands": [
            "MTX",
            "Cytosar"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Methotrexate",
            "Cytarabine"
        ],
        "regimen": "Hyper-CVAD & Imatinib",
        "regimen_names": [
            "Hyper-CVAD & Imatinib"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "HyperCHidam": {
        "brands": [
            "MTX",
            "Cytoxan",
            "Cytosar"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Cyclophosphamide",
            "Cytarabine"
        ],
        "regimen": "HyperCHidam",
        "regimen_names": [
            "HyperCHidam"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ICE": {
        "brands": [
            "Ifex",
            "Paraplatin",
            "Vepesid"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Carboplatin",
            "Etoposide"
        ],
        "regimen": "ICE",
        "regimen_names": [
            "ICE"
        ],
        "regimen_type": "Relapsed or refractory or metastatic",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ICL": {
        "brands": [
            "Idamycin",
            "Cytosar",
            "Ceenu"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Idarubicin",
            "Cytarabine",
            "Lomustine"
        ],
        "regimen": "ICL",
        "regimen_names": [
            "ICL"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IDAC": {
        "brands": [
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine"
        ],
        "regimen": "IDAC",
        "regimen_names": [
            "IDAC",
            "mIDAC"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IDAC & Sorafenib": {
        "brands": [
            "Cytosar",
            "Nexavar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_FLT3-positive"
        ],
        "drugs": [
            "Cytarabine",
            "Sorafenib"
        ],
        "regimen": "IDAC & Sorafenib",
        "regimen_names": [
            "IDAC  and  Sorafenib",
            "IDAC & Sorafenib",
            "IDAC + Sorafenib",
            "IDAC / Sorafenib",
            "IDAC and Sorafenib",
            "IDAC+Sorafenib",
            "IDAC/Sorafenib"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IE": {
        "brands": [
            "Ifex",
            "Vepesid"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Etoposide"
        ],
        "regimen": "IE",
        "regimen_names": [
            "IE"
        ],
        "regimen_type": "Relapsed or refractory or metastatic",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IFL": {
        "brands": [
            "Camptosar",
            "5-FU",
            "Leucovorin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Irinotecan",
            "Fluorouracil",
            "Folinic acid"
        ],
        "regimen": "IFL",
        "regimen_names": [
            "IFL",
            "mIFL"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IFL & Bevacizumab": {
        "brands": [
            "Camptosar",
            "5-FU",
            "Leucovorin",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Irinotecan",
            "Fluorouracil",
            "Folinic acid",
            "Bevacizumab"
        ],
        "regimen": "IFL & Bevacizumab",
        "regimen_names": [
            "IFL  and  Bevacizumab",
            "IFL & Bevacizumab",
            "IFL + Bevacizumab",
            "IFL / Bevacizumab",
            "IFL and Bevacizumab",
            "IFL+Bevacizumab",
            "IFL/Bevacizumab",
            "mIFL  and  Bevacizumab",
            "mIFL & Bevacizumab",
            "mIFL + Bevacizumab",
            "mIFL / Bevacizumab",
            "mIFL and Bevacizumab",
            "mIFL+Bevacizumab",
            "mIFL/Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IGEV": {
        "brands": [
            "Ifex",
            "Gemzar",
            "Navelbine",
            "Millipred"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Gemcitabine",
            "Vinorelbine",
            "Prednisolone"
        ],
        "regimen": "IGEV",
        "regimen_names": [
            "IGEV"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IGEV & G-CSF": {
        "brands": [
            "Ifex",
            "Gemzar",
            "Navelbine",
            "Millipred"
        ],
        "cancers": [
            "Stem_cell_mobilization",
            "Stem_cell_mobilization"
        ],
        "drugs": [
            "Ifosfamide",
            "Gemcitabine",
            "Vinorelbine",
            "Prednisolone"
        ],
        "regimen": "IGEV & G-CSF",
        "regimen_names": [
            "IGEV  and  G-CSF",
            "IGEV & G-CSF",
            "IGEV + G-CSF",
            "IGEV / G-CSF",
            "IGEV and G-CSF",
            "IGEV+G-CSF",
            "IGEV/G-CSF"
        ],
        "regimen_type": "Stem cell mobilization, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IP-BCD": {
        "brands": [
            "Ifex",
            "Platinol",
            "Blenoxane",
            "Cytoxan",
            "Cosmegen"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Cisplatin",
            "Bleomycin",
            "Cyclophosphamide",
            "Dactinomycin"
        ],
        "regimen": "IP-BCD",
        "regimen_names": [
            "IP-BCD",
            "IP/BCD",
            "IPBCD"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IRIS": {
        "brands": [
            "Camptosar",
            "S-1"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Irinotecan",
            "Tegafur, gimeracil, oteracil"
        ],
        "regimen": "IRIS",
        "regimen_names": [
            "IRIS"
        ],
        "regimen_type": "Advanced or metastatic disease, second-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IRIS & Bevacizumab": {
        "brands": [
            "Camptosar",
            "S-1",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Irinotecan",
            "Tegafur, gimeracil, oteracil",
            "Bevacizumab"
        ],
        "regimen": "IRIS & Bevacizumab",
        "regimen_names": [
            "IRIS  and  Bevacizumab",
            "IRIS & Bevacizumab",
            "IRIS + Bevacizumab",
            "IRIS / Bevacizumab",
            "IRIS and Bevacizumab",
            "IRIS+Bevacizumab",
            "IRIS/Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IROX": {
        "brands": [
            "Camptosar",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Irinotecan",
            "Oxaliplatin"
        ],
        "regimen": "IROX",
        "regimen_names": [
            "IROX"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IRd": {
        "brands": [
            "Ninlaro",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Ixazomib",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "IRd",
        "regimen_names": [
            "IRd"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IT Cytarabine & WBRT": {
        "brands": [
            "Cytosar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "CNS_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "IT Cytarabine & WBRT",
        "regimen_names": [
            "Cytarabine  and  WBRT",
            "Cytarabine & WBRT",
            "Cytarabine + WBRT",
            "Cytarabine / WBRT",
            "Cytarabine and WBRT",
            "Cytarabine+WBRT",
            "Cytarabine/WBRT",
            "IT Cytarabine  and  WBRT",
            "IT Cytarabine & WBRT",
            "IT Cytarabine + WBRT",
            "IT Cytarabine / WBRT",
            "IT Cytarabine and WBRT",
            "IT Cytarabine+WBRT",
            "IT Cytarabine/WBRT"
        ],
        "regimen_type": "CNS prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IT Cytarabine liposomal monotherapy": {
        "brands": [
            "DepoCyt"
        ],
        "cancers": [
            "CNS_lymphoma"
        ],
        "drugs": [
            "Cytarabine liposomal"
        ],
        "regimen": "IT Cytarabine liposomal monotherapy",
        "regimen_names": [
            "IT Cytarabine liposomal monotherapy"
        ],
        "regimen_type": "Intrathecal, treatment",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IT Cytarabine monotherapy": {
        "brands": [
            "Cytosar"
        ],
        "cancers": [
            "CNS_lymphoma"
        ],
        "drugs": [
            "Cytarabine"
        ],
        "regimen": "IT Cytarabine monotherapy",
        "regimen_names": [
            "IT Cytarabine monotherapy"
        ],
        "regimen_type": "Intrathecal, treatment",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IT Cytarabine, Methotrexate, WBRT": {
        "brands": [
            "MTX",
            "Cytosar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "CNS_leukemia"
        ],
        "drugs": [
            "Methotrexate",
            "Cytarabine",
            "External_beam_radiotherapy"
        ],
        "regimen": "IT Cytarabine, Methotrexate, WBRT",
        "regimen_names": [
            "Cytarabine, Methotrexate, WBRT",
            "IT Cytarabine, Methotrexate, WBRT"
        ],
        "regimen_type": "CNS treatment",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IT Methotrexate & WBRT": {
        "brands": [
            "MTX",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "CNS_leukemia",
            "CNS_leukemia"
        ],
        "drugs": [
            "Methotrexate",
            "External_beam_radiotherapy"
        ],
        "regimen": "IT Methotrexate & WBRT",
        "regimen_names": [
            "IT Methotrexate & WBRT"
        ],
        "regimen_type": "CNS prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "IT Methotrexate monotherapy": {
        "brands": [
            "MTX"
        ],
        "cancers": [
            "CNS_leukemia"
        ],
        "drugs": [
            "Methotrexate"
        ],
        "regimen": "IT Methotrexate monotherapy",
        "regimen_names": [
            "IT Methotrexate monotherapy"
        ],
        "regimen_type": "CNS treatment",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ibritumomab tiuxetan monotherapy": {
        "brands": [
            "Rituxan",
            "Zevalin"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Ibritumomab tiuxetan"
        ],
        "regimen": "Ibritumomab tiuxetan monotherapy",
        "regimen_names": [
            "Ibritumomab tiuxetan monotherapy"
        ],
        "regimen_type": "Early disease, definitive therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ibrutinib & Obinutuzumab": {
        "brands": [
            "Imbruvica",
            "Gazyva"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Ibrutinib",
            "Obinutuzumab"
        ],
        "regimen": "Ibrutinib & Obinutuzumab",
        "regimen_names": [
            "Ibrutinib & Obinutuzumab"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ibrutinib & Ofatumumab": {
        "brands": [
            "Imbruvica",
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Ibrutinib",
            "Ofatumumab"
        ],
        "regimen": "Ibrutinib & Ofatumumab",
        "regimen_names": [
            "Ibrutinib & Ofatumumab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ibrutinib & Rituximab": {
        "brands": [
            "Imbruvica",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Mantle_cell_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Ibrutinib",
            "Rituximab"
        ],
        "regimen": "Ibrutinib & Rituximab",
        "regimen_names": [
            "Ibrutinib & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ibrutinib & Venetoclax": {
        "brands": [
            "Imbruvica",
            "Venclexta"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Ibrutinib",
            "Venetoclax"
        ],
        "regimen": "Ibrutinib & Venetoclax",
        "regimen_names": [
            "Ibrutinib & Venetoclax"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ibrutinib monotherapy": {
        "brands": [
            "Imbruvica"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Graft_versus_host_disease_(GVHD)",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Ibrutinib"
        ],
        "regimen": "Ibrutinib monotherapy",
        "regimen_names": [
            "Ibrutinib monotherapy"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Icotinib monotherapy": {
        "brands": [
            "Conmana"
        ],
        "cancers": [
            "CNS_carcinoma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Icotinib"
        ],
        "regimen": "Icotinib monotherapy",
        "regimen_names": [
            "Icotinib monotherapy"
        ],
        "regimen_type": "Non-small cell lung cancer, EGFR-mutated, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Idarubicin, then Mitoxantrone, then Idarubicin": {
        "brands": [
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Idarubicin"
        ],
        "regimen": "Idarubicin, then Mitoxantrone, then Idarubicin",
        "regimen_names": [
            "Idarubicin, then Mitoxantrone, then Idarubicin"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA": {
        "brands": [
            "ATRA",
            "Idamycin"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "All-trans retinoic acid",
            "Idarubicin"
        ],
        "regimen": "Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA",
        "regimen_names": [
            "Idarubicin, then Mitoxantrone, then Idarubicin, with ATRA"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Idelalisib & Ofatumumab": {
        "brands": [
            "Zydelig",
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Idelalisib",
            "Ofatumumab"
        ],
        "regimen": "Idelalisib & Ofatumumab",
        "regimen_names": [
            "Idelalisib & Ofatumumab"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Idelalisib & Rituximab": {
        "brands": [
            "Zydelig",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Idelalisib",
            "Rituximab"
        ],
        "regimen": "Idelalisib & Rituximab",
        "regimen_names": [
            "Idelalisib & Rituximab"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Idelalisib monotherapy": {
        "brands": [
            "Zydelig"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Follicular_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Idelalisib"
        ],
        "regimen": "Idelalisib monotherapy",
        "regimen_names": [
            "Idelalisib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ifosfamide & Methotrexate": {
        "brands": [
            "Ifex",
            "MTX"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Methotrexate"
        ],
        "regimen": "Ifosfamide & Methotrexate",
        "regimen_names": [
            "Ifosfamide & Methotrexate"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ifosfamide & Paclitaxel": {
        "brands": [
            "Ifex",
            "Taxol"
        ],
        "cancers": [
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Ifosfamide",
            "Paclitaxel"
        ],
        "regimen": "Ifosfamide & Paclitaxel",
        "regimen_names": [
            "Ifosfamide & Paclitaxel"
        ],
        "regimen_type": "Chemotherapy for advanced, recurrent, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ifosfamide & Vinorelbine": {
        "brands": [
            "Ifex",
            "Navelbine"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Vinorelbine"
        ],
        "regimen": "Ifosfamide & Vinorelbine",
        "regimen_names": [
            "Ifosfamide & Vinorelbine"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ifosfamide monotherapy": {
        "brands": [
            "Ifex"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Thymoma",
            "Thymoma",
            "Thymoma",
            "Thymoma"
        ],
        "drugs": [
            "Ifosfamide"
        ],
        "regimen": "Ifosfamide monotherapy",
        "regimen_names": [
            "Ifosfamide monotherapy"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib & LoDAC": {
        "brands": [
            "Gleevec",
            "Cytosar"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Imatinib",
            "Cytarabine"
        ],
        "regimen": "Imatinib & LoDAC",
        "regimen_names": [
            "Imatinib  and  LoDAC",
            "Imatinib & LoDAC",
            "Imatinib + LoDAC",
            "Imatinib / LoDAC",
            "Imatinib and LoDAC",
            "Imatinib+LoDAC",
            "Imatinib/LoDAC"
        ],
        "regimen_type": "Chronic phase, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib & Prednisone": {
        "brands": [
            "Gleevec",
            "Sterapred"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Imatinib",
            "Prednisone"
        ],
        "regimen": "Imatinib & Prednisone",
        "regimen_names": [
            "Imatinib & Prednisone"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib monotherapy": {
        "brands": [
            "Gleevec"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Gastrointestinal_stromal_tumor",
            "Gastrointestinal_stromal_tumor",
            "Gastrointestinal_stromal_tumor",
            "Gastrointestinal_stromal_tumor",
            "Gastrointestinal_stromal_tumor",
            "Gastrointestinal_stromal_tumor",
            "Gastrointestinal_stromal_tumor",
            "Hypereosinophilic_syndrome",
            "Melanoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis",
            "Systemic_mastocytosis"
        ],
        "drugs": [
            "Imatinib"
        ],
        "regimen": "Imatinib monotherapy",
        "regimen_names": [
            "Imatinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib monotherapy, high dose": {
        "brands": [
            "Gleevec"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Imatinib"
        ],
        "regimen": "Imatinib monotherapy, high dose",
        "regimen_names": [
            "Imatinib monotherapy, high dose"
        ],
        "regimen_type": "Chronic phase, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib monotherapy, intermittent therapy": {
        "brands": [
            "Gleevec"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Imatinib"
        ],
        "regimen": "Imatinib monotherapy, intermittent therapy",
        "regimen_names": [
            "Imatinib monotherapy, intermittent therapy"
        ],
        "regimen_type": "Chronic phase, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib monotherapy, planned discontinuation": {
        "brands": [
            "Gleevec"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Imatinib"
        ],
        "regimen": "Imatinib monotherapy, planned discontinuation",
        "regimen_names": [
            "Imatinib monotherapy, planned discontinuation"
        ],
        "regimen_type": "Chronic phase, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Imatinib, Vincristine, Dexamethasone": {
        "brands": [
            "Gleevec",
            "Oncovin",
            "Decadron"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive"
        ],
        "drugs": [
            "Imatinib",
            "Vincristine",
            "Dexamethasone"
        ],
        "regimen": "Imatinib, Vincristine, Dexamethasone",
        "regimen_names": [
            "Imatinib, Vincristine, Dexamethasone"
        ],
        "regimen_type": "Upfront induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Inotuzumab ozogamicin monotherapy": {
        "brands": [
            "Besponsa"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Inotuzumab ozogamicin"
        ],
        "regimen": "Inotuzumab ozogamicin monotherapy",
        "regimen_names": [
            "Inotuzumab ozogamicin monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Interferon alfa monotherapy": {
        "brands": [
            ":Category:Interferons"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia",
            "Hairy_cell_leukemia",
            "Mantle_cell_lymphoma",
            "Vascular_sarcoma"
        ],
        "drugs": [
            ":Category:Interferons"
        ],
        "regimen": "Interferon alfa monotherapy",
        "regimen_names": [
            "Interferon alfa monotherapy"
        ],
        "regimen_type": "Chronic phase, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Interferon alfa-2a & Interleukin-2": {
        "brands": [
            "Roferon-A",
            "Proleukin"
        ],
        "cancers": [
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Interferon alfa-2a",
            "Aldesleukin"
        ],
        "regimen": "Interferon alfa-2a & Interleukin-2",
        "regimen_names": [
            "Interferon alfa-2a & Interleukin-2"
        ],
        "regimen_type": "Metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Interferon alfa-2a monotherapy": {
        "brands": [
            "Roferon-A"
        ],
        "cancers": [
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Interferon alfa-2a"
        ],
        "regimen": "Interferon alfa-2a monotherapy",
        "regimen_names": [
            "Interferon alfa-2a monotherapy"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Interferon alfa-2b & DLI": {
        "brands": [
            "Intron-A"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Interferon alfa-2b"
        ],
        "regimen": "Interferon alfa-2b & DLI",
        "regimen_names": [
            "DLI",
            "Interferon alfa-2b & DLI"
        ],
        "regimen_type": "Chronic phase, relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Interferon alfa-2b & Zidovudine": {
        "brands": [
            "Intron-A",
            "Retrovir"
        ],
        "cancers": [
            "Adult_T-cell_leukemia-lymphoma"
        ],
        "drugs": [
            "Interferon alfa-2b",
            "Zidovudine"
        ],
        "regimen": "Interferon alfa-2b & Zidovudine",
        "regimen_names": [
            "Interferon alfa-2b & Zidovudine"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Interferon alfa-2b monotherapy": {
        "brands": [
            "Intron-A"
        ],
        "cancers": [
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Neuroendocrine_tumors",
            "Renal_cell_carcinoma",
            "Systemic_mastocytosis"
        ],
        "drugs": [
            "Interferon alfa-2b"
        ],
        "regimen": "Interferon alfa-2b monotherapy",
        "regimen_names": [
            "HDI",
            "Interferon alfa-2b monotherapy"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Intraperitoneal 5-FU": {
        "brands": [
            "5-FU",
            "Leucovorin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid"
        ],
        "regimen": "Intraperitoneal 5-FU",
        "regimen_names": [
            "Intraperitoneal 5-FU"
        ],
        "regimen_type": "Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Intraperitoneal hyperthermic mitomycin": {
        "brands": [
            "Mutamycin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Mitomycin"
        ],
        "regimen": "Intraperitoneal hyperthermic mitomycin",
        "regimen_names": [
            "Intraperitoneal hyperthermic mitomycin"
        ],
        "regimen_type": "Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Intravenous immunoglobuin monotherapy": {
        "brands": [
            "IVIG"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Intravenous immunoglobulin"
        ],
        "regimen": "Intravenous immunoglobuin monotherapy",
        "regimen_names": [
            "IVIG",
            "Intravenous immunoglobuin monotherapy"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ipilimumab & Nivolumab": {
        "brands": [
            "Yervoy",
            "Opdivo"
        ],
        "cancers": [
            "Melanoma",
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Ipilimumab",
            "Nivolumab"
        ],
        "regimen": "Ipilimumab & Nivolumab",
        "regimen_names": [
            "Ipilimumab & Nivolumab"
        ],
        "regimen_type": "Maintenance immunotherapy for metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ipilimumab monotherapy": {
        "brands": [
            "Yervoy"
        ],
        "cancers": [
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Non-small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Ipilimumab"
        ],
        "regimen": "Ipilimumab monotherapy",
        "regimen_names": [
            "Ipilimumab monotherapy"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Irinotecan & Bevacizumab": {
        "brands": [
            "Camptosar",
            "Avastin"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma"
        ],
        "drugs": [
            "Irinotecan",
            "Bevacizumab"
        ],
        "regimen": "Irinotecan & Bevacizumab",
        "regimen_names": [
            "Irinotecan & Bevacizumab"
        ],
        "regimen_type": "Recurrent disease, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Irinotecan & Cetuximab": {
        "brands": [
            "Camptosar",
            "Performance status",
            "Erbitux"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Irinotecan",
            "Performance status",
            "Cetuximab"
        ],
        "regimen": "Irinotecan & Cetuximab",
        "regimen_names": [
            "Irinotecan & Cetuximab"
        ],
        "regimen_type": "Advanced or metastatic disease, second-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Irinotecan & Mitomycin": {
        "brands": [
            "Camptosar",
            "Mutamycin"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Irinotecan",
            "Mitomycin"
        ],
        "regimen": "Irinotecan & Mitomycin",
        "regimen_names": [
            "Irinotecan & Mitomycin"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Irinotecan & Temozolomide": {
        "brands": [
            "Camptosar",
            "Temodar"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma"
        ],
        "drugs": [
            "Irinotecan",
            "Temozolomide"
        ],
        "regimen": "Irinotecan & Temozolomide",
        "regimen_names": [
            "Irinotecan & Temozolomide"
        ],
        "regimen_type": "Relapsed or refractory or metastatic",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Irinotecan liposomal monotherapy": {
        "brands": [
            "Onivyde"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Irinotecan liposome"
        ],
        "regimen": "Irinotecan liposomal monotherapy",
        "regimen_names": [
            "Irinotecan liposomal monotherapy"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Irinotecan monotherapy": {
        "brands": [
            "Camptosar"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Cervical_cancer",
            "Cervical_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Glioblastoma",
            "Glioblastoma",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Irinotecan"
        ],
        "regimen": "Irinotecan monotherapy",
        "regimen_names": [
            "Irinotecan monotherapy"
        ],
        "regimen_type": "Recurrent disease, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Isotretinoin monotherapy": {
        "brands": [
            "Accutane"
        ],
        "cancers": [
            "Neuroblastoma"
        ],
        "drugs": [
            "Isotretinoin"
        ],
        "regimen": "Isotretinoin monotherapy",
        "regimen_names": [
            "Isotretinoin monotherapy"
        ],
        "regimen_type": "High-risk, consolidation",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ivosidenib monotherapy": {
        "brands": [
            "Tibsovo"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_IDH-mutated"
        ],
        "drugs": [
            "Ivosidenib"
        ],
        "regimen": "Ivosidenib monotherapy",
        "regimen_names": [
            "Ivosidenib monotherapy"
        ],
        "regimen_type": "IDH1 relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ixazomib & Dexamethasone": {
        "brands": [
            "Ninlaro",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Ixazomib",
            "Dexamethasone"
        ],
        "regimen": "Ixazomib & Dexamethasone",
        "regimen_names": [
            "Ixazomib & Dexamethasone"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ixazomib monotherapy": {
        "brands": [
            "Ninlaro"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Ixazomib"
        ],
        "regimen": "Ixazomib monotherapy",
        "regimen_names": [
            "Ixazomib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "KTd": {
        "brands": [
            "Velcade",
            "Thalomid"
        ],
        "cancers": [
            "Multiple_myeloma_consolidation_and_maintenance"
        ],
        "drugs": [
            "Bortezomib",
            "Thalidomide"
        ],
        "regimen": "KTd",
        "regimen_names": [
            "KTd"
        ],
        "regimen_type": "Consolidation after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "L-Asparaginase, Vincristine, Prednisolone": {
        "brands": [
            "Elspar",
            "Oncovin",
            "Millipred"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Asparaginase",
            "Vincristine",
            "Prednisolone"
        ],
        "regimen": "L-Asparaginase, Vincristine, Prednisolone",
        "regimen_names": [
            "L-Asparaginase, Vincristine, Prednisolone",
            "LVP"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "L-glutamine monotherapy": {
        "brands": [
            "Endari"
        ],
        "cancers": [
            "Sickle_cell_anemia"
        ],
        "drugs": [
            "L-glutamine"
        ],
        "regimen": "L-glutamine monotherapy",
        "regimen_names": [
            "L-glutamine monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "LEED": {
        "brands": [
            "Alkeran",
            "Cytoxan",
            "Vepesid",
            "Decadron"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Melphalan",
            "Cyclophosphamide",
            "Etoposide",
            "Dexamethasone"
        ],
        "regimen": "LEED",
        "regimen_names": [
            "LEED"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "LSG15": {
        "brands": [
            "Oncovin",
            "Cytoxan",
            "Adriamycin",
            "Sterapred",
            "Cymerin",
            "Eldisine",
            "Vepesid",
            "Paraplatin"
        ],
        "cancers": [
            "Adult_T-cell_leukemia-lymphoma"
        ],
        "drugs": [
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin",
            "Prednisone",
            "Ranimustine",
            "Vindesine",
            "Etoposide",
            "Carboplatin"
        ],
        "regimen": "LSG15",
        "regimen_names": [
            "LSG15"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "LVP \"Sandwich\"": {
        "brands": [
            "Elspar",
            "Oncovin",
            "Millipred"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Asparaginase",
            "Vincristine",
            "Prednisolone"
        ],
        "regimen": "LVP \"Sandwich\"",
        "regimen_names": [
            "LVP",
            "LVP \"Sandwich\""
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lapatinib & Trastuzumab": {
        "brands": [
            "Tykerb",
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Lapatinib",
            "Trastuzumab"
        ],
        "regimen": "Lapatinib & Trastuzumab",
        "regimen_names": [
            "Lapatinib & Trastuzumab"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lenalidomide & Ofatumumab": {
        "brands": [
            "Revlimid",
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Lenalidomide",
            "Ofatumumab"
        ],
        "regimen": "Lenalidomide & Ofatumumab",
        "regimen_names": [
            "Lenalidomide & Ofatumumab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lenalidomide & Rituximab": {
        "brands": [
            "Revlimid",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Lenalidomide",
            "Rituximab"
        ],
        "regimen": "Lenalidomide & Rituximab",
        "regimen_names": [
            "Lenalidomide & Rituximab"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lenalidomide monotherapy": {
        "brands": [
            "Revlimid"
        ],
        "cancers": [
            "Adult_T-cell_leukemia-lymphoma",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Cutaneous_T-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Multiple_myeloma_relapsedrefractory",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome",
            "Myelofibrosis",
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma",
            "Plasma_cell_leukemia",
            "Polycythemia_vera",
            "Transformed_lymphoma",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Lenalidomide"
        ],
        "regimen": "Lenalidomide monotherapy",
        "regimen_names": [
            "Lenalidomide monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lenalidomide, Dexamethasone, Rituximab": {
        "brands": [
            "Revlimid",
            "Decadron",
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Lenalidomide",
            "Dexamethasone",
            "Rituximab"
        ],
        "regimen": "Lenalidomide, Dexamethasone, Rituximab",
        "regimen_names": [
            "Lenalidomide, Dexamethasone, Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lenvatinib monotherapy": {
        "brands": [
            "Lenvima"
        ],
        "cancers": [
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma",
            "Renal_cell_carcinoma",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Lenvatinib"
        ],
        "regimen": "Lenvatinib monotherapy",
        "regimen_names": [
            "Lenvatinib monotherapy"
        ],
        "regimen_type": "First-line therapy for advanced or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lepirudin monotherapy": {
        "brands": [
            "Refludan"
        ],
        "cancers": [
            "Heparin-induced_thrombocytopenia_(HIT)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Lepirudin"
        ],
        "regimen": "Lepirudin monotherapy",
        "regimen_names": [
            "Lepirudin monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "LoDAC": {
        "brands": [
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Cytarabine"
        ],
        "regimen": "LoDAC",
        "regimen_names": [
            "LDAC",
            "LoDAC"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "LoDAC & Venetoclax": {
        "brands": [
            "Cytosar",
            "Venclexta"
        ],
        "cancers": [
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Cytarabine",
            "Venetoclax"
        ],
        "regimen": "LoDAC & Venetoclax",
        "regimen_names": [
            "LoDAC  and  Venetoclax",
            "LoDAC & Venetoclax",
            "LoDAC + Venetoclax",
            "LoDAC / Venetoclax",
            "LoDAC and Venetoclax",
            "LoDAC+Venetoclax",
            "LoDAC/Venetoclax"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lomustine monotherapy": {
        "brands": [
            "Ceenu"
        ],
        "cancers": [
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma"
        ],
        "drugs": [
            "Lomustine"
        ],
        "regimen": "Lomustine monotherapy",
        "regimen_names": [
            "Lomustine monotherapy"
        ],
        "regimen_type": "Recurrent disease, non-curative therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lomustine, Methotrexate, Procarbazine": {
        "brands": [
            "Ceenu",
            "MTX",
            "Matulane"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Lomustine",
            "Methotrexate",
            "Procarbazine"
        ],
        "regimen": "Lomustine, Methotrexate, Procarbazine",
        "regimen_names": [
            "Lomustine, Methotrexate, Procarbazine",
            "MCP"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lomustine, Methotrexate, Procarbazine, Methylprednisolone": {
        "brands": [
            "MTX",
            "Ceenu",
            "Matulane",
            "Solumedrol"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Lomustine",
            "Procarbazine",
            "Methylprednisolone"
        ],
        "regimen": "Lomustine, Methotrexate, Procarbazine, Methylprednisolone",
        "regimen_names": [
            "Lomustine, Methotrexate, Procarbazine, Methylprednisolone"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lomustine, Vincristine, Prednisone": {
        "brands": [
            "Ceenu",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Anaplastic_glioma"
        ],
        "drugs": [
            "Lomustine",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "Lomustine, Vincristine, Prednisone",
        "regimen_names": [
            "Lomustine, Vincristine, Prednisone"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lorlatinib monotherapy": {
        "brands": [
            "Lorbrena"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer_ALK-positive",
            "Non-small_cell_lung_cancer_ROS1-positive"
        ],
        "drugs": [
            "Lorlatinib"
        ],
        "regimen": "Lorlatinib monotherapy",
        "regimen_names": [
            "Lorlatinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, ALK inhibitor-exposed",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Low-dose Interleukin-2": {
        "brands": [
            "Proleukin"
        ],
        "cancers": [
            "Melanoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Aldesleukin"
        ],
        "regimen": "Low-dose Interleukin-2",
        "regimen_names": [
            "LD IL-2",
            "LD IL/2",
            "LD IL2",
            "LDIL2",
            "Low-dose Interleukin-2"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Lutetium Lu 177 dotatate & Octreotide LAR": {
        "brands": [
            "Lutathera",
            "Sandostatin"
        ],
        "cancers": [
            "Neuroendocrine_tumors"
        ],
        "drugs": [
            "Lutetium Lu 177 dotatate",
            "Octreotide"
        ],
        "regimen": "Lutetium Lu 177 dotatate & Octreotide LAR",
        "regimen_names": [
            "Lutetium Lu 177 dotatate & Octreotide LAR"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "M-BCD": {
        "brands": [
            "MTX",
            "Blenoxane",
            "Cytoxan",
            "Cosmegen"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Bleomycin",
            "Cyclophosphamide",
            "Dactinomycin"
        ],
        "regimen": "M-BCD",
        "regimen_names": [
            "M-BCD",
            "M/BCD",
            "MBCD"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "M-DEX": {
        "brands": [
            "Alkeran",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Melphalan",
            "Dexamethasone"
        ],
        "regimen": "M-DEX",
        "regimen_names": [
            "M-DEX",
            "M/DEX",
            "MDEX"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "M-EI": {
        "brands": [
            "MTX",
            "Vepesid",
            "Ifex"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Etoposide",
            "Ifosfamide"
        ],
        "regimen": "M-EI",
        "regimen_names": [
            "M-EI",
            "M/EI",
            "MEI"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "M-TIP": {
        "brands": [
            "MTX",
            "Taxol",
            "Ifex",
            "Platinol"
        ],
        "cancers": [
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Methotrexate",
            "Paclitaxel",
            "Ifosfamide",
            "Cisplatin"
        ],
        "regimen": "M-TIP",
        "regimen_names": [
            "M-TIP",
            "M/TIP",
            "MTIP"
        ],
        "regimen_type": "Upfront therapy for disseminated disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MA": {
        "brands": [
            "MTX",
            "Adriamycin"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Doxorubicin"
        ],
        "regimen": "MA",
        "regimen_names": [
            "MA"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MA-BCD": {
        "brands": [
            "Adriamycin"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Doxorubicin"
        ],
        "regimen": "MA-BCD",
        "regimen_names": [
            "MA-BCD",
            "MA/BCD",
            "MABCD"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MA-BCD/AP": {
        "brands": [
            "MTX",
            "Adriamycin",
            "Blenoxane",
            "Cytoxan",
            "Cosmegen",
            "Adriamycin",
            "Platinol"
        ],
        "cancers": [
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Doxorubicin",
            "Bleomycin",
            "Cyclophosphamide",
            "Dactinomycin",
            "Doxorubicin",
            "Cisplatin"
        ],
        "regimen": "MA-BCD/AP",
        "regimen_names": [
            "MA-BCD/AP",
            "MA/BCD/AP",
            "MABCD/AP",
            "MABCDAP"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MAID": {
        "brands": [
            "Adriamycin",
            "Ifex",
            "DTIC"
        ],
        "cancers": [
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Ifosfamide",
            "Dacarbazine"
        ],
        "regimen": "MAID",
        "regimen_names": [
            "MAID"
        ],
        "regimen_type": "Locally advanced or metastatic disease, combination regimens",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MAP": {
        "brands": [
            "MTX",
            "Adriamycin",
            "Platinol"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Doxorubicin",
            "Cisplatin"
        ],
        "regimen": "MAP",
        "regimen_names": [
            "MAP"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MAPI": {
        "brands": [
            "MTX",
            "Platinol",
            "Adriamycin",
            "Ifex"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Cisplatin",
            "Doxorubicin",
            "Ifosfamide"
        ],
        "regimen": "MAPI",
        "regimen_names": [
            "MAPI"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MAPIE": {
        "brands": [
            "MTX",
            "Adriamycin",
            "Platinol",
            "Ifex",
            "Vepesid"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Doxorubicin",
            "Cisplatin",
            "Ifosfamide",
            "Etoposide"
        ],
        "regimen": "MAPIE",
        "regimen_names": [
            "MAPIE"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MATRix": {
        "brands": [
            "MTX",
            "Cytosar",
            "Thioplex",
            "Rituxan"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Cytarabine",
            "Thiotepa",
            "Rituximab"
        ],
        "regimen": "MATRix",
        "regimen_names": [
            "MATRix"
        ],
        "regimen_type": "Upfront therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MCF": {
        "brands": [
            "Mutamycin",
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Mitomycin",
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "MCF",
        "regimen_names": [
            "MCF"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MCP": {
        "brands": [
            "Novantrone",
            "Leukeran",
            "Sterapred"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma"
        ],
        "drugs": [
            "Mitoxantrone",
            "Chlorambucil",
            "Prednisone"
        ],
        "regimen": "MCP",
        "regimen_names": [
            "MCP"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MCV": {
        "brands": [
            "MTX",
            "Platinol",
            "Velban"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer"
        ],
        "drugs": [
            "Methotrexate",
            "Cisplatin",
            "Vinblastine"
        ],
        "regimen": "MCV",
        "regimen_names": [
            "CMV",
            "MCV"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MEC": {
        "brands": [
            "Novantrone",
            "Vepesid",
            "Cytosar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia"
        ],
        "drugs": [
            "Mitoxantrone",
            "Etoposide",
            "Cytarabine"
        ],
        "regimen": "MEC",
        "regimen_names": [
            "MEC",
            "MICE"
        ],
        "regimen_type": "Upfront induction therapy, standard and older \"fit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MESA": {
        "brands": [
            "MTX",
            "Vepesid",
            "Decadron",
            "Oncaspar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Methotrexate",
            "Etoposide",
            "Dexamethasone",
            "Pegaspargase",
            "External_beam_radiotherapy"
        ],
        "regimen": "MESA",
        "regimen_names": [
            "MESA"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MINE": {
        "brands": [
            "Ifex",
            "Novantrone",
            "Vepesid"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Ifosfamide",
            "Mitoxantrone",
            "Etoposide"
        ],
        "regimen": "MINE",
        "regimen_names": [
            "MINE"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MOPP": {
        "brands": [
            "Mustargen",
            "Oncovin",
            "Matulane",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Mechlorethamine",
            "Vincristine",
            "Procarbazine",
            "Prednisone"
        ],
        "regimen": "MOPP",
        "regimen_names": [
            "MOPP"
        ],
        "regimen_type": "Untreated, advanced stage",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MOPP-ABV": {
        "brands": [
            "Mustargen",
            "Oncovin",
            "Matulane",
            "Sterapred",
            "Adriamycin",
            "Blenoxane",
            "Velban"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Mechlorethamine",
            "Vincristine",
            "Procarbazine",
            "Prednisone",
            "Doxorubicin",
            "Bleomycin",
            "Vinblastine"
        ],
        "regimen": "MOPP-ABV",
        "regimen_names": [
            "MOPP-ABV",
            "MOPP/ABV",
            "MOPPABV"
        ],
        "regimen_type": "Untreated, early-stage favorable (ESF)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MP": {
        "brands": [
            "Alkeran",
            "Sterapred"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Melphalan",
            "Prednisone"
        ],
        "regimen": "MP",
        "regimen_names": [
            "MP"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MPR": {
        "brands": [
            "Alkeran",
            "Sterapred",
            "Revlimid"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Melphalan",
            "Prednisone",
            "Lenalidomide"
        ],
        "regimen": "MPR",
        "regimen_names": [
            "MPL",
            "MPR"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MPT": {
        "brands": [
            "Alkeran",
            "Sterapred",
            "Thalomid"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Melphalan",
            "Prednisone",
            "Thalidomide"
        ],
        "regimen": "MPT",
        "regimen_names": [
            "MPT"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MPV": {
        "brands": [
            "MTX",
            "Matulane",
            "Oncovin"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Procarbazine",
            "Vincristine"
        ],
        "regimen": "MPV",
        "regimen_names": [
            "MPV"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MRD": {
        "brands": [
            "Revlimid",
            "Alkeran",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Lenalidomide",
            "Melphalan",
            "Dexamethasone"
        ],
        "regimen": "MRD",
        "regimen_names": [
            "L-M-Dex",
            "L/M/Dex",
            "LMDex",
            "MRD"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MT-R": {
        "brands": [
            "MTX",
            "Temodar",
            "Rituxan"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Temozolomide",
            "Rituximab"
        ],
        "regimen": "MT-R",
        "regimen_names": [
            "MT-R",
            "MT/R",
            "MTR"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MVAC": {
        "brands": [
            "MTX",
            "Velban",
            "Adriamycin",
            "Platinol"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer"
        ],
        "drugs": [
            "Methotrexate",
            "Vinblastine",
            "Doxorubicin",
            "Cisplatin"
        ],
        "regimen": "MVAC",
        "regimen_names": [
            "MVAC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MVAC, dose-dense": {
        "brands": [
            "MTX",
            "Velban",
            "Adriamycin",
            "Platinol"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer"
        ],
        "drugs": [
            "Methotrexate",
            "Vinblastine",
            "Doxorubicin",
            "Cisplatin"
        ],
        "regimen": "MVAC, dose-dense",
        "regimen_names": [
            "AMVAC",
            "MVAC, dose-dense",
            "ddMVAC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "MVBP": {
        "brands": [
            "MTX",
            "Vepesid",
            "BiCNU",
            "Solumedrol"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Etoposide",
            "Carmustine",
            "Methylprednisolone"
        ],
        "regimen": "MVBP",
        "regimen_names": [
            "MVBP"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Melphalan & TBI": {
        "brands": [
            "Alkeran",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Melphalan",
            "External_beam_radiotherapy"
        ],
        "regimen": "Melphalan & TBI",
        "regimen_names": [
            "Melphalan  and  TBI",
            "Melphalan & TBI",
            "Melphalan + TBI",
            "Melphalan / TBI",
            "Melphalan and TBI",
            "Melphalan+TBI",
            "Melphalan/TBI"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Melphalan monotherapy": {
        "brands": [
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Melphalan"
        ],
        "regimen": "Melphalan monotherapy",
        "regimen_names": [
            "Melphalan monotherapy"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Melphalan, then auto HSCT": {
        "brands": [
            "Alkeran"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Plasma_cell_leukemia"
        ],
        "drugs": [
            "Melphalan"
        ],
        "regimen": "Melphalan, then auto HSCT",
        "regimen_names": [
            "Melphalan, then auto HSCT"
        ],
        "regimen_type": "Consolidation after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mepolizumab monotherapy": {
        "brands": [
            "Nucala"
        ],
        "cancers": [
            "Hypereosinophilic_syndrome"
        ],
        "drugs": [
            "Mepolizumab"
        ],
        "regimen": "Mepolizumab monotherapy",
        "regimen_names": [
            "Mepolizumab monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mercaptopurine & Methotrexate": {
        "brands": [
            "Purinethol",
            "MTX"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia",
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Mercaptopurine",
            "Methotrexate"
        ],
        "regimen": "Mercaptopurine & Methotrexate",
        "regimen_names": [
            "Mercaptopurine & Methotrexate"
        ],
        "regimen_type": "Maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mercaptopurine & WBRT": {
        "brands": [
            "Purinethol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "CNS_leukemia",
            "CNS_leukemia"
        ],
        "drugs": [
            "Mercaptopurine",
            "External_beam_radiotherapy"
        ],
        "regimen": "Mercaptopurine & WBRT",
        "regimen_names": [
            "Mercaptopurine & WBRT"
        ],
        "regimen_type": "CNS prophylaxis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mercaptopurine, Methotrexate, Vinblastine, Prednisolone": {
        "brands": [
            "Purinethol",
            "MTX",
            "Velban",
            "Millipred"
        ],
        "cancers": [
            "Langerhans_cell_histiocytosis"
        ],
        "drugs": [
            "Mercaptopurine",
            "Methotrexate",
            "Vinblastine",
            "Prednisolone"
        ],
        "regimen": "Mercaptopurine, Methotrexate, Vinblastine, Prednisolone",
        "regimen_names": [
            "Mercaptopurine, Methotrexate, Vinblastine, Prednisolone"
        ],
        "regimen_type": "Relapsed or refractory, maintenance",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate & Prednisone": {
        "brands": [
            "MTX",
            "Sterapred"
        ],
        "cancers": [
            "Large_granular_lymphocytic_leukemia"
        ],
        "drugs": [
            "Methotrexate",
            "Prednisone"
        ],
        "regimen": "Methotrexate & Prednisone",
        "regimen_names": [
            "Methotrexate & Prednisone"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate & Rituximab": {
        "brands": [
            "MTX",
            "Rituxan"
        ],
        "cancers": [
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Rituximab"
        ],
        "regimen": "Methotrexate & Rituximab",
        "regimen_names": [
            "Methotrexate & Rituximab"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate & Vincristine": {
        "brands": [
            "MTX",
            "Oncovin"
        ],
        "cancers": [
            "Osteosarcoma",
            "Osteosarcoma"
        ],
        "drugs": [
            "Methotrexate",
            "Vincristine"
        ],
        "regimen": "Methotrexate & Vincristine",
        "regimen_names": [
            "Methotrexate & Vincristine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate monotherapy": {
        "brands": [
            "MTX"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "Cutaneous_T-cell_lymphoma",
            "Gestational_trophoblastic_neoplasia",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Methotrexate"
        ],
        "regimen": "Methotrexate monotherapy",
        "regimen_names": [
            "Methotrexate monotherapy"
        ],
        "regimen_type": "Upfront therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate, Tacrolimus, Tocilizumab": {
        "brands": [
            "MTX",
            "Prograf",
            "Actemra"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            "Methotrexate",
            "Tacrolimus",
            "Tocilizumab"
        ],
        "regimen": "Methotrexate, Tacrolimus, Tocilizumab",
        "regimen_names": [
            "Methotrexate, Tacrolimus, Tocilizumab"
        ],
        "regimen_type": "Prevention",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate, Tacrolimus, Vorinostat": {
        "brands": [
            "MTX",
            "Prograf",
            "Zolinza"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            "Methotrexate",
            "Tacrolimus",
            "Vorinostat"
        ],
        "regimen": "Methotrexate, Tacrolimus, Vorinostat",
        "regimen_names": [
            "Methotrexate, Tacrolimus, Vorinostat"
        ],
        "regimen_type": "Prevention",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate, Vinblastine, Prednisone": {
        "brands": [
            "MTX",
            "Velban",
            "Sterapred"
        ],
        "cancers": [
            "Langerhans_cell_histiocytosis"
        ],
        "drugs": [
            "Methotrexate",
            "Vinblastine",
            "Prednisone"
        ],
        "regimen": "Methotrexate, Vinblastine, Prednisone",
        "regimen_names": [
            "Methotrexate, Vinblastine, Prednisone"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate, then Cytarabine": {
        "brands": [
            "MTX"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate"
        ],
        "regimen": "Methotrexate, then Cytarabine",
        "regimen_names": [
            "Methotrexate, then Cytarabine"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methotrexate, then Cytarabine & Thiotepa": {
        "brands": [
            "MTX"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Methotrexate"
        ],
        "regimen": "Methotrexate, then Cytarabine & Thiotepa",
        "regimen_names": [
            "Methotrexate, then Cytarabine & Thiotepa"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Methylprednisolone monotherapy": {
        "brands": [
            "Solumedrol"
        ],
        "cancers": [
            "Thrombotic_thrombocytopenic_purpura",
            "Thrombotic_thrombocytopenic_purpura"
        ],
        "drugs": [
            "Methylprednisolone"
        ],
        "regimen": "Methylprednisolone monotherapy",
        "regimen_names": [
            "Methylprednisolone monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Midostaurin monotherapy": {
        "brands": [
            "Rydapt"
        ],
        "cancers": [
            "Acute_myeloid_leukemia_FLT3-positive",
            "Acute_myeloid_leukemia_FLT3-positive",
            "Acute_myeloid_leukemia_FLT3-positive",
            "Myelodysplastic_syndrome",
            "Myelodysplastic_syndrome"
        ],
        "drugs": [
            "Midostaurin"
        ],
        "regimen": "Midostaurin monotherapy",
        "regimen_names": [
            "Midostaurin monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mini-BEAM": {
        "brands": [
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "Mini-BEAM",
        "regimen_names": [
            "Mini-BEAM",
            "Mini/BEAM",
            "MiniBEAM"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mitomycin monotherapy": {
        "brands": [
            "Mutamycin"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer"
        ],
        "drugs": [
            "Mitomycin"
        ],
        "regimen": "Mitomycin monotherapy",
        "regimen_names": [
            "Mitomycin monotherapy"
        ],
        "regimen_type": "Intravesical chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mitotane & EDP": {
        "brands": [
            "Lysodren",
            "Vepesid",
            "Adriamycin",
            "Platinol"
        ],
        "cancers": [
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma"
        ],
        "drugs": [
            "Mitotane",
            "Etoposide",
            "Doxorubicin",
            "Cisplatin"
        ],
        "regimen": "Mitotane & EDP",
        "regimen_names": [
            "Mitotane  and  EDP",
            "Mitotane & EDP",
            "Mitotane + EDP",
            "Mitotane / EDP",
            "Mitotane and EDP",
            "Mitotane+EDP",
            "Mitotane/EDP"
        ],
        "regimen_type": "Recurrent, locally advanced, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mitotane & Streptozocin": {
        "brands": [
            "Lysodren",
            "Zanosar"
        ],
        "cancers": [
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma"
        ],
        "drugs": [
            "Mitotane",
            "Streptozocin"
        ],
        "regimen": "Mitotane & Streptozocin",
        "regimen_names": [
            "Mitotane & Streptozocin"
        ],
        "regimen_type": "Recurrent, locally advanced, or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mitotane monotherapy": {
        "brands": [
            "Lysodren"
        ],
        "cancers": [
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma",
            "Adrenocortical_carcinoma"
        ],
        "drugs": [
            "Mitotane"
        ],
        "regimen": "Mitotane monotherapy",
        "regimen_names": [
            "Mitotane monotherapy"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mitoxantrone monotherapy": {
        "brands": [
            "Novantrone"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Mitoxantrone"
        ],
        "regimen": "Mitoxantrone monotherapy",
        "regimen_names": [
            "Mitoxantrone monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mogamulizumab monotherapy": {
        "brands": [
            "Poteligeo"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma",
            "Cutaneous_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Mogamulizumab"
        ],
        "regimen": "Mogamulizumab monotherapy",
        "regimen_names": [
            "Mogamulizumab monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Moxetumomab pasudotox monotherapy": {
        "brands": [
            "Lumoxiti"
        ],
        "cancers": [
            "Hairy_cell_leukemia"
        ],
        "drugs": [
            "Moxetumomab pasudotox"
        ],
        "regimen": "Moxetumomab pasudotox monotherapy",
        "regimen_names": [
            "Moxetumomab pasudotox monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Mycophenolate mofetil monotherapy": {
        "brands": [
            "CellCept"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Mycophenolate mofetil"
        ],
        "regimen": "Mycophenolate mofetil monotherapy",
        "regimen_names": [
            "Mycophenolate mofetil monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Necitumumab monotherapy": {
        "brands": [
            "Portrazza"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Necitumumab"
        ],
        "regimen": "Necitumumab monotherapy",
        "regimen_names": [
            "Necitumumab monotherapy"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Neratinib & Paclitaxel": {
        "brands": [
            "Nerlynx",
            "Taxol"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Neratinib",
            "Paclitaxel"
        ],
        "regimen": "Neratinib & Paclitaxel",
        "regimen_names": [
            "Neratinib & Paclitaxel"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Neratinib monotherapy": {
        "brands": [
            "Nerlynx"
        ],
        "cancers": [
            "ERBB2_(HER2)",
            "ERBB2_(HER2)",
            "ERBB3_(HER3)",
            "ERBB3_(HER3)"
        ],
        "drugs": [
            "Neratinib"
        ],
        "regimen": "Neratinib monotherapy",
        "regimen_names": [
            "Neratinib monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Nilotinib monotherapy": {
        "brands": [
            "Tasigna"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia",
            "Hypereosinophilic_syndrome",
            "Systemic_mastocytosis"
        ],
        "drugs": [
            "Nilotinib"
        ],
        "regimen": "Nilotinib monotherapy",
        "regimen_names": [
            "Nilotinib monotherapy"
        ],
        "regimen_type": "Maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Nimustine & RT": {
        "brands": [
            "ACNU",
            "External beam radiotherapy"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Nimustine",
            "External beam radiotherapy"
        ],
        "regimen": "Nimustine & RT",
        "regimen_names": [
            "Nimustine  and  RT",
            "Nimustine & RT",
            "Nimustine + RT",
            "Nimustine / RT",
            "Nimustine and RT",
            "Nimustine+RT",
            "Nimustine/RT"
        ],
        "regimen_type": "Adjuvant therapy, standard patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Niraparib monotherapy": {
        "brands": [
            "Zejula"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Niraparib"
        ],
        "regimen": "Niraparib monotherapy",
        "regimen_names": [
            "Niraparib monotherapy"
        ],
        "regimen_type": "Maintenance after second-line therapy for platinum-sensitive disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Nivolumab monotherapy": {
        "brands": [
            "Opdivo"
        ],
        "cancers": [
            "Anal_cancer",
            "Gastric_cancer",
            "Head_and_neck_cancer",
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Nivolumab"
        ],
        "regimen": "Nivolumab monotherapy",
        "regimen_names": [
            "Nivolumab monotherapy"
        ],
        "regimen_type": "Metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Nordic FLOX": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin"
        ],
        "regimen": "Nordic FLOX",
        "regimen_names": [
            "FLOX",
            "Nordic FLOX"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "O-CHOP": {
        "brands": [
            "Arzerra",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Ofatumumab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "O-CHOP",
        "regimen_names": [
            "O-CHOP",
            "O/CHOP",
            "OCHOP"
        ],
        "regimen_type": "Advanced disease, first-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "O-ESHAP": {
        "brands": [
            "Arzerra",
            "Vepesid",
            "Solumedrol",
            "Cytosar",
            "Platinol"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Ofatumumab",
            "Etoposide",
            "Methylprednisolone",
            "Cytarabine",
            "Cisplatin"
        ],
        "regimen": "O-ESHAP",
        "regimen_names": [
            "O-ESHAP",
            "O/ESHAP",
            "OESHAP"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "O-FC": {
        "brands": [
            "Arzerra",
            "Fludara",
            "Cytoxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Ofatumumab",
            "Fludarabine",
            "Cyclophosphamide"
        ],
        "regimen": "O-FC",
        "regimen_names": [
            "O-FC",
            "O/FC",
            "OFC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "O-miniCHOP": {
        "brands": [
            "Arzerra",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Ofatumumab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "O-miniCHOP",
        "regimen_names": [
            "O-miniCHOP",
            "O/miniCHOP",
            "OminiCHOP"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "OEPA": {
        "brands": [
            "Oncovin",
            "Vepesid",
            "Sterapred",
            "Adriamycin"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Vincristine",
            "Etoposide",
            "Prednisone",
            "Doxorubicin"
        ],
        "regimen": "OEPA",
        "regimen_names": [
            "OEPA"
        ],
        "regimen_type": "Untreated, pediatric",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "OFAR": {
        "brands": [
            "Eloxatin",
            "Fludara",
            "Cytosar",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Transformed_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Oxaliplatin",
            "Fludarabine",
            "Cytarabine",
            "Rituximab"
        ],
        "regimen": "OFAR",
        "regimen_names": [
            "OFAR"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "OLF": {
        "brands": [
            "Eloxatin",
            "Leucovorin",
            "5-FU"
        ],
        "cancers": [
            "Gastric_cancer",
            "Gastric_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Oxaliplatin",
            "Folinic acid",
            "Fluorouracil"
        ],
        "regimen": "OLF",
        "regimen_names": [
            "FLO",
            "OLF"
        ],
        "regimen_type": "Metastatic or locally advanced disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "OPPA": {
        "brands": [
            "Oncovin",
            "Matulane",
            "Sterapred",
            "Adriamycin"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Vincristine",
            "Procarbazine",
            "Prednisone",
            "Doxorubicin"
        ],
        "regimen": "OPPA",
        "regimen_names": [
            "OPPA"
        ],
        "regimen_type": "Untreated, pediatric",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "OXAFAFU": {
        "brands": [
            "Eloxatin",
            "Leucovorin",
            "5-FU"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Oxaliplatin",
            "Folinic acid",
            "Fluorouracil"
        ],
        "regimen": "OXAFAFU",
        "regimen_names": [
            "OXAFAFU"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Obinutuzumab monotherapy": {
        "brands": [
            "Gazyva"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Obinutuzumab"
        ],
        "regimen": "Obinutuzumab monotherapy",
        "regimen_names": [
            "Obinutuzumab monotherapy"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ofatumumab monotherapy": {
        "brands": [
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Ofatumumab"
        ],
        "regimen": "Ofatumumab monotherapy",
        "regimen_names": [
            "Ofatumumab monotherapy"
        ],
        "regimen_type": "Consolidation and/or maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Olaparib monotherapy": {
        "brands": [
            "Lynparza"
        ],
        "cancers": [
            "Breast_cancer_BRCA-mutated",
            "Breast_cancer_BRCA-mutated",
            "Breast_cancer_BRCA-mutated",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Pancreatic_cancer",
            "Prostate_cancer"
        ],
        "drugs": [
            "Olaparib"
        ],
        "regimen": "Olaparib monotherapy",
        "regimen_names": [
            "Olaparib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Osimertinib monotherapy": {
        "brands": [
            "Tagrisso"
        ],
        "cancers": [
            "CNS_carcinoma",
            "Non-small_cell_lung_cancer_EGFR-mutated",
            "Non-small_cell_lung_cancer_EGFR-mutated"
        ],
        "drugs": [
            "Osimertinib"
        ],
        "regimen": "Osimertinib monotherapy",
        "regimen_names": [
            "Osimertinib monotherapy"
        ],
        "regimen_type": "Non-small cell lung cancer, EGFR-mutated, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ox-P": {
        "brands": [
            "Eloxatin",
            "Sterapred"
        ],
        "cancers": [
            "Marginal_zone_lymphoma"
        ],
        "drugs": [
            "Oxaliplatin",
            "Prednisone"
        ],
        "regimen": "Ox-P",
        "regimen_names": [
            "Ox-P",
            "Ox/P",
            "OxP"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Oxaliplatin & Bevacizumab": {
        "brands": [
            "Eloxatin",
            "Avastin"
        ],
        "cancers": [
            "Testicular_cancer"
        ],
        "drugs": [
            "Oxaliplatin",
            "Bevacizumab"
        ],
        "regimen": "Oxaliplatin & Bevacizumab",
        "regimen_names": [
            "Oxaliplatin & Bevacizumab"
        ],
        "regimen_type": "Subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Oxaliplatin monotherapy": {
        "brands": [
            "Eloxatin"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Oxaliplatin"
        ],
        "regimen": "Oxaliplatin monotherapy",
        "regimen_names": [
            "Oxaliplatin monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PAC": {
        "brands": [
            "Platinol",
            "Adriamycin",
            "Cytoxan",
            "Sterapred"
        ],
        "cancers": [
            "Thymoma",
            "Thymoma",
            "Thymoma",
            "Thymoma",
            "Thymoma"
        ],
        "drugs": [
            "Cisplatin",
            "Doxorubicin",
            "Cyclophosphamide",
            "Prednisone"
        ],
        "regimen": "PAC",
        "regimen_names": [
            "CAP",
            "PAC"
        ],
        "regimen_type": "Neoadjuvant therapy for borderline resectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PAD": {
        "brands": [
            "Velcade",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "PAD",
        "regimen_names": [
            "BDD",
            "PAD",
            "PAd",
            "VAD"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PCE": {
        "brands": [
            "Taxol",
            "Paraplatin",
            "Vepesid"
        ],
        "cancers": [
            "Adenocarcinoma_of_unknown_primary",
            "Adenocarcinoma_of_unknown_primary"
        ],
        "drugs": [
            "Paclitaxel",
            "Carboplatin",
            "Etoposide"
        ],
        "regimen": "PCE",
        "regimen_names": [
            "PCE"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PCF": {
        "brands": [
            "Taxol",
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Penile_cancer",
            "Penile_cancer",
            "SCC_of_unknown_primary",
            "SCC_of_unknown_primary"
        ],
        "drugs": [
            "Paclitaxel",
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "PCF",
        "regimen_names": [
            "PCF"
        ],
        "regimen_type": "Neoadjuvant induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PCO": {
        "brands": [
            "Nipent",
            "Cytoxan",
            "Arzerra"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Pentostatin",
            "Cyclophosphamide",
            "Ofatumumab"
        ],
        "regimen": "PCO",
        "regimen_names": [
            "PCO"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PCP": {
        "brands": [
            "Pomalyst",
            "Cytoxan",
            "Sterapred"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Pomalidomide",
            "Cyclophosphamide",
            "Prednisone"
        ],
        "regimen": "PCP",
        "regimen_names": [
            "PCP"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PCR": {
        "brands": [
            "Nipent",
            "Cytoxan",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Pentostatin",
            "Cyclophosphamide",
            "Rituximab"
        ],
        "regimen": "PCR",
        "regimen_names": [
            "PCR"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PCV": {
        "brands": [
            "Matulane",
            "Ceenu",
            "Oncovin"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Glioblastoma",
            "Glioblastoma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Low-grade_glioma"
        ],
        "drugs": [
            "Procarbazine",
            "Lomustine",
            "Vincristine"
        ],
        "regimen": "PCV",
        "regimen_names": [
            "PCV"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PGC": {
        "brands": [
            "Taxol",
            "Gemzar",
            "Platinol"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Bladder_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "Gemcitabine",
            "Cisplatin"
        ],
        "regimen": "PGC",
        "regimen_names": [
            "PCG",
            "PGC"
        ],
        "regimen_type": "Adjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PVAG": {
        "brands": [
            "Sterapred",
            "Velban",
            "Adriamycin",
            "Gemzar"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Prednisone",
            "Vinblastine",
            "Doxorubicin",
            "Gemcitabine"
        ],
        "regimen": "PVAG",
        "regimen_names": [
            "PVAG"
        ],
        "regimen_type": "Untreated, elderly",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PVD": {
        "brands": [
            "Pomalyst",
            "Velcade",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Pomalidomide",
            "Bortezomib",
            "Dexamethasone"
        ],
        "regimen": "PVD",
        "regimen_names": [
            "PVD"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PVeBV": {
        "brands": [
            "Platinol",
            "Velban",
            "Blenoxane",
            "Vepesid"
        ],
        "cancers": [
            "Testicular_cancer"
        ],
        "drugs": [
            "Cisplatin",
            "Vinblastine",
            "Bleomycin",
            "Etoposide"
        ],
        "regimen": "PVeBV",
        "regimen_names": [
            "PVeBV",
            "VBEP"
        ],
        "regimen_type": "Upfront therapy for disseminated disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel & Bevacizumab": {
        "brands": [
            "Taxol",
            "Avastin"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "Bevacizumab"
        ],
        "regimen": "Paclitaxel & Bevacizumab",
        "regimen_names": [
            "Paclitaxel & Bevacizumab"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel & Pazopanib": {
        "brands": [
            "Taxol",
            "Votrient"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "Pazopanib"
        ],
        "regimen": "Paclitaxel & Pazopanib",
        "regimen_names": [
            "Paclitaxel & Pazopanib"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel & RT": {
        "brands": [
            "Taxol",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "External_beam_radiotherapy"
        ],
        "regimen": "Paclitaxel & RT",
        "regimen_names": [
            "Paclitaxel  and  RT",
            "Paclitaxel & RT",
            "Paclitaxel + RT",
            "Paclitaxel / RT",
            "Paclitaxel and RT",
            "Paclitaxel+RT",
            "Paclitaxel/RT"
        ],
        "regimen_type": "Induction chemoradiotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel & Ramucirumab": {
        "brands": [
            "Cyramza",
            "Taxol"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Ramucirumab",
            "Paclitaxel"
        ],
        "regimen": "Paclitaxel & Ramucirumab",
        "regimen_names": [
            "Paclitaxel & Ramucirumab"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel & Topotecan": {
        "brands": [
            "Taxol",
            "Hycamtin"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "Topotecan"
        ],
        "regimen": "Paclitaxel & Topotecan",
        "regimen_names": [
            "Paclitaxel & Topotecan"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel monotherapy": {
        "brands": [
            "Taxol"
        ],
        "cancers": [
            "Bladder_cancer",
            "Bladder_cancer",
            "Breast_cancer_triple_negative",
            "Breast_cancer_triple_negative",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Endometrial_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Penile_cancer",
            "Penile_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Vascular_sarcoma",
            "Vascular_sarcoma",
            "Vascular_sarcoma",
            "Vulvar_cancer"
        ],
        "drugs": [
            "Paclitaxel"
        ],
        "regimen": "Paclitaxel monotherapy",
        "regimen_names": [
            "Paclitaxel monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel monotherapy, dose-dense (q2wk)": {
        "brands": [
            "Taxol"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer"
        ],
        "drugs": [
            "Paclitaxel"
        ],
        "regimen": "Paclitaxel monotherapy, dose-dense (q2wk)",
        "regimen_names": [
            "Paclitaxel monotherapy, dose-dense (q2wk)",
            "ddT"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel monotherapy, weekly": {
        "brands": [
            "Taxol"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer"
        ],
        "drugs": [
            "Paclitaxel"
        ],
        "regimen": "Paclitaxel monotherapy, weekly",
        "regimen_names": [
            "Paclitaxel monotherapy, weekly"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel, Topotecan, Bevacizumab": {
        "brands": [
            "Taxol",
            "Hycamtin",
            "Avastin"
        ],
        "cancers": [
            "Cervical_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "Topotecan",
            "Bevacizumab"
        ],
        "regimen": "Paclitaxel, Topotecan, Bevacizumab",
        "regimen_names": [
            "Paclitaxel, Topotecan, Bevacizumab",
            "TP & Bev",
            "TP / Bev",
            "TP and Bev",
            "TP&Bev",
            "TP+Bev",
            "TP/Bev",
            "TPBev"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Paclitaxel, nanoparticle albumin-bound monotherapy": {
        "brands": [
            "Abraxane"
        ],
        "cancers": [
            "Bladder_cancer",
            "Breast_cancer",
            "Gastric_cancer",
            "Melanoma",
            "Melanoma",
            "Ovarian_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Paclitaxel, nanoparticle albumin-bound"
        ],
        "regimen": "Paclitaxel, nanoparticle albumin-bound monotherapy",
        "regimen_names": [
            "Paclitaxel, nanoparticle albumin-bound monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Panitumumab monotherapy": {
        "brands": [
            "Vectibix"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type",
            "Penile_cancer"
        ],
        "drugs": [
            "Panitumumab"
        ],
        "regimen": "Panitumumab monotherapy",
        "regimen_names": [
            "Panitumumab monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Panobinostat & Rituximab": {
        "brands": [
            "Farydak",
            "Rituxan"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Panobinostat",
            "Rituximab"
        ],
        "regimen": "Panobinostat & Rituximab",
        "regimen_names": [
            "Panobinostat & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Panobinostat monotherapy": {
        "brands": [
            "Farydak"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Hodgkin_lymphoma",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Panobinostat"
        ],
        "regimen": "Panobinostat monotherapy",
        "regimen_names": [
            "Panobinostat monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pazopanib monotherapy": {
        "brands": [
            "Votrient"
        ],
        "cancers": [
            "Gastrointestinal_stromal_tumor",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Soft_tissue_sarcoma",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Pazopanib"
        ],
        "regimen": "Pazopanib monotherapy",
        "regimen_names": [
            "Pazopanib monotherapy"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Peginterferon alfa-2a monotherapy": {
        "brands": [
            "Pegasys"
        ],
        "cancers": [
            "Essential_thrombocythemia",
            "Essential_thrombocythemia",
            "Hypereosinophilic_syndrome",
            "Polycythemia_vera",
            "Polycythemia_vera"
        ],
        "drugs": [
            "Peginterferon alfa-2a"
        ],
        "regimen": "Peginterferon alfa-2a monotherapy",
        "regimen_names": [
            "Peginterferon alfa-2a monotherapy"
        ],
        "regimen_type": "First-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Peginterferon alfa-2b monotherapy": {
        "brands": [
            "Sylatron"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Peginterferon alfa-2b"
        ],
        "regimen": "Peginterferon alfa-2b monotherapy",
        "regimen_names": [
            "Peginterferon alfa-2b monotherapy"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pembrolizumab monotherapy": {
        "brands": [
            "Keytruda"
        ],
        "cancers": [
            "Anal_cancer",
            "Bladder_cancer",
            "Bladder_cancer",
            "Cervical_cancer",
            "Cholangiocarcinoma",
            "Endometrial_cancer",
            "Gastric_cancer",
            "Head_and_neck_cancer",
            "Head_and_neck_cancer",
            "Hepatocellular_carcinoma",
            "Hodgkin_lymphoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Melanoma",
            "Merkel_cell_carcinoma",
            "MSI-H_or_dMMR",
            "MSI-H_or_dMMR",
            "MSI-H_or_dMMR",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Primary_mediastinal_B-cell_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Pembrolizumab"
        ],
        "regimen": "Pembrolizumab monotherapy",
        "regimen_names": [
            "Pembrolizumab monotherapy"
        ],
        "regimen_type": "Metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pemetrexed & Bevacizumab": {
        "brands": [
            "Alimta",
            "Avastin"
        ],
        "cancers": [
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Pemetrexed",
            "Bevacizumab"
        ],
        "regimen": "Pemetrexed & Bevacizumab",
        "regimen_names": [
            "Pemetrexed & Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line, elderly or poor performance status",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pemetrexed monotherapy": {
        "brands": [
            "Alimta"
        ],
        "cancers": [
            "Bladder_cancer",
            "Cervical_cancer",
            "Cervical_cancer",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Pemetrexed"
        ],
        "regimen": "Pemetrexed monotherapy",
        "regimen_names": [
            "Pemetrexed monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pentostatin monotherapy": {
        "brands": [
            "Nipent"
        ],
        "cancers": [
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia"
        ],
        "drugs": [
            "Pentostatin"
        ],
        "regimen": "Pentostatin monotherapy",
        "regimen_names": [
            "Pentostatin monotherapy"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pertuzumab & Trastuzumab": {
        "brands": [
            "Perjeta",
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive",
            "ERBB2_(HER2)"
        ],
        "drugs": [
            "Pertuzumab",
            "Trastuzumab"
        ],
        "regimen": "Pertuzumab & Trastuzumab",
        "regimen_names": [
            "Pertuzumab & Trastuzumab"
        ],
        "regimen_type": "Maintenance for metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pipobroman monotherapy": {
        "brands": [
            "Vercyte"
        ],
        "cancers": [
            "Polycythemia_vera"
        ],
        "drugs": [
            "Pipobroman"
        ],
        "regimen": "Pipobroman monotherapy",
        "regimen_names": [
            "Pipobroman monotherapy"
        ],
        "regimen_type": "Relapsed, refractory, or intolerant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pirarubicin monotherapy": {
        "brands": [
            "THP"
        ],
        "cancers": [
            "Bladder_cancer"
        ],
        "drugs": [
            "Pirarubicin"
        ],
        "regimen": "Pirarubicin monotherapy",
        "regimen_names": [
            "Pirarubicin monotherapy"
        ],
        "regimen_type": "Intravesical chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pixantrone monotherapy": {
        "brands": [
            "Pixuvri"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Pixantrone"
        ],
        "regimen": "Pixantrone monotherapy",
        "regimen_names": [
            "Pixantrone monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "PomCyDex": {
        "brands": [
            "Pomalyst",
            "Cytoxan",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Pomalidomide",
            "Cyclophosphamide",
            "Dexamethasone"
        ],
        "regimen": "PomCyDex",
        "regimen_names": [
            "PCD",
            "PomCyDex"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pomalidomide & Dexamethasone": {
        "brands": [
            "Pomalyst",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Pomalidomide",
            "Dexamethasone"
        ],
        "regimen": "Pomalidomide & Dexamethasone",
        "regimen_names": [
            "Pomalidomide & Dexamethasone"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pomalidomide & Prednisone": {
        "brands": [
            "Pomalyst",
            "Sterapred"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Myelofibrosis",
            "Myelofibrosis"
        ],
        "drugs": [
            "Pomalidomide",
            "Prednisone"
        ],
        "regimen": "Pomalidomide & Prednisone",
        "regimen_names": [
            "Pomalidomide & Prednisone"
        ],
        "regimen_type": "Maintenance after second-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pomalidomide monotherapy": {
        "brands": [
            "Pomalyst"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Myelofibrosis",
            "Myelofibrosis"
        ],
        "drugs": [
            "Pomalidomide"
        ],
        "regimen": "Pomalidomide monotherapy",
        "regimen_names": [
            "Pomalidomide monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pomalidomide, Dexamethasone, Daratumumab": {
        "brands": [
            "Pomalyst",
            "Decadron",
            "Darzalex"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Pomalidomide",
            "Dexamethasone",
            "Daratumumab"
        ],
        "regimen": "Pomalidomide, Dexamethasone, Daratumumab",
        "regimen_names": [
            "Pomalidomide, Dexamethasone, Daratumumab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ponatinib monotherapy": {
        "brands": [
            "Iclusig"
        ],
        "cancers": [
            "B-cell_acute_lymphoblastic_leukemia_Ph-positive",
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Ponatinib"
        ],
        "regimen": "Ponatinib monotherapy",
        "regimen_names": [
            "Ponatinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Pralatrexate monotherapy": {
        "brands": [
            "Folotyn"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma",
            "Cutaneous_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Pralatrexate"
        ],
        "regimen": "Pralatrexate monotherapy",
        "regimen_names": [
            "Pralatrexate monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Prednisolone monotherapy": {
        "brands": [
            "Millipred"
        ],
        "cancers": [
            "Acquired_coagulopathy"
        ],
        "drugs": [
            "Prednisolone"
        ],
        "regimen": "Prednisolone monotherapy",
        "regimen_names": [
            "Prednisolone monotherapy"
        ],
        "regimen_type": "Acquired hemophilia A, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Prednisone monotherapy": {
        "brands": [
            "Sterapred"
        ],
        "cancers": [
            "Acquired_coagulopathy",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Myelofibrosis"
        ],
        "drugs": [
            "Prednisone"
        ],
        "regimen": "Prednisone monotherapy",
        "regimen_names": [
            "Prednisone monotherapy"
        ],
        "regimen_type": "Acquired hemophilia A, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Procarbazine monotherapy": {
        "brands": [
            "Matulane"
        ],
        "cancers": [
            "CNS_lymphoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma"
        ],
        "drugs": [
            "Procarbazine"
        ],
        "regimen": "Procarbazine monotherapy",
        "regimen_names": [
            "Procarbazine monotherapy"
        ],
        "regimen_type": "Consolidation and/or maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-BAC": {
        "brands": [
            "Rituxan",
            "Bendamustine",
            "Cytosar"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Bendamustine",
            "Cytarabine"
        ],
        "regimen": "R-BAC",
        "regimen_names": [
            "R-BAC",
            "R/BAC",
            "RBAC"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-BEAM": {
        "brands": [
            "Rituxan",
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "Rituximab",
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "R-BEAM",
        "regimen_names": [
            "R-BEAM",
            "R/BEAM",
            "RBEAM"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-BL": {
        "brands": [
            "Rituxan",
            "Bendamustine",
            "Revlimid"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Bendamustine",
            "Lenalidomide"
        ],
        "regimen": "R-BL",
        "regimen_names": [
            "R-BL",
            "R/BL",
            "RBL"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CDOP": {
        "brands": [
            "Doxil",
            "Rituxan",
            "Cytoxan",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Pegylated liposomal doxorubicin",
            "Rituximab",
            "Cyclophosphamide",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "R-CDOP",
        "regimen_names": [
            "DRCOP",
            "R-CDOP",
            "R/CDOP",
            "RCDOP"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CEOP90 (Epirubicin)": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Ellence",
            "Oncovin",
            "Millipred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Epirubicin",
            "Vincristine",
            "Prednisolone"
        ],
        "regimen": "R-CEOP90 (Epirubicin)",
        "regimen_names": [
            "R-CEOP90",
            "R-CEOP90 (Epirubicin)",
            "R/CEOP90",
            "RCEOP90"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CHOEP-14": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Vepesid",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Etoposide",
            "Prednisone"
        ],
        "regimen": "R-CHOEP-14",
        "regimen_names": [
            "R-CHOEP-14",
            "R/CHOEP/14",
            "RCHOEP14"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CHOP": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Millipred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Post-transplant_lymphoproliferative_disorder",
            "Post-transplant_lymphoproliferative_disorder",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisolone"
        ],
        "regimen": "R-CHOP",
        "regimen_names": [
            "CHOP-R",
            "CHOP/R",
            "CHOPR",
            "R-CHOP",
            "R-CHOP-21",
            "R/CHOP",
            "R/CHOP/21",
            "RCHOP",
            "RCHOP21"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CHOP-14": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "R-CHOP-14",
        "regimen_names": [
            "R-CHOP-14",
            "R/CHOP/14",
            "RCHOP14"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CHVP+I": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Vepesid",
            "Millipred"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Etoposide",
            "Prednisolone"
        ],
        "regimen": "R-CHVP+I",
        "regimen_names": [
            "R-CHVP & I",
            "R-CHVP / I",
            "R-CHVP and I",
            "R-CHVP&I",
            "R-CHVP+I",
            "R-CHVP/I",
            "R-CHVPI",
            "R/CHVP+I",
            "RCHVP+I",
            "RCHVPI"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CMD": {
        "brands": [
            "Rituxan",
            "Leustatin",
            "Novantrone",
            "Decadron"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cladribine",
            "Mitoxantrone",
            "Dexamethasone"
        ],
        "regimen": "R-CMD",
        "regimen_names": [
            "R-CMD",
            "R/CMD",
            "RCMD"
        ],
        "regimen_type": "Advanced disease, first-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CODOX-M": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Oncovin",
            "Adriamycin",
            "MTX"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Vincristine",
            "Doxorubicin",
            "Methotrexate"
        ],
        "regimen": "R-CODOX-M",
        "regimen_names": [
            "R-CODOX-M",
            "R/CODOX/M",
            "RCODOXM"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CODOX-M/R-IVAC": {
        "brands": [
            "Cytosar",
            "MTX",
            "Cortef"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Cytarabine",
            "Methotrexate",
            "Hydrocortisone"
        ],
        "regimen": "R-CODOX-M/R-IVAC",
        "regimen_names": [
            "R-CODOX-M/R-IVAC"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CP": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Sterapred",
            "Solumedrol"
        ],
        "cancers": [
            "Post-transplant_lymphoproliferative_disorder"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Prednisone",
            "Methylprednisolone"
        ],
        "regimen": "R-CP",
        "regimen_names": [
            "R-CP",
            "R/CP",
            "RCP"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CVEP": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Zolinza",
            "Vepesid",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Vorinostat",
            "Etoposide",
            "Prednisone"
        ],
        "regimen": "R-CVEP",
        "regimen_names": [
            "R-CVEP",
            "R/CVEP",
            "RCVEP"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-CVP": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "R-CVP",
        "regimen_names": [
            "R-CVP",
            "R/CVP",
            "RCVP"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-DHAC": {
        "brands": [
            "Rituxan",
            "Decadron",
            "Cytosar",
            "Paraplatin"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Dexamethasone",
            "Cytarabine",
            "Carboplatin"
        ],
        "regimen": "R-DHAC",
        "regimen_names": [
            "R-DHAC",
            "R/DHAC",
            "RDHAC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-DHAOx": {
        "brands": [
            "Rituxan",
            "Decadron",
            "Cytosar",
            "Eloxatin"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Dexamethasone",
            "Cytarabine",
            "Oxaliplatin"
        ],
        "regimen": "R-DHAOx",
        "regimen_names": [
            "R-DHAOx",
            "R/DHAOx",
            "RDHAOx"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-DHAP": {
        "brands": [
            "Rituxan",
            "Decadron",
            "Cytosar",
            "Platinol"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Primary_mediastinal_B-cell_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Dexamethasone",
            "Cytarabine",
            "Cisplatin"
        ],
        "regimen": "R-DHAP",
        "regimen_names": [
            "R-DHAP",
            "R/DHAP",
            "RDHAP"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-DexaBEAM": {
        "brands": [
            "Rituxan",
            "Decadron",
            "BiCNU",
            "Vepesid",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Dexamethasone",
            "Carmustine",
            "Etoposide",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "R-DexaBEAM",
        "regimen_names": [
            "R-DexaBEAM",
            "R/DexaBEAM",
            "RDexaBEAM"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-EPOCH": {
        "brands": [
            "Rituxan",
            "Vepesid",
            "Sterapred",
            "Oncovin",
            "Adriamycin",
            "Cytoxan"
        ],
        "cancers": [
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Etoposide",
            "Prednisone",
            "Vincristine",
            "Doxorubicin",
            "Cyclophosphamide"
        ],
        "regimen": "R-EPOCH",
        "regimen_names": [
            "R-EPOCH",
            "R/EPOCH",
            "REPOCH"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-EPOCH, dose-escalated": {
        "brands": [
            "Rituxan",
            "Vepesid",
            "Sterapred",
            "Oncovin",
            "Cytoxan",
            "Adriamycin"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Etoposide",
            "Prednisone",
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin"
        ],
        "regimen": "R-EPOCH, dose-escalated",
        "regimen_names": [
            "R-EPOCH",
            "R-EPOCH, dose-escalated",
            "R/EPOCH",
            "REPOCH"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-FCM": {
        "brands": [
            "Rituxan",
            "Fludara",
            "Cytoxan",
            "Novantrone"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Fludarabine",
            "Cyclophosphamide",
            "Mitoxantrone"
        ],
        "regimen": "R-FCM",
        "regimen_names": [
            "R-FCM",
            "R/FCM",
            "RFCM"
        ],
        "regimen_type": "Advanced disease, first-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-FM": {
        "brands": [
            "Fludara",
            "Novantrone",
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Fludarabine",
            "Mitoxantrone",
            "Rituximab"
        ],
        "regimen": "R-FM",
        "regimen_names": [
            "FMR",
            "R-FM",
            "R/FM",
            "RFM"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-FND": {
        "brands": [
            "Rituxan",
            "Fludara",
            "Novantrone",
            "Decadron"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Fludarabine",
            "Mitoxantrone",
            "Dexamethasone"
        ],
        "regimen": "R-FND",
        "regimen_names": [
            "R-FND",
            "R/FND",
            "RFND"
        ],
        "regimen_type": "Advanced disease, first-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-GDP": {
        "brands": [
            "Rituxan",
            "Gemzar",
            "Decadron",
            "Platinol"
        ],
        "cancers": [
            "Primary_mediastinal_B-cell_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Gemcitabine",
            "Dexamethasone",
            "Cisplatin"
        ],
        "regimen": "R-GDP",
        "regimen_names": [
            "R-GDP",
            "R/GDP",
            "RGDP"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-GemOx": {
        "brands": [
            "Rituxan",
            "Gemzar",
            "Eloxatin"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Gemcitabine",
            "Oxaliplatin"
        ],
        "regimen": "R-GemOx",
        "regimen_names": [
            "R-GemOx",
            "R/GemOx",
            "RGemOx"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-HiDAC": {
        "brands": [
            "Rituxan",
            "Cytosar"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cytarabine"
        ],
        "regimen": "R-HiDAC",
        "regimen_names": [
            "R-HiDAC",
            "R/HiDAC",
            "RHiDAC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-IFE": {
        "brands": [
            "Rituxan",
            "Ifex",
            "Vepesid"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Ifosfamide",
            "Etoposide"
        ],
        "regimen": "R-IFE",
        "regimen_names": [
            "R-IFE",
            "R/IFE",
            "RIFE"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-INO": {
        "brands": [
            "Rituxan",
            "Besponsa"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Inotuzumab ozogamicin"
        ],
        "regimen": "R-INO",
        "regimen_names": [
            "R-INO",
            "R/INO",
            "RINO"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-M-CHOP": {
        "brands": [
            "Rituxan",
            "MTX",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Methotrexate",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "R-M-CHOP",
        "regimen_names": [
            "R-M-CHOP",
            "R/M/CHOP",
            "RMCHOP"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-MCP": {
        "brands": [
            "Rituxan",
            "MTX",
            "Ceenu",
            "Matulane"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Methotrexate",
            "Lomustine",
            "Procarbazine"
        ],
        "regimen": "R-MCP",
        "regimen_names": [
            "R-MCP",
            "R/MCP",
            "RMCP"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-MP": {
        "brands": [
            "Rituxan",
            "MTX",
            "Matulane"
        ],
        "cancers": [
            "CNS_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Methotrexate",
            "Procarbazine"
        ],
        "regimen": "R-MP",
        "regimen_names": [
            "R-MP",
            "R/MP",
            "RMP"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-MPV": {
        "brands": [
            "Rituxan",
            "MTX",
            "Matulane",
            "Oncovin"
        ],
        "cancers": [
            "CNS_lymphoma",
            "CNS_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Methotrexate",
            "Procarbazine",
            "Vincristine"
        ],
        "regimen": "R-MPV",
        "regimen_names": [
            "R-MPV",
            "R/MPV",
            "RMPV"
        ],
        "regimen_type": "Upfront therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-MegaCHOP-14": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "R-MegaCHOP-14",
        "regimen_names": [
            "R-MegaCHOP-14"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-NIMP": {
        "brands": [
            "Rituxan",
            "Navelbine",
            "Ifex",
            "Novantrone",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Vinorelbine",
            "Ifosfamide",
            "Mitoxantrone",
            "Prednisone"
        ],
        "regimen": "R-NIMP",
        "regimen_names": [
            "R-NIMP",
            "R/NIMP",
            "RNIMP"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-TBI/Cy": {
        "brands": [
            "Rituxan",
            "External_beam_radiotherapy",
            "Cytoxan"
        ],
        "cancers": [
            "Autologous_HSCT"
        ],
        "drugs": [
            "Rituximab",
            "External_beam_radiotherapy",
            "Cyclophosphamide"
        ],
        "regimen": "R-TBI/Cy",
        "regimen_names": [
            "R-TBI/Cy",
            "R/TBI/Cy",
            "RTBI/Cy",
            "RTBICy"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-VAD+C": {
        "brands": [
            "Rituxan",
            "Oncovin",
            "Adriamycin",
            "Decadron",
            "Leukeran"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Vincristine",
            "Doxorubicin",
            "Dexamethasone",
            "Chlorambucil"
        ],
        "regimen": "R-VAD+C",
        "regimen_names": [
            "R-VAD & C",
            "R-VAD / C",
            "R-VAD and C",
            "R-VAD&C",
            "R-VAD+C",
            "R-VAD/C",
            "R-VADC",
            "R/VAD+C",
            "RVAD+C",
            "RVADC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "R-miniCEOP": {
        "brands": [
            "Rituxan",
            "Cytoxan",
            "Ellence",
            "Velban",
            "Sterapred"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Cyclophosphamide",
            "Epirubicin",
            "Vinblastine",
            "Prednisone"
        ],
        "regimen": "R-miniCEOP",
        "regimen_names": [
            "R-miniCEOP",
            "R/miniCEOP",
            "RminiCEOP"
        ],
        "regimen_type": "Untreated, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RABVD": {
        "brands": [
            "Rituxan",
            "Adriamycin",
            "Blenoxane",
            "Velban",
            "DTIC"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Doxorubicin",
            "Bleomycin",
            "Vinblastine",
            "Dacarbazine"
        ],
        "regimen": "RABVD",
        "regimen_names": [
            "RABVD"
        ],
        "regimen_type": "Untreated, early-stage unfavorable (ESU)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RD": {
        "brands": [
            "Revlimid",
            "Decadron",
            "AL",
            "Category:Disease-specific pages",
            "Category:Plasma cell dyscrasias"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "POEMS",
            "POEMS"
        ],
        "drugs": [
            "Lenalidomide",
            "Dexamethasone",
            "Category:Light-chain",
            "Category:Disease-specific pages",
            "Category:Plasma cell dyscrasias"
        ],
        "regimen": "RD",
        "regimen_names": [
            "RD"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RICER": {
        "brands": [
            "Rituxan",
            "Ifex",
            "Paraplatin",
            "Vepesid",
            "Revlimid"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Ifosfamide",
            "Carboplatin",
            "Etoposide",
            "Lenalidomide"
        ],
        "regimen": "RICER",
        "regimen_names": [
            "RICER"
        ],
        "regimen_type": "Untreated, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RT, then Carmustine": {
        "brands": [
            "BiCNU"
        ],
        "cancers": [
            "Anaplastic_glioma"
        ],
        "drugs": [
            "Carmustine"
        ],
        "regimen": "RT, then Carmustine",
        "regimen_names": [
            "RT, then Carmustine"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RT, then Temozolomide": {
        "brands": [
            "Temodar"
        ],
        "cancers": [
            "Anaplastic_glioma"
        ],
        "drugs": [
            "Temozolomide"
        ],
        "regimen": "RT, then Temozolomide",
        "regimen_names": [
            "RT, then Temozolomide"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RVD": {
        "brands": [
            "Revlimid",
            "Velcade",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone"
        ],
        "regimen": "RVD",
        "regimen_names": [
            "RVD",
            "VDR",
            "VRD",
            "VRd"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RVDC": {
        "brands": [
            "Revlimid",
            "Velcade",
            "Decadron",
            "Cytoxan"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone",
            "Cyclophosphamide"
        ],
        "regimen": "RVDC",
        "regimen_names": [
            "RVDC",
            "VDCR"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RVR": {
        "brands": [
            "Afinitor",
            "Velcade",
            "Rituxan"
        ],
        "cancers": [
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Everolimus",
            "Bortezomib",
            "Rituximab"
        ],
        "regimen": "RVR",
        "regimen_names": [
            "RVR"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rabbit ATG": {
        "brands": [
            "Thymoglobulin"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            "Antithymocyte globulin, rabbit ATG"
        ],
        "regimen": "Rabbit ATG",
        "regimen_names": [
            "Rabbit ATG"
        ],
        "regimen_type": "Prevention",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Radotinib monotherapy": {
        "brands": [
            "Supect"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia",
            "Chronic_myelogenous_leukemia"
        ],
        "drugs": [
            "Radotinib"
        ],
        "regimen": "Radotinib monotherapy",
        "regimen_names": [
            "Radotinib monotherapy"
        ],
        "regimen_type": "Chronic phase, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ramucirumab monotherapy": {
        "brands": [
            "Cyramza"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Ramucirumab"
        ],
        "regimen": "Ramucirumab monotherapy",
        "regimen_names": [
            "Ramucirumab monotherapy"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rd": {
        "brands": [
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Plasma_cell_leukemia"
        ],
        "drugs": [
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "Rd",
        "regimen_names": [
            "LenDex",
            "Rd",
            "RevDex"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Regorafenib monotherapy": {
        "brands": [
            "Stivarga"
        ],
        "cancers": [
            "Colon_cancer",
            "Gastric_cancer",
            "Gastrointestinal_stromal_tumor",
            "Hepatocellular_carcinoma",
            "Renal_cell_carcinoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Regorafenib"
        ],
        "regimen": "Regorafenib monotherapy",
        "regimen_names": [
            "Regorafenib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RhIG monotherapy": {
        "brands": [
            "D"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Rho"
        ],
        "regimen": "RhIG monotherapy",
        "regimen_names": [
            "RhIG",
            "RhIG monotherapy"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "RiPAD+C": {
        "brands": [
            "Rituxan",
            "Velcade",
            "Adriamycin",
            "Decadron",
            "Leukeran"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Bortezomib",
            "Doxorubicin",
            "Dexamethasone",
            "Chlorambucil"
        ],
        "regimen": "RiPAD+C",
        "regimen_names": [
            "RiPAD & C",
            "RiPAD / C",
            "RiPAD and C",
            "RiPAD&C",
            "RiPAD+C",
            "RiPAD/C",
            "RiPADC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rituximab monotherapy": {
        "brands": [
            "Rituxan"
        ],
        "cancers": [
            "Acquired_coagulopathy",
            "Acquired_coagulopathy",
            "Castleman_disease",
            "Castleman_disease",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "CNS_lymphoma",
            "Cold_agglutinin_disease",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Hairy_cell_leukemia",
            "Hairy_cell_leukemia",
            "HIV-associated_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Hodgkin_lymphoma_nodular_lymphocyte-predominant",
            "Immune_thrombocytopenia_(ITP)",
            "Immune_thrombocytopenia_(ITP)",
            "Inherited_coagulopathy",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Marginal_zone_lymphoma",
            "Thrombotic_thrombocytopenic_purpura",
            "Thrombotic_thrombocytopenic_purpura",
            "Thrombotic_thrombocytopenic_purpura",
            "Thrombotic_thrombocytopenic_purpura",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Rituximab"
        ],
        "regimen": "Rituximab monotherapy",
        "regimen_names": [
            "Rituximab monotherapy"
        ],
        "regimen_type": "Acquired hemophilia A, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rituximab monotherapy, abbreviated course": {
        "brands": [
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab"
        ],
        "regimen": "Rituximab monotherapy, abbreviated course",
        "regimen_names": [
            "Rituximab monotherapy, abbreviated course"
        ],
        "regimen_type": "Consolidation after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rituximab monotherapy, extended course": {
        "brands": [
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab"
        ],
        "regimen": "Rituximab monotherapy, extended course",
        "regimen_names": [
            "Rituximab monotherapy, extended course"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rituximab monotherapy, very extended course": {
        "brands": [
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Rituximab"
        ],
        "regimen": "Rituximab monotherapy, very extended course",
        "regimen_names": [
            "Rituximab monotherapy, very extended course"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rivaroxaban monotherapy": {
        "brands": [
            "Xarelto"
        ],
        "cancers": [
            "Antiphospholipid_antibody_syndrome",
            "Heparin-induced_thrombocytopenia_(HIT)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Rivaroxaban"
        ],
        "regimen": "Rivaroxaban monotherapy",
        "regimen_names": [
            "Rivaroxaban monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Romidepsin monotherapy": {
        "brands": [
            "Istodax"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma",
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Romidepsin"
        ],
        "regimen": "Romidepsin monotherapy",
        "regimen_names": [
            "Romidepsin monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Rucaparib monotherapy": {
        "brands": [
            "Rubraca"
        ],
        "cancers": [
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Rucaparib"
        ],
        "regimen": "Rucaparib monotherapy",
        "regimen_names": [
            "Rucaparib monotherapy"
        ],
        "regimen_type": "Second-line therapy for relapsed or recurrent disease, platinum-sensitive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Ruxolitinib monotherapy": {
        "brands": [
            "Jakafi"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Essential_thrombocythemia",
            "Hypereosinophilic_syndrome",
            "Myelofibrosis",
            "Polycythemia_vera"
        ],
        "drugs": [
            "Ruxolitinib"
        ],
        "regimen": "Ruxolitinib monotherapy",
        "regimen_names": [
            "Ruxolitinib monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "S-1 monotherapy": {
        "brands": [
            "S-1"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Gastric_cancer",
            "Non-small_cell_lung_cancer",
            "Pancreatic_cancer",
            "Pancreatic_cancer",
            "Rectal_cancer"
        ],
        "drugs": [
            "Tegafur, gimeracil, oteracil"
        ],
        "regimen": "S-1 monotherapy",
        "regimen_names": [
            "S-1 monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "SC-EPOCH-RR": {
        "brands": [
            "Rituxan",
            "Vepesid",
            "Sterapred",
            "Oncovin",
            "Cytoxan",
            "Adriamycin"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Rituximab",
            "Etoposide",
            "Prednisone",
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin"
        ],
        "regimen": "SC-EPOCH-RR",
        "regimen_names": [
            "SC-EPOCH-RR"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "SMILE": {
        "brands": [
            "Decadron",
            "MTX",
            "Ifex",
            "Elspar",
            "Vepesid"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "NKT-cell_lymphoma",
            "NKT-cell_lymphoma"
        ],
        "drugs": [
            "Dexamethasone",
            "Methotrexate",
            "Ifosfamide",
            "Asparaginase",
            "Etoposide"
        ],
        "regimen": "SMILE",
        "regimen_names": [
            "SMILE"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "SOX": {
        "brands": [
            "S-1",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer"
        ],
        "drugs": [
            "Tegafur, gimeracil, oteracil",
            "Oxaliplatin"
        ],
        "regimen": "SOX",
        "regimen_names": [
            "SOX"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Siltuximab monotherapy": {
        "brands": [
            "Sylvant"
        ],
        "cancers": [
            "Castleman_disease",
            "Castleman_disease"
        ],
        "drugs": [
            "Siltuximab"
        ],
        "regimen": "Siltuximab monotherapy",
        "regimen_names": [
            "Siltuximab monotherapy"
        ],
        "regimen_type": "HHV-8-negative/\"Idiopathic\" multicentric Castleman disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sipuleucel-T monotherapy": {
        "brands": [
            "Provenge"
        ],
        "cancers": [
            "Prostate_cancer",
            "Prostate_cancer"
        ],
        "drugs": [
            "Sipuleucel-T"
        ],
        "regimen": "Sipuleucel-T monotherapy",
        "regimen_names": [
            "Sipuleucel-T monotherapy"
        ],
        "regimen_type": "Immunotherapy for metastatic castrate-resistant disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sirolimus & Prednisone": {
        "brands": [
            "Rapamune",
            "Sterapred"
        ],
        "cancers": [
            "Erdheim-Chester_disease"
        ],
        "drugs": [
            "Sirolimus",
            "Prednisone"
        ],
        "regimen": "Sirolimus & Prednisone",
        "regimen_names": [
            "Sirolimus & Prednisone"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sirolimus monotherapy": {
        "brands": [
            "Rapamune"
        ],
        "cancers": [
            "Autoimmune_cytopenias",
            "Castleman_disease"
        ],
        "drugs": [
            "Sirolimus"
        ],
        "regimen": "Sirolimus monotherapy",
        "regimen_names": [
            "Sirolimus monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sirolimus, Tacrolimus, Prednisone": {
        "brands": [
            "Rapamune",
            "Prograf",
            "Sterapred"
        ],
        "cancers": [
            "Graft_versus_host_disease_(GVHD)"
        ],
        "drugs": [
            "Sirolimus",
            "Tacrolimus",
            "Prednisone"
        ],
        "regimen": "Sirolimus, Tacrolimus, Prednisone",
        "regimen_names": [
            "Sirolimus, Tacrolimus, Prednisone"
        ],
        "regimen_type": "Treatment, cGVHD, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sonidegib monotherapy": {
        "brands": [
            "Odomzo"
        ],
        "cancers": [
            "Cutaneous_basal_cell_carcinoma"
        ],
        "drugs": [
            "Sonidegib"
        ],
        "regimen": "Sonidegib monotherapy",
        "regimen_names": [
            "Sonidegib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sorafenib monotherapy": {
        "brands": [
            "Nexavar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Acute_myeloid_leukemia_FLT3-positive",
            "Hepatocellular_carcinoma",
            "Non-small_cell_lung_cancer",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Soft_tissue_sarcoma",
            "Thyroid_cancer",
            "Thyroid_cancer",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Sorafenib"
        ],
        "regimen": "Sorafenib monotherapy",
        "regimen_names": [
            "Sorafenib monotherapy"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Stanford V": {
        "brands": [
            "Adriamycin",
            "Velban",
            "Mustargen",
            "Vepesid",
            "Oncovin",
            "Blenoxane",
            "Sterapred"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Doxorubicin",
            "Vinblastine",
            "Mechlorethamine",
            "Etoposide",
            "Vincristine",
            "Bleomycin",
            "Prednisone"
        ],
        "regimen": "Stanford V",
        "regimen_names": [
            "Stanford V"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Sunitinib monotherapy": {
        "brands": [
            "Sutent"
        ],
        "cancers": [
            "Gastrointestinal_stromal_tumor",
            "Pancreatic_NET",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma",
            "Small_cell_lung_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Thymoma",
            "Thyroid_cancer",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Sunitinib"
        ],
        "regimen": "Sunitinib monotherapy",
        "regimen_names": [
            "Sunitinib monotherapy"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TAC (Taxotere)": {
        "brands": [
            "Taxotere",
            "Adriamycin",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Doxorubicin",
            "Cyclophosphamide"
        ],
        "regimen": "TAC (Taxotere)",
        "regimen_names": [
            "ATC",
            "TAC",
            "TAC (Taxotere)"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TACE": {
        "brands": [
            "TACE"
        ],
        "cancers": [
            "Hepatocellular_carcinoma",
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "TACE"
        ],
        "regimen": "TACE",
        "regimen_names": [
            "TACE"
        ],
        "regimen_type": "Local therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TACE, then 5-FU": {
        "brands": [
            "5-FU"
        ],
        "cancers": [
            "Hepatocellular_carcinoma"
        ],
        "drugs": [
            "Fluorouracil"
        ],
        "regimen": "TACE, then 5-FU",
        "regimen_names": [
            "TACE, then 5-FU"
        ],
        "regimen_type": "First-line therapy for advanced or metastatic disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TAD": {
        "brands": [
            "Thalomid",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Thalidomide",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "TAD",
        "regimen_names": [
            "TAD"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TAM6": {
        "brands": [
            "External_beam_radiotherapy",
            "Cytosar",
            "Alkeran"
        ],
        "cancers": [
            "Autologous_HSCT",
            "Autologous_HSCT"
        ],
        "drugs": [
            "External_beam_radiotherapy",
            "Cytarabine",
            "Melphalan"
        ],
        "regimen": "TAM6",
        "regimen_names": [
            "TAM",
            "TAM6"
        ],
        "regimen_type": "High dose therapy conditioning regimens, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TCHP (Taxotere)": {
        "brands": [
            "Taxotere",
            "Paraplatin",
            "Herceptin",
            "Perjeta"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Docetaxel",
            "Carboplatin",
            "Trastuzumab",
            "Pertuzumab"
        ],
        "regimen": "TCHP (Taxotere)",
        "regimen_names": [
            "TCHP",
            "TCHP (Taxotere)"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TFC, then allo HSCT": {
        "brands": [
            "Thioplex",
            "Fludara",
            "Cytoxan"
        ],
        "cancers": [
            "Peripheral_T-cell_lymphoma"
        ],
        "drugs": [
            "Thiotepa",
            "Fludarabine",
            "Cyclophosphamide"
        ],
        "regimen": "TFC, then allo HSCT",
        "regimen_names": [
            "TFC",
            "TFC, then allo HSCT"
        ],
        "regimen_type": "Consolidation and/or maintenance after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TH (Taxol)": {
        "brands": [
            "Taxol",
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Paclitaxel",
            "Trastuzumab"
        ],
        "regimen": "TH (Taxol)",
        "regimen_names": [
            "T-T",
            "T/T",
            "TH (Taxol)"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TIP": {
        "brands": [
            "Taxol",
            "Ifex",
            "Platinol"
        ],
        "cancers": [
            "Penile_cancer",
            "Penile_cancer",
            "Penile_cancer",
            "Penile_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Paclitaxel",
            "Ifosfamide",
            "Cisplatin"
        ],
        "regimen": "TIP",
        "regimen_names": [
            "TIP"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TLI & ATG": {
        "brands": [
            "Thymoglobulin"
        ],
        "cancers": [
            "Allogeneic_HSCT"
        ],
        "drugs": [
            "Antithymocyte globulin, rabbit ATG"
        ],
        "regimen": "TLI & ATG",
        "regimen_names": [
            "TLI  and  ATG",
            "TLI & ATG",
            "TLI + ATG",
            "TLI / ATG",
            "TLI and ATG",
            "TLI+ATG",
            "TLI/ATG",
            "TLIATG"
        ],
        "regimen_type": "Reduced-intensity conditioning (RIC), all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TT4": {
        "brands": [
            "Decadron",
            ":Category:Cyclosporines",
            "Rituxan"
        ],
        "cancers": [
            "Immune_thrombocytopenia_(ITP)"
        ],
        "drugs": [
            "Dexamethasone",
            ":Category:Cyclosporines",
            "Rituximab"
        ],
        "regimen": "TT4",
        "regimen_names": [
            "TT4"
        ],
        "regimen_type": "Initial therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "TTR": {
        "brands": [
            "Taxol",
            "Hycamtin",
            "Rituxan"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Paclitaxel",
            "Topotecan",
            "Rituximab"
        ],
        "regimen": "TTR",
        "regimen_names": [
            "TTR"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tagraxofusp monotherapy": {
        "brands": [
            "Elzonris"
        ],
        "cancers": [
            "Blastic_plasmacytoid_dendritic_cell_neoplasm"
        ],
        "drugs": [
            "Tagraxofusp"
        ],
        "regimen": "Tagraxofusp monotherapy",
        "regimen_names": [
            "Tagraxofusp monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Talazoparib monotherapy": {
        "brands": [
            "Talzenna"
        ],
        "cancers": [
            "Breast_cancer_BRCA-mutated"
        ],
        "drugs": [
            "Talazoparib"
        ],
        "regimen": "Talazoparib monotherapy",
        "regimen_names": [
            "Talazoparib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Talimogene laherparepvec monotherapy": {
        "brands": [
            "Imlygic"
        ],
        "cancers": [
            "Melanoma"
        ],
        "drugs": [
            "Talimogene laherparepvec"
        ],
        "regimen": "Talimogene laherparepvec monotherapy",
        "regimen_names": [
            "Talimogene laherparepvec monotherapy"
        ],
        "regimen_type": "Local therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tamibarotene monotherapy": {
        "brands": [
            "Amnoid"
        ],
        "cancers": [
            "Acute_promyelocytic_leukemia"
        ],
        "drugs": [
            "Tamibarotene"
        ],
        "regimen": "Tamibarotene monotherapy",
        "regimen_names": [
            "Tamibarotene monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, salvage induction therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tegafur & Uracil": {
        "brands": [
            "UFT"
        ],
        "cancers": [
            "Head_and_neck_cancer",
            "Non-small_cell_lung_cancer"
        ],
        "drugs": [
            "Tegafur and uracil"
        ],
        "regimen": "Tegafur & Uracil",
        "regimen_names": [
            "Tegafur  and  Uracil",
            "Tegafur & Uracil",
            "Tegafur + Uracil",
            "Tegafur / Uracil",
            "Tegafur and Uracil",
            "Tegafur+Uracil",
            "Tegafur/Uracil"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tegafur, Uracil, Folinic acid": {
        "brands": [
            "UFT",
            "Leucovorin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Tegafur and uracil",
            "Folinic acid"
        ],
        "regimen": "Tegafur, Uracil, Folinic acid",
        "regimen_names": [
            "Tegafur, Uracil, Folinic acid",
            "UFT  &  LV",
            "UFT  /  LV",
            "UFT  LV",
            "UFT  and  LV",
            "UFT & LV",
            "UFT + LV",
            "UFT / LV",
            "UFTLV"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide & Bevacizumab": {
        "brands": [
            "Temodar",
            "Avastin"
        ],
        "cancers": [
            "Melanoma",
            "Pancreatic_NET",
            "Pancreatic_NET"
        ],
        "drugs": [
            "Temozolomide",
            "Bevacizumab"
        ],
        "regimen": "Temozolomide & Bevacizumab",
        "regimen_names": [
            "Temozolomide & Bevacizumab"
        ],
        "regimen_type": "Metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide & NovoTTF-100A": {
        "brands": [
            "Temodar",
            "Optune"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Temozolomide",
            "NovoTTF-100A system"
        ],
        "regimen": "Temozolomide & NovoTTF-100A",
        "regimen_names": [
            "Temozolomide & NovoTTF-100A"
        ],
        "regimen_type": "Maintenance after first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide & RT": {
        "brands": [
            "Temodar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Glioblastoma",
            "Glioblastoma"
        ],
        "drugs": [
            "Temozolomide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Temozolomide & RT",
        "regimen_names": [
            "Temozolomide  and  RT",
            "Temozolomide & RT",
            "Temozolomide + RT",
            "Temozolomide / RT",
            "Temozolomide and RT",
            "Temozolomide+RT",
            "Temozolomide/RT"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide & RT, then Temozolomide": {
        "brands": [
            "Temodar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma"
        ],
        "drugs": [
            "Temozolomide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Temozolomide & RT, then Temozolomide",
        "regimen_names": [
            "Temozolomide & RT, then Temozolomide"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide & Thalidomide": {
        "brands": [
            "Temodar",
            "Thalomid"
        ],
        "cancers": [
            "Pancreatic_NET"
        ],
        "drugs": [
            "Temozolomide",
            "Thalidomide"
        ],
        "regimen": "Temozolomide & Thalidomide",
        "regimen_names": [
            "Temozolomide & Thalidomide"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide & low-dose RT": {
        "brands": [
            "Temodar",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Glioblastoma"
        ],
        "drugs": [
            "Temozolomide",
            "External_beam_radiotherapy"
        ],
        "regimen": "Temozolomide & low-dose RT",
        "regimen_names": [
            "LDRT",
            "Temozolomide & low-dose RT"
        ],
        "regimen_type": "Adjuvant therapy, elderly or poor performance status patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide monotherapy": {
        "brands": [
            "Temodar"
        ],
        "cancers": [
            "Acute_myeloid_leukemia",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Glioblastoma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Low-grade_glioma",
            "Melanoma",
            "Myelodysplastic_syndrome",
            "Neuroendocrine_tumors",
            "Neuroendocrine_tumors",
            "Pancreatic_NET",
            "Pancreatic_NET",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Temozolomide"
        ],
        "regimen": "Temozolomide monotherapy",
        "regimen_names": [
            "Temozolomide monotherapy"
        ],
        "regimen_type": "First-line induction therapy, older or \"unfit\" patients",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temozolomide, then Temozolomide & RT, then Temozolomide": {
        "brands": [
            "Temodar"
        ],
        "cancers": [
            "Anaplastic_glioma",
            "Anaplastic_glioma",
            "Anaplastic_glioma"
        ],
        "drugs": [
            "Temozolomide"
        ],
        "regimen": "Temozolomide, then Temozolomide & RT, then Temozolomide",
        "regimen_names": [
            "Temozolomide, then Temozolomide & RT, then Temozolomide"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temsirolimus & Rituximab": {
        "brands": [
            "Torisel",
            "Rituxan"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Temsirolimus",
            "Rituximab"
        ],
        "regimen": "Temsirolimus & Rituximab",
        "regimen_names": [
            "Temsirolimus & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Temsirolimus monotherapy": {
        "brands": [
            "Torisel"
        ],
        "cancers": [
            "CNS_lymphoma",
            "Diffuse_large_B-cell_lymphoma",
            "Endometrial_cancer",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Renal_cell_carcinoma",
            "Renal_cell_carcinoma"
        ],
        "drugs": [
            "Temsirolimus"
        ],
        "regimen": "Temsirolimus monotherapy",
        "regimen_names": [
            "Temsirolimus monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Teniposide monotherapy": {
        "brands": [
            "Vumon"
        ],
        "cancers": [
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Teniposide"
        ],
        "regimen": "Teniposide monotherapy",
        "regimen_names": [
            "Teniposide monotherapy"
        ],
        "regimen_type": "Extensive stage, induction",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Thal-Dex": {
        "brands": [
            "Thalomid",
            "Thalomid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_induction",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Thalidomide",
            "Thalidomide",
            "Dexamethasone"
        ],
        "regimen": "Thal-Dex",
        "regimen_names": [
            "Thal-Dex",
            "Thal/Dex",
            "ThalDex"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Thalidomide & Rituximab": {
        "brands": [
            "Thalomid",
            "Rituxan"
        ],
        "cancers": [
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Thalidomide",
            "Rituximab"
        ],
        "regimen": "Thalidomide & Rituximab",
        "regimen_names": [
            "Thalidomide & Rituximab"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Thalidomide monotherapy": {
        "brands": [
            "Thalomid"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Polycythemia_vera"
        ],
        "drugs": [
            "Thalidomide"
        ],
        "regimen": "Thalidomide monotherapy",
        "regimen_names": [
            "Thalidomide monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Thioguanine monotherapy": {
        "brands": [
            "Tabloid"
        ],
        "cancers": [
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Thioguanine"
        ],
        "regimen": "Thioguanine monotherapy",
        "regimen_names": [
            "Thioguanine monotherapy"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Thiotepa monotherapy": {
        "brands": [
            "Thioplex"
        ],
        "cancers": [
            "Bladder_cancer"
        ],
        "drugs": [
            "Thiotepa"
        ],
        "regimen": "Thiotepa monotherapy",
        "regimen_names": [
            "Thiotepa monotherapy"
        ],
        "regimen_type": "Intravesical chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tinzaparin monotherapy": {
        "brands": [
            "Innohep"
        ],
        "cancers": [
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Tinzaparin"
        ],
        "regimen": "Tinzaparin monotherapy",
        "regimen_names": [
            "Tinzaparin monotherapy"
        ],
        "regimen_type": "VTE treatment, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tisagenlecleucel monotherapy": {
        "brands": [
            "Kymriah"
        ],
        "cancers": [
            "Diffuse_large_B-cell_lymphoma",
            "Transformed_lymphoma"
        ],
        "drugs": [
            "Tisagenlecleucel"
        ],
        "regimen": "Tisagenlecleucel monotherapy",
        "regimen_names": [
            "Tisagenlecleucel monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, further lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Tocilizumab monotherapy": {
        "brands": [
            "Actemra"
        ],
        "cancers": [
            "Castleman_disease"
        ],
        "drugs": [
            "Tocilizumab"
        ],
        "regimen": "Tocilizumab monotherapy",
        "regimen_names": [
            "Tocilizumab monotherapy"
        ],
        "regimen_type": "HHV-8-negative/\"Idiopathic\" multicentric Castleman disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Topotecan & Bevacizumab": {
        "brands": [
            "Hycamtin",
            "Avastin"
        ],
        "cancers": [
            "Ovarian_cancer",
            "Ovarian_cancer"
        ],
        "drugs": [
            "Topotecan",
            "Bevacizumab"
        ],
        "regimen": "Topotecan & Bevacizumab",
        "regimen_names": [
            "Topotecan & Bevacizumab"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Topotecan monotherapy": {
        "brands": [
            "Hycamtin"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer",
            "CNS_lymphoma",
            "CNS_lymphoma",
            "Endometrial_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Ovarian_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Topotecan"
        ],
        "regimen": "Topotecan monotherapy",
        "regimen_names": [
            "Topotecan monotherapy"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Trabectedin monotherapy": {
        "brands": [
            "Yondelis"
        ],
        "cancers": [
            "Ovarian_cancer",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma",
            "Soft_tissue_sarcoma"
        ],
        "drugs": [
            "Trabectedin"
        ],
        "regimen": "Trabectedin monotherapy",
        "regimen_names": [
            "Trabectedin monotherapy"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Trametinib monotherapy": {
        "brands": [
            "Mekinist"
        ],
        "cancers": [
            "Melanoma_BRAF-mutated",
            "Melanoma_BRAF-mutated"
        ],
        "drugs": [
            "Trametinib"
        ],
        "regimen": "Trametinib monotherapy",
        "regimen_names": [
            "Trametinib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, BRAF inhibitor-naive",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Trastuzumab monotherapy": {
        "brands": [
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive",
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Trastuzumab"
        ],
        "regimen": "Trastuzumab monotherapy",
        "regimen_names": [
            "Trastuzumab monotherapy"
        ],
        "regimen_type": "Maintenance for metastatic or unresectable disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Treosulfan monotherapy": {
        "brands": [
            "Ovastat"
        ],
        "cancers": [
            "Ovarian_cancer"
        ],
        "drugs": [
            "Treosulfan"
        ],
        "regimen": "Treosulfan monotherapy",
        "regimen_names": [
            "Treosulfan monotherapy"
        ],
        "regimen_type": "Relapsed or recurrent disease, platinum-resistant",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Trifluridine and tipiracil monotherapy": {
        "brands": [
            "Lonsurf"
        ],
        "cancers": [
            "Colon_cancer",
            "Gastric_cancer"
        ],
        "drugs": [
            "Trifluridine and tipiracil"
        ],
        "regimen": "Trifluridine and tipiracil monotherapy",
        "regimen_names": [
            "Trifluridine and tipiracil monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, subsequent lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "UFT monotherapy": {
        "brands": [
            "UFT"
        ],
        "cancers": [
            "Rectal_cancer"
        ],
        "drugs": [
            "Tegafur and uracil"
        ],
        "regimen": "UFT monotherapy",
        "regimen_names": [
            "UFT monotherapy"
        ],
        "regimen_type": "Adjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "UFTM": {
        "brands": [
            "UFT",
            "Mutamycin"
        ],
        "cancers": [
            "Gastric_cancer"
        ],
        "drugs": [
            "Tegafur and uracil",
            "Mitomycin"
        ],
        "regimen": "UFTM",
        "regimen_names": [
            "UFTM"
        ],
        "regimen_type": "Metastatic or locally advanced disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VA": {
        "brands": [
            "Oncovin",
            "Cosmegen"
        ],
        "cancers": [
            "Rhabdomyosarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Dactinomycin"
        ],
        "regimen": "VA",
        "regimen_names": [
            "VA"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VAC": {
        "brands": [
            "Oncovin",
            "Cosmegen",
            "Cytoxan"
        ],
        "cancers": [
            "Rhabdomyosarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Dactinomycin",
            "Cyclophosphamide"
        ],
        "regimen": "VAC",
        "regimen_names": [
            "VAC"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VACA": {
        "brands": [
            "Oncovin",
            "Adriamycin",
            "Cytoxan",
            "Cosmegen"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Doxorubicin",
            "Cyclophosphamide",
            "Dactinomycin"
        ],
        "regimen": "VACA",
        "regimen_names": [
            "VACA"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VAD+C": {
        "brands": [
            "Oncovin",
            "Adriamycin",
            "Decadron",
            "Leukeran"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Vincristine",
            "Doxorubicin",
            "Dexamethasone",
            "Chlorambucil"
        ],
        "regimen": "VAD+C",
        "regimen_names": [
            "VAD & C",
            "VAD / C",
            "VAD and C",
            "VAD&C",
            "VAD+C",
            "VAD/C",
            "VADC"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VAI": {
        "brands": [
            "Oncovin",
            "Cosmegen",
            "Ifex"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Rhabdomyosarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Dactinomycin",
            "Ifosfamide"
        ],
        "regimen": "VAI",
        "regimen_names": [
            "IVA",
            "VAI"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VAIA": {
        "brands": [
            "Oncovin",
            "Adriamycin",
            "Ifex",
            "Cosmegen"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Doxorubicin",
            "Ifosfamide",
            "Dactinomycin"
        ],
        "regimen": "VAIA",
        "regimen_names": [
            "VAIA"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VAMP": {
        "brands": [
            "Velban",
            "Adriamycin",
            "MTX",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Vinblastine",
            "Doxorubicin",
            "Methotrexate",
            "Prednisone"
        ],
        "regimen": "VAMP",
        "regimen_names": [
            "VAMP"
        ],
        "regimen_type": "Untreated, early-stage favorable (ESF)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VAdCA": {
        "brands": [
            "Oncovin",
            "Adriamycin",
            "Cytoxan",
            "Cosmegen"
        ],
        "cancers": [
            "Ewings_sarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Doxorubicin",
            "Cyclophosphamide",
            "Dactinomycin"
        ],
        "regimen": "VAdCA",
        "regimen_names": [
            "VAdCA"
        ],
        "regimen_type": "Relapsed or refractory or metastatic",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VBM": {
        "brands": [
            "Blenoxane",
            "Oncovin",
            "MTX"
        ],
        "cancers": [
            "Penile_cancer"
        ],
        "drugs": [
            "Bleomycin",
            "Vincristine",
            "Methotrexate"
        ],
        "regimen": "VBM",
        "regimen_names": [
            "VBM"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VDC": {
        "brands": [
            "Cytoxan",
            "Velcade",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Light-chain_(AL)_amyloidosis",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Bortezomib",
            "Dexamethasone"
        ],
        "regimen": "VDC",
        "regimen_names": [
            "CyBorD",
            "VDC"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VEBEP": {
        "brands": [
            "Vepesid",
            "Ellence",
            "Blenoxane",
            "Cytoxan",
            "Millipred"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Etoposide",
            "Epirubicin",
            "Bleomycin",
            "Cyclophosphamide",
            "Prednisolone"
        ],
        "regimen": "VEBEP",
        "regimen_names": [
            "VEBEP"
        ],
        "regimen_type": "Untreated, advanced stage",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VEPEMB": {
        "brands": [
            "Velban",
            "Cytoxan",
            "Matulane",
            "Sterapred",
            "Vepesid",
            "Novantrone",
            "Blenoxane"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Vinblastine",
            "Cyclophosphamide",
            "Procarbazine",
            "Prednisone",
            "Etoposide",
            "Mitoxantrone",
            "Bleomycin"
        ],
        "regimen": "VEPEMB",
        "regimen_names": [
            "VEPEMB"
        ],
        "regimen_type": "Untreated, elderly",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VH": {
        "brands": [
            "Navelbine",
            "Herceptin"
        ],
        "cancers": [
            "Breast_cancer_HER2-positive"
        ],
        "drugs": [
            "Vinorelbine",
            "Trastuzumab"
        ],
        "regimen": "VH",
        "regimen_names": [
            "VH"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VIDE": {
        "brands": [
            "Oncovin",
            "Ifex",
            "Adriamycin",
            "Vepesid"
        ],
        "cancers": [
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma",
            "Ewings_sarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Ifosfamide",
            "Doxorubicin",
            "Etoposide"
        ],
        "regimen": "VIDE",
        "regimen_names": [
            "VIDE"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VIE": {
        "brands": [
            "Oncovin",
            "Ifex",
            "Vepesid"
        ],
        "cancers": [
            "Rhabdomyosarcoma"
        ],
        "drugs": [
            "Vincristine",
            "Ifosfamide",
            "Etoposide"
        ],
        "regimen": "VIE",
        "regimen_names": [
            "VIE"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VIP": {
        "brands": [
            "Vepesid",
            "Ifex",
            "Platinol"
        ],
        "cancers": [
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Testicular_cancer",
            "Thymoma",
            "Thymoma"
        ],
        "drugs": [
            "Etoposide",
            "Ifosfamide",
            "Cisplatin"
        ],
        "regimen": "VIP",
        "regimen_names": [
            "VIP"
        ],
        "regimen_type": "Upfront therapy for disseminated disease",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VIPD": {
        "brands": [
            "Vepesid",
            "Ifex",
            "Platinol",
            "Decadron"
        ],
        "cancers": [
            "Extranodal_NKT-cell_lymphoma_nasal_type",
            "Extranodal_NKT-cell_lymphoma_nasal_type"
        ],
        "drugs": [
            "Etoposide",
            "Ifosfamide",
            "Cisplatin",
            "Dexamethasone"
        ],
        "regimen": "VIPD",
        "regimen_names": [
            "VIPD"
        ],
        "regimen_type": "Consolidation after upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VMD": {
        "brands": [
            "Velcade",
            "Alkeran",
            "Decadron"
        ],
        "cancers": [
            "Light-chain_(AL)_amyloidosis"
        ],
        "drugs": [
            "Bortezomib",
            "Melphalan",
            "Dexamethasone"
        ],
        "regimen": "VMD",
        "regimen_names": [
            "VMD"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VMPT": {
        "brands": [
            "Velcade",
            "Alkeran",
            "Sterapred",
            "Thalomid"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Melphalan",
            "Prednisone",
            "Thalidomide"
        ],
        "regimen": "VMPT",
        "regimen_names": [
            "VMPT"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VP": {
        "brands": [
            "Velcade",
            "Sterapred"
        ],
        "cancers": [
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Bortezomib",
            "Prednisone"
        ],
        "regimen": "VP",
        "regimen_names": [
            "VP"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VR": {
        "brands": [
            "Velcade",
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia",
            "Waldenstrom_macroglobulinemia"
        ],
        "drugs": [
            "Bortezomib",
            "Rituximab"
        ],
        "regimen": "VR",
        "regimen_names": [
            "VR"
        ],
        "regimen_type": "Advanced disease, first-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VR-CAP": {
        "brands": [
            "Velcade",
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Sterapred"
        ],
        "cancers": [
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Prednisone"
        ],
        "regimen": "VR-CAP",
        "regimen_names": [
            "VR-CAP",
            "VR/CAP",
            "VRCAP"
        ],
        "regimen_type": "First-line therapy, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VR-CHOP": {
        "brands": [
            "Velcade",
            "Rituxan",
            "Cytoxan",
            "Adriamycin",
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Rituximab",
            "Cyclophosphamide",
            "Doxorubicin",
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "VR-CHOP",
        "regimen_names": [
            "VR-CHOP",
            "VR/CHOP",
            "VRCHOP"
        ],
        "regimen_type": "Advanced disease, first-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VR-CP": {
        "brands": [
            "Velcade",
            "Rituxan",
            "Cytoxan",
            "Sterapred"
        ],
        "cancers": [
            "Follicular_lymphoma",
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Rituximab",
            "Cyclophosphamide",
            "Prednisone"
        ],
        "regimen": "VR-CP",
        "regimen_names": [
            "VR-CP",
            "VR/CP",
            "VRCP"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VTD": {
        "brands": [
            "Velcade",
            "Thalomid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory",
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Bortezomib",
            "Thalidomide",
            "Dexamethasone"
        ],
        "regimen": "VTD",
        "regimen_names": [
            "VTD"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VTD-PACE": {
        "brands": [
            "Velcade",
            "Thalomid",
            "Decadron",
            "Platinol",
            "Adriamycin",
            "Cytoxan",
            "Vepesid"
        ],
        "cancers": [
            "Multiple_myeloma_induction"
        ],
        "drugs": [
            "Bortezomib",
            "Thalidomide",
            "Dexamethasone",
            "Cisplatin",
            "Doxorubicin",
            "Cyclophosphamide",
            "Etoposide"
        ],
        "regimen": "VTD-PACE",
        "regimen_names": [
            "VTD-PACE",
            "VTD/PACE",
            "VTDPACE"
        ],
        "regimen_type": "First-line therapy (including transplant ineligible), randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vandetanib monotherapy": {
        "brands": [
            "Caprelsa"
        ],
        "cancers": [
            "Thyroid_cancer",
            "Thyroid_cancer",
            "Thyroid_cancer"
        ],
        "drugs": [
            "Vandetanib"
        ],
        "regimen": "Vandetanib monotherapy",
        "regimen_names": [
            "Vandetanib monotherapy"
        ],
        "regimen_type": "Differentiated thyroid cancer, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VcR-CVAD": {
        "brands": [
            "Velcade",
            "Rituxan",
            "Cytoxan",
            "Oncovin",
            "Adriamycin",
            "Decadron"
        ],
        "cancers": [
            "Mantle_cell_lymphoma",
            "Mantle_cell_lymphoma"
        ],
        "drugs": [
            "Bortezomib",
            "Rituximab",
            "Cyclophosphamide",
            "Vincristine",
            "Doxorubicin",
            "Dexamethasone"
        ],
        "regimen": "VcR-CVAD",
        "regimen_names": [
            "VcR-CVAD",
            "VcR/CVAD",
            "VcRCVAD"
        ],
        "regimen_type": "First-line therapy, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "VeIP": {
        "brands": [
            "Velban",
            "Ifex",
            "Platinol"
        ],
        "cancers": [
            "Testicular_cancer",
            "Testicular_cancer"
        ],
        "drugs": [
            "Vinblastine",
            "Ifosfamide",
            "Cisplatin"
        ],
        "regimen": "VeIP",
        "regimen_names": [
            "VeIP"
        ],
        "regimen_type": "Relapsed or refractory, salvage therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vemurafenib monotherapy": {
        "brands": [
            "Zelboraf"
        ],
        "cancers": [
            "BRAF",
            "Erdheim-Chester_disease",
            "Erdheim-Chester_disease",
            "Hairy_cell_leukemia",
            "Langerhans_cell_histiocytosis",
            "Melanoma_BRAF-mutated",
            "Multiple_myeloma_relapsedrefractory",
            "Thyroid_cancer_BRAF-mutated"
        ],
        "drugs": [
            "Vemurafenib"
        ],
        "regimen": "Vemurafenib monotherapy",
        "regimen_names": [
            "Vemurafenib monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Venetoclax & Rituximab": {
        "brands": [
            "Venclexta",
            "Rituxan"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Venetoclax",
            "Rituximab"
        ],
        "regimen": "Venetoclax & Rituximab",
        "regimen_names": [
            "VEN & R",
            "VEN / R",
            "VEN and R",
            "VEN&R",
            "VEN+R",
            "VEN/R",
            "VENR",
            "Venetoclax & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, randomized data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Venetoclax monotherapy": {
        "brands": [
            "Venclexta"
        ],
        "cancers": [
            "Chronic_lymphocytic_leukemia_(CLLSLL)",
            "Chronic_lymphocytic_leukemia_(CLLSLL)"
        ],
        "drugs": [
            "Venetoclax"
        ],
        "regimen": "Venetoclax monotherapy",
        "regimen_names": [
            "Venetoclax monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vinblastine monotherapy": {
        "brands": [
            "Velban"
        ],
        "cancers": [
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Vinblastine"
        ],
        "regimen": "Vinblastine monotherapy",
        "regimen_names": [
            "Vinblastine monotherapy"
        ],
        "regimen_type": "Relapsed or refractory, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vincristine & Prednisone": {
        "brands": [
            "Oncovin",
            "Sterapred"
        ],
        "cancers": [
            "Chronic_myelogenous_leukemia",
            "Diffuse_large_B-cell_lymphoma",
            "Diffuse_large_B-cell_lymphoma"
        ],
        "drugs": [
            "Vincristine",
            "Prednisone"
        ],
        "regimen": "Vincristine & Prednisone",
        "regimen_names": [
            "Vincristine & Prednisone"
        ],
        "regimen_type": "Blast crisis",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vincristine monotherapy": {
        "brands": [
            "Oncovin"
        ],
        "cancers": [
            "Thrombotic_thrombocytopenic_purpura",
            "Wilms_tumor"
        ],
        "drugs": [
            "Vincristine"
        ],
        "regimen": "Vincristine monotherapy",
        "regimen_names": [
            "Vincristine monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vinflunine monotherapy": {
        "brands": [
            "Javlor"
        ],
        "cancers": [
            "Bladder_cancer"
        ],
        "drugs": [
            "Vinflunine"
        ],
        "regimen": "Vinflunine monotherapy",
        "regimen_names": [
            "Vinflunine monotherapy"
        ],
        "regimen_type": "Locally advanced or metastatic disease, subsequent lines",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vinorelbine monotherapy": {
        "brands": [
            "Navelbine"
        ],
        "cancers": [
            "Cervical_cancer",
            "Cervical_cancer",
            "Diffuse_large_B-cell_lymphoma",
            "Hodgkin_lymphoma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Mesothelioma",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Non-small_cell_lung_cancer",
            "Ovarian_cancer",
            "Small_cell_lung_cancer",
            "Small_cell_lung_cancer"
        ],
        "drugs": [
            "Vinorelbine"
        ],
        "regimen": "Vinorelbine monotherapy",
        "regimen_names": [
            "Vinorelbine monotherapy"
        ],
        "regimen_type": "Persistent, recurrent, or metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vismodegib monotherapy": {
        "brands": [
            "Erivedge"
        ],
        "cancers": [
            "Cutaneous_basal_cell_carcinoma",
            "SMO_or_PTCH-1_(Hedgehog)"
        ],
        "drugs": [
            "Vismodegib"
        ],
        "regimen": "Vismodegib monotherapy",
        "regimen_names": [
            "Vismodegib monotherapy"
        ],
        "regimen_type": "Advanced or metastatic disease, all lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vorinostat & Rituximab": {
        "brands": [
            "Zolinza",
            "Rituxan"
        ],
        "cancers": [
            "Follicular_lymphoma"
        ],
        "drugs": [
            "Vorinostat",
            "Rituximab"
        ],
        "regimen": "Vorinostat & Rituximab",
        "regimen_names": [
            "Vorinostat & Rituximab"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Vorinostat monotherapy": {
        "brands": [
            "Zolinza"
        ],
        "cancers": [
            "Cutaneous_T-cell_lymphoma",
            "Follicular_lymphoma",
            "Marginal_zone_lymphoma"
        ],
        "drugs": [
            "Vorinostat"
        ],
        "regimen": "Vorinostat monotherapy",
        "regimen_names": [
            "Vorinostat monotherapy"
        ],
        "regimen_type": "Relapsed or refractory",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "Warfarin monotherapy": {
        "brands": [
            "Coumadin"
        ],
        "cancers": [
            "Antiphospholipid_antibody_syndrome",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)",
            "Venous_thromboembolism_(VTE)"
        ],
        "drugs": [
            "Warfarin"
        ],
        "regimen": "Warfarin monotherapy",
        "regimen_names": [
            "Warfarin monotherapy"
        ],
        "regimen_type": "All lines of therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ZRd": {
        "brands": [
            "Zolinza",
            "Revlimid",
            "Decadron"
        ],
        "cancers": [
            "Multiple_myeloma_relapsedrefractory"
        ],
        "drugs": [
            "Vorinostat",
            "Lenalidomide",
            "Dexamethasone"
        ],
        "regimen": "ZRd",
        "regimen_names": [
            "ZRd"
        ],
        "regimen_type": "Relapsed or refractory, non-randomized or retrospective data",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "ddAC": {
        "brands": [
            "Adriamycin",
            "Cytoxan"
        ],
        "cancers": [
            "Breast_cancer",
            "Breast_cancer",
            "Breast_cancer_triple_negative",
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Doxorubicin",
            "Cyclophosphamide"
        ],
        "regimen": "ddAC",
        "regimen_names": [
            "ddAC"
        ],
        "regimen_type": "Neoadjuvant chemotherapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "dmCODOX-M - Modified Magrath": {
        "brands": [
            "Cytoxan",
            "Oncovin",
            "Adriamycin",
            "MTX"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Cyclophosphamide",
            "Vincristine",
            "Doxorubicin",
            "Methotrexate"
        ],
        "regimen": "dmCODOX-M - Modified Magrath",
        "regimen_names": [
            "dmCODOX-M",
            "dmCODOX-M - Modified Magrath",
            "dmCODOX/M",
            "dmCODOXM"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "dmCODOX-M/IVAC - Modified Magrath": {
        "brands": [
            "Cytosar",
            "MTX",
            "Cytosar",
            "MTX",
            "Leucovorin",
            "MTX"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Cytarabine",
            "Methotrexate",
            "Cytarabine",
            "Methotrexate",
            "Folinic acid",
            "Methotrexate"
        ],
        "regimen": "dmCODOX-M/IVAC - Modified Magrath",
        "regimen_names": [
            "dmCODOX-M/IVAC",
            "dmCODOX-M/IVAC - Modified Magrath"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "eBEACOPP": {
        "brands": [
            "Blenoxane",
            "Vepesid",
            "Adriamycin",
            "Cytoxan",
            "Oncovin",
            "Matulane",
            "Sterapred"
        ],
        "cancers": [
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma",
            "Hodgkin_lymphoma"
        ],
        "drugs": [
            "Bleomycin",
            "Etoposide",
            "Doxorubicin",
            "Cyclophosphamide",
            "Vincristine",
            "Procarbazine",
            "Prednisone"
        ],
        "regimen": "eBEACOPP",
        "regimen_names": [
            "eBEACOPP"
        ],
        "regimen_type": "Untreated, early-stage unfavorable (ESU)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "m-BACOD": {
        "brands": [
            "MTX",
            "Blenoxane",
            "Adriamycin",
            "Cytoxan",
            "Oncovin",
            "Decadron"
        ],
        "cancers": [
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma",
            "HIV-associated_lymphoma"
        ],
        "drugs": [
            "Methotrexate",
            "Bleomycin",
            "Doxorubicin",
            "Cyclophosphamide",
            "Vincristine",
            "Dexamethasone"
        ],
        "regimen": "m-BACOD",
        "regimen_names": [
            "m-BACOD",
            "m/BACOD",
            "mBACOD"
        ],
        "regimen_type": "Upfront therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mDCF": {
        "brands": [
            "Taxotere",
            "Platinol",
            "5-FU"
        ],
        "cancers": [
            "Anal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Cisplatin",
            "Fluorouracil"
        ],
        "regimen": "mDCF",
        "regimen_names": [
            "mDCF"
        ],
        "regimen_type": "Metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mDCF & Bevacizumab": {
        "brands": [
            "Taxotere",
            "Platinol",
            "Leucovorin",
            "5-FU",
            "Avastin"
        ],
        "cancers": [
            "Esophageal_cancer",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Docetaxel",
            "Cisplatin",
            "Folinic acid",
            "Fluorouracil",
            "Bevacizumab"
        ],
        "regimen": "mDCF & Bevacizumab",
        "regimen_names": [
            "mDCF",
            "mDCF  and  Bevacizumab",
            "mDCF & Bevacizumab",
            "mDCF + Bevacizumab",
            "mDCF / Bevacizumab",
            "mDCF and Bevacizumab",
            "mDCF+Bevacizumab",
            "mDCF/Bevacizumab"
        ],
        "regimen_type": "Metastatic or locally advanced disease (non-radiation/surgery candidate)",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFIRINOX": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Camptosar",
            "Eloxatin"
        ],
        "cancers": [
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Irinotecan",
            "Oxaliplatin"
        ],
        "regimen": "mFOLFIRINOX",
        "regimen_names": [
            "mFOLFIRINOX"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFIRINOX, Gemcitabine, RT": {
        "brands": [
            "Gemzar",
            "External beam radiotherapy"
        ],
        "cancers": [
            "Pancreatic_cancer",
            "Pancreatic_cancer"
        ],
        "drugs": [
            "Gemcitabine",
            "External beam radiotherapy"
        ],
        "regimen": "mFOLFIRINOX, Gemcitabine, RT",
        "regimen_names": [
            "mFOLFIRINOX, Gemcitabine, RT"
        ],
        "regimen_type": "Induction therapy for locally advanced disease, potentially resectable",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFOX6": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Fusilev",
            "Eloxatin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Levoleucovorin",
            "Oxaliplatin"
        ],
        "regimen": "mFOLFOX6",
        "regimen_names": [
            "mFOLFOX6"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFOX6 & Bevacizumab": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Avastin"
        ],
        "cancers": [
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer",
            "Colon_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Bevacizumab"
        ],
        "regimen": "mFOLFOX6 & Bevacizumab",
        "regimen_names": [
            "FOLFOX-B",
            "FOLFOX/B",
            "FOLFOXB",
            "mFOLFOX6 & Bevacizumab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFOX6 & Cetuximab": {
        "brands": [
            "5-FU",
            "Leucovorin",
            "Eloxatin",
            "Erbitux"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Colon_cancer_KRAS_wild-type",
            "Esophageal_cancer"
        ],
        "drugs": [
            "Fluorouracil",
            "Folinic acid",
            "Oxaliplatin",
            "Cetuximab"
        ],
        "regimen": "mFOLFOX6 & Cetuximab",
        "regimen_names": [
            "mFOLFOX6  and  Cetuximab",
            "mFOLFOX6 & Cetuximab",
            "mFOLFOX6 + Cetuximab",
            "mFOLFOX6 / Cetuximab",
            "mFOLFOX6 and Cetuximab",
            "mFOLFOX6+Cetuximab",
            "mFOLFOX6/Cetuximab"
        ],
        "regimen_type": "Adjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFOX6 & RT": {
        "brands": [
            "Leucovorin",
            "5-FU",
            "Eloxatin",
            "External_beam_radiotherapy"
        ],
        "cancers": [
            "Rectal_cancer"
        ],
        "drugs": [
            "Folinic acid",
            "Fluorouracil",
            "Oxaliplatin",
            "External_beam_radiotherapy"
        ],
        "regimen": "mFOLFOX6 & RT",
        "regimen_names": [
            "mFOLFOX6  and  RT",
            "mFOLFOX6 & RT",
            "mFOLFOX6 + RT",
            "mFOLFOX6 / RT",
            "mFOLFOX6 and RT",
            "mFOLFOX6+RT",
            "mFOLFOX6/RT"
        ],
        "regimen_type": "Neoadjuvant therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mFOLFOXIRI & Cetuximab": {
        "brands": [
            "5-FU",
            "Fusilev",
            "Eloxatin",
            "Camptosar",
            "Erbitux"
        ],
        "cancers": [
            "Colon_cancer_KRAS_wild-type"
        ],
        "drugs": [
            "Fluorouracil",
            "Levoleucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Cetuximab"
        ],
        "regimen": "mFOLFOXIRI & Cetuximab",
        "regimen_names": [
            "mFOLFOXIRI & Cetuximab"
        ],
        "regimen_type": "Advanced or metastatic disease, first-line",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "mLSG15": {
        "brands": [
            "Oncovin",
            "Cytoxan",
            "Adriamycin",
            "Sterapred",
            "Cymerin",
            "Eldisine",
            "Vepesid",
            "Paraplatin"
        ],
        "cancers": [
            "Adult_T-cell_leukemia-lymphoma",
            "Adult_T-cell_leukemia-lymphoma"
        ],
        "drugs": [
            "Vincristine",
            "Cyclophosphamide",
            "Doxorubicin",
            "Prednisone",
            "Ranimustine",
            "Vindesine",
            "Etoposide",
            "Carboplatin"
        ],
        "regimen": "mLSG15",
        "regimen_names": [
            "mLSG15"
        ],
        "regimen_type": "Untreated",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "nab-Paclitaxel & Atezolizumab": {
        "brands": [
            "Abraxane",
            "Tecentriq"
        ],
        "cancers": [
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Paclitaxel, nanoparticle albumin-bound",
            "Atezolizumab"
        ],
        "regimen": "nab-Paclitaxel & Atezolizumab",
        "regimen_names": [
            "nab-Paclitaxel & Atezolizumab"
        ],
        "regimen_type": "Metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    },
    "nab-Paclitaxel monotherapy": {
        "brands": [
            "Abraxane"
        ],
        "cancers": [
            "Breast_cancer_triple_negative"
        ],
        "drugs": [
            "Paclitaxel, nanoparticle albumin-bound"
        ],
        "regimen": "nab-Paclitaxel monotherapy",
        "regimen_names": [
            "nab-Paclitaxel monotherapy"
        ],
        "regimen_type": "Metastatic disease, first-line therapy",
        "supportive_brands": [],
        "supportive_drugs": []
    }
}